



ΕΚΠΑ  
Α. Π.: 35593  
Ημ.: 10/04/2023

ΠΑΡΑΡΤΗΜΑ

Α Ι Τ Η Σ Η

ΕΠΩΝΥΜΟ:.....ΔΗΜΗΤΡΙΟΣ.....  
ΟΝΟΜΑ:.....ΚΟΝΤΟΓΙΑΝΝΗΣ.....  
ΠΑΤΡΩΝΥΜΟ:.....ΠΑΝΑΓΙΩΤΟΥ.....  
ΗΜΕΡ.ΓΕΝΝΗΣΗΣ:.....17 Μαΐου 1963.....  
ΙΔΙΟΤΗΤΑ:..Καθηγητης.....Ιατρικη  
ς.....  
Α.Δ.Τ./Αρ. Διαβατηρίου:....ΑΥ 2057899.....  
E-mail:dkontoyi@mdanderson.org.....

**Θέμα:** Υποψηφιότητα για τη θέση εξωτερικού μέλους του Συμβουλίου Διοίκησης του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών»

Τόπος/Ημερομηνία:

Houston, TX, USA....., 4./4./2023.....

Συνημμένα:

- α) Αντίγραφο Δελτίου Αστυνομικής Ταυτότητας ή Αντίγραφο Διαβατηρίου.
- β) Πλήρες βιογραφικό σημείωμα.
- γ) Οποιαδήποτε έγγραφα ή στοιχεία κρίνει ο/η υποψήφιος/α ότι θα υποστηρίξει την υποψηφιότητά του/ης (προαιρετικό).
- δ) Επιστολή εκδήλωσης ενδιαφέροντος για την επιλογή στη θέση του εξωτερικού μέλους (προαιρετικό).

Π Ρ Ο Σ  
ΤΟΝ ΠΡΥΤΑΝΗ ΤΟΥ  
ΕΘΝΙΚΟΥ  
ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟΥ  
ΠΑΝΕΠΙΣΤΗΜΙΟΥ  
ΑΘΗΝΩΝ

Με την παρούσα αίτηση:

Α) υποβάλλω υποψηφιότητα για τη θέση εξωτερικού μέλους του Συμβουλίου Διοίκησης του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών σύμφωνα με την ισχύουσα νομοθεσία στο πλαίσιο της με

αριθμ.πρωτ**17890/28-2-023**.

διεθνούς πρόσκλησης για την ανάδειξη των εξωτερικών μελών του Συμβουλίου Διοίκησης του Ιδρύματος.

β) αποδέχομαι τους όρους συμμετοχής στην παρούσα και δηλώνω ότι γνωρίζω τις υποχρεώσεις που απορρέουν από την ιδιότητα του εξωτερικού μέλους σε περίπτωση εκλογής μου, καθώς και τις αρμοδιότητες που ασκεί το Συμβούλιο Διοίκησης του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών σύμφωνα με το άρθρο 14 του ν. 4957/2022.

γ) δηλώνω ότι συναινώ στη συλλογή και επεξεργασία των προσωπικών δεδομένων μου, όπως αυτά αναφέρονται στην παρούσα πρόταση και στα συνυποβαλλόμενα με αυτήν δικαιολογητικά αποκλειστικά για

την αξιολόγηση της αίτησής μου  
στο πλαίσιο της διαδικασίας της  
παρούσας.

Ο Αιτών



ΔημητρηςΠ Κοντογιαννης

6 Απριλίου 2023

Αίτηση υποψηφιότητας του Καθηγητή Δημήτριου Π. Κοντογιάννη για εξωτερικό μέλος του Συμβουλίου Διοίκησης του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών

Έχω την τιμή να υποβάλλω υποψηφιότητα για εξωτερικό μέλος του Συμβουλίου Διοίκησης του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών.

Είμαι απόφοιτος της Ιατρικής Σχολής του ΕΚΠΑ (1981-1987) και αποφοίτησα πρώτος στο έτος μου. Μετά την εκπλήρωση της στρατιωτικής μου θητείας, από το 1990 διαμένω στις Η.Π.Α όπου αρχικά ολοκλήρωσα την εκπαίδευσή μου στην Εσωτερική Παθολογία, στη συνέχεια εξειδικεύτηκα στον Τομέα των Λοιμώξεων και ανήλθα όλες τις βαθμίδες της ακαδημαϊκής ιεραρχίας (επισυνάπτεται βιογραφικό σημείωμα και πλήρης επιστολή ενδιαφέροντος μου στα Αγγλικά). Τα τελευταία 33 χρόνια διατηρώ στενές και πολύπλευρες σχέσεις με πολλά μέλη ΔΕΠ του ΕΚΠΑ, ιδιαίτερα στα γνωστικά αντικείμενα της Παθολογίας, Αιματολογίας/Ογκολογίας, Μικροβιολογίας και Λοιμώξεων. Θέλω να σημειώσω ότι αρκετοί απόφοιτοιατρικών Σχολών Ελληνικών ΑΕΙ καθώς και Μέλη ΔΕΠ από διάφορες Ιατρικές Σχολές της Ελλάδας εντάχθηκαν στο ερευνητικό μου πρόγραμμα για να κάνουν κλινική και εργαστηριακή έρευνα και να επεκτείνουν την κλινική τους κατάρτιση. Είμαι περήφανος που, με την καθοδήγησή μου, αρκετοί από τους νεότερους συναδέλφους είχαν μία σημαντική

---

ακαδημαϊκή εξέλιξη και διεθνή αναγνώριση. Επιπλέον, έχω μετάσχει, ως προσκεκλημένος ομιλητής, σε πολλά Ιατρικά Συνέδρια στην Ελλάδα και έχω δώσει πολλές διαλέξεις σε διάφορες Ελληνικές Ιατρικές Σχολές. Θεωρώ ιδιαίτερη τιμή για εμένα ότι η Σύγκλητος του ΕΚΠΑ με ανακήρυξε το 2017 Επίτιμο Διδάκτορα της Ιατρικής Σχολής. Πιστεύω ότι, με βάση την πολύχρονη εμπειρία μου στο ανταγωνιστικό ακαδημαϊκό περιβάλλον των ΗΠΑ, τη διεθνή μου αναγνώριση και τη συνεχή επαφή μου με τα ακαδημαϊκά δρόμενα στο ΕΚΠΑ, θα μπορέσω αν επιλεγώ ως Εξωτερικό Μέλος του Συμβουλίου Διοίκησης του Ιδρύματος να συμβάλλω στην περαιτέρω ανάπτυξη του αρχαιότερου Πανεπιστημίου της Ελλάδας.

Με τιμή



Καθηγητής Δημήτριος Π. Κοντογιάννης



THE UNIVERSITY OF TEXAS

**MD Anderson  
Cancer Center**

Making Cancer History®

**Dimitrios P. Kontoyiannis, MD, ScD, PhD  
(Hon), FACP, FIDSA, FECMM, FAAM, FAAAA**  
Robert C Hickey Chair in Clinical Care  
Deputy Head, Division of Internal Medicine  
dkontoyi@mdanderson.org

**Division of Internal Medicine**  
T 713-792-6517 F 713-563-3108  
1500 Holcombe Blvd., Unit 1463  
Houston, Texas 77030

April 4, 2023

**Re:** Application for selection as one of the members of the External Advisory Board for University of Athens, Greece- Dr. Dimitrios P. Kontoyiannis

Dear Selection Committee

I am excited and honored to be considered for selection as one of the members of the External Advisory Board for University of Athens, Greece. Below, I outline my credentials in several key areas in order to demonstrate my multi-faceted contributions and highlight the leadership positions I have held that are most pertinent to the position of external advisor (please also refer to the attached CV and the 1 page synopsis for more information).

#### **Experience in Faculty Development and Engagement**

In my 25 years at MD Anderson cancer center in Houston, Texas, I have had increasingly progressive leadership roles and made many significant contributions to academic life.

In 2008, I was appointed the Deputy Chair in the Department of Infectious Diseases, Infection Control, and Employee Health. As Deputy Chair in the Department of Infectious Diseases, I oversaw or influenced several key initiatives in mentorship, research and strategic planning. In 2011, I was appointed Deputy Head of the Division of Internal Medicine (DoIM) and have served in that role ever since. As an active member of the Division's Executive Council, I have given input and helped shape several strategic initiatives in recruitment, laboratory/clinical research administration, resource stewardship, research metrics and grant submission. I have initiated several divisional initiatives to energize research programs. For example, I started the "Wall of Fame" in Research project in an effort to increase recognition of quality research throughout the Division. I have promoted our division's research in various ways and overseen the DoIM annual research retreat. I have also worked both formally (mentee presentation series), but even more importantly, informally on an individual basis with investigators in order to facilitate mentoring and career guidance in DoIM.

In addition, throughout my tenure as faculty at MD Anderson, I have served on several key institutional committees related to the academic process (Animal welfare Committee, Internal research grants committee, IRB, Clinical Research Council, Pharmacy & Therapeutics Committee, Clinical Impact Research Committee, Technology Task Force, Clinical Evaluation Programs Committee, Burn out mitigation efforts Committee, Promotion and Tenure Committee, Technology Task Force, Academic, Mentoring committee, new facilities planning think tank and ad hoc committee for external evaluation of departments). I have also taken the initiative and sent ideas/proposals regarding senior faculty engagement/transitions and vitality to upper administration. In summer 2020, I was appointed by the Chief Academic Officer (CAO) as the inaugural chair of the institution's Senior Faculty Committee (SFC). In this role, we have spearheaded and are actively working on several very exciting projects. In my role as SFC chair, I have joined important committees in the CAO office such as the Academic Leadership Team and the Employee Engagement Council.

---

## **Developing Academic Partnerships**

I am a very active scholar. I have been a member of the scientific planning committees in all key national and international conferences in my field and a member of the executive board of all key academic international or national committees in my area such as the Mycoses Study Group Education Consortium (MSGERC) Immunocompromised Host Society (ICHS), Trends in Mycology Meeting. I was president-elect of ICHS (2018-2020) and I am the next president-elect (2024-2026) for MSGERC. As president of these societies, I did successful fundraising and organized the highly successful international meetings. I have lectured extensively (grand rounds, visiting professorships, national and international meetings). I have also served as a member of ad hoc promotion committees in several prestigious institutions and as an external reviewer for several NIH Study sections and Research programs in various universities. I am or have been associate editor in subspecialty journals in mycology and sit on the editorial boards of several journals in the field of infectious diseases.

At MD Anderson, I have initiated and established successful interactions with several departments. For example, in my role as DoIM Deputy Head for research, I helped to organize a working group to study immunotoxicities of cancer therapy and started the microbiome initiative in collaboration with the leukemia department. Under my direction as chairman of the DoIM Research Committee, we organized a series of very successful research retreats for our division and started key initiatives for strengthening the research infrastructure and creating opportunities for trans-departmental research collaborations within the Division.

Finally, I have developed and led a robust and comprehensive multi-disciplinary program in my own area, that of experimental and clinical mycology. This institution-wide program (comprised of 15 investigators) has both translational and clinical components, and has achieved notable recognition and awards, including the highest designation (Diamond Status) as an ECMM Center of Excellence (<http://www.ecmm.info>) - the first U.S. center to achieve such distinction.

## **Research**

---

I have had a continuously funded lab for the past 25 years and our research program has been widely acclaimed as both prolific and innovative. As a big proponent of quality teamwork, we have established several successful collaborations in mycology, both within and outside of the institution. In addition, I am considered the leading expert in clinical and experimental mycology world-wide and among the 2 most frequently cited investigators in the area of mycology with over 670 peer-reviewed publications and over 65500 citations with an H index of 124(Google Scholar, accessed March 30, 2023). I believe that my research experience in both clinical and translational lab research and sustained track record of success would allow me to lead by example and understand both your faculty perspectives and academic needs

### **Mentorship and Education**

Mentorship has been very important to me and a source of both satisfaction and pride as I advance in my career. Several mentees from my laboratory have won a variety of post-doctoral research fellowships and institutional research awards. Some of these mentees have progressed to promising academic careers as independent investigators.

I have also mentored many junior faculty members in ID, Internal Medicine and even in Oncology at MD Anderson. These efforts were recognized by multiple nominations for the MDACC Chamberlain Award (for post-doctoral fellows, in 2006, 2008, 2014), and the receipt of the MDACC Mentor of the Year award (for clinical faculty) in 2012 after nomination by both clinicians and researchers. I was also the recent recipient of an Institutional LEADership award, reflecting my commitment to the career development of my junior colleagues. I am a long-standing and active member of the institutional Mentorship Committee. As mentorship of trainees and early /mid-career faculty is more important than ever in modern medicine, I believe that my commitment to the growth of others will serve me well in a broad scope of advisory endeavors and academic affairs.

In terms of my experiences as an educator, I was named educator of the month at MDACC and nominated in the past for the UT Shine Academy for educators. I am an active core teaching faculty for our Internal Medicine residency program and ID fellows and co-chair of the DoIM educational task force.

I believe my experiences and distinction as mentor and as an educator will serve me well as it relates to the broader scope of the advisory position for academic affairs in University of Athens.

### **Patient Care**

For the last 25 years, I have been an active clinician in various inpatient ID consultative services and part of the multidisciplinary care model. I also have a busy weekly clinic. I have developed guidelines for management of fungal infections for the departments of Leukemia and Stem Cell Transplantation, in parallel to my participation in national and international guideline development. I am also regularly consulted by colleagues throughout the U.S. and the world for difficult cases in cancer infectious diseases. As recognition for the quality and contributions to patient care I have made while at MD Anderson Cancer Center, I received the 2007 MDACC Achievement Award in clinical care - the only clinical consultant (non-primary provider) to receive such distinction. Because of these achievements in clinical care, I believe I can win the respect of academic clinicians and understand both their perspectives and needs.

### **Commitment to Diversity**

CARING      INTEGRITY      DISCOVERY

---

I am a firm believer that diversity brings richness of perspective and increases the collective emotional intelligence and problem-solving abilities in teams. Over 25 years, I have mentored 54 junior colleagues all the way from summer students, observers and ID fellows to advanced post-doctoral clinical and research fellows. Twenty of the 54 were female; and most of my trainees came from various backgrounds, ethnic groups and countries. I had the same experience with my faculty mentees, several of whom were women and/ or coming, from various backgrounds and countries. In fact, 3 of the 6 nominees for the LEADership award I recently received from MD Anderson Cancer Center were female junior faculty with 2 of them being from minority groups.

I prize authenticity. I am deeply interested in other people and cultures and recognize that people have different styles of communication. One appealing aspect of an institutional leadership position is that one can be more effective and have broader impact in removing barriers.

#### Relationship with University of Athens

*I am a graduate of University of Athens Medical School (1981-1987). I was valedictorian all the 6 years of my training as medical student in University of Athens Medical School and I graduated first in my class, summa cum laude in 1987. After the fulfillment of my 2 year military obligation, I left in 1990 for US to pursue further medical training. In the last 33 years, I have kept close and multifaceted relationships with multiple faculty members in University of Athens, especially in the fields of Internal Medicine, Hematology/Oncology, Microbiology and in my own specialty of Infectious Diseases. Importantly, several graduates and junior faculty from several Greek Medical Schools joined me do clinical and laboratory research and expand their clinical training. I am proud that, with my mentoring, several of these junior colleagues have risen in the academic ranks, some of them becoming superstars in their own discipline. I have functioned as visiting professor and gave many lectures in several Greek Medical schools, especially in the University of Athens Medical School. I was given the honor to be a key note speaker for several annual professional medical meetings in greekmedical community. For all these contributions, the University of Athens has given me the distinct privilege of honorary (honoris causa) in March 2017. I believe I have close knowledge and the advantage of an "insider-outsider" to cross-fertilize with ideas this historic University which is my Alma mater and help with my vast experience of a very successful career in academic medicine.*

Σχόλιο [ΚΡ1]: Thanos, can you also take a look in that section?


In summary, I believe that the University-wide advisory position aligns quite well with my experiences and qualifications as my career reflects sustained and multi-faceted accomplishments in academics with combined activities in clinical care, clinical and translational research. In addition, throughout my journey, I have displayed a strong caring for others which is reflected by recognition in education, mentoring and faculty development. These accomplishments have been coupled with progressive and relevant administrative experience within the institution, along with local, national and international leadership. Most importantly, I have remained in close contact with the issues surrounding what it means to "be in the trenches", wear "multiple hats" and contribute effectively in all mission areas of a large and distinguished academic exercise such is MD Anderson.

I believe everything I have prepared me for multifaceted contributions in a complex academic environment. I consider the university-wide External Advisory Board Position to be a nice "career consolidation" opportunity where all of the fundamental elements of my career can be translated more broadly and result in wider impact, as legacy to contribution to the University where my academic life begun, is an important intrinsic reward of such position.

Thank you for your consideration.

---

Sincerely,



Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM, FAAAS  
Robert C Hickey Chair in Clinical Care  
Deputy Head, Division of Internal Medicine  
Adj Professor Baylor College of Medicine  
Adj Professor UT School of Public Health  
Adj Professor University of Houston

ECMM Diamond Excellence in Mycology Center/[www.ecmm.info](http://www.ecmm.info)

**Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon)**, is the Robert C Hickey Chair in Clinical Care and Deputy Head for Research in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. He received his medical degree as *validectorian Summa Cum Laude* from the National and Kapodistrian University of Athens, Greece. Kontoyiannis was trained in Internal Medicine at Baylor College of Medicine in Houston, TX, where he served as a Chief Medical Resident. He was subsequently trained as a clinical fellow in Infectious Diseases at Massachusetts General Hospital and obtained a Master in Clinical Sciences from Harvard Medical School in Boston. He spent 3 years at the Whitehead Institute for Biomedical Sciences/Massachusetts Institute of Technology as a fellow in the Harvard MIT Clinical Investigators Training Program. He is the recipient of many institutional, national and international awards such as the 2004 American Society for Microbiology award for Outstanding Research in the Pathogenesis of Microbial Diseases (mentor), The Billy Cooper Memorial award from The Medical Mycology Society of Americas (MMSA, 2013), The Drouhet Medal from the European Confederation of Medical Mycology (ECMM, 2015), Littman award from the Mycology Society of NY (2016), emeritus member of Paul-Ehrlich-Society (2016). Kontoyiannis was an American Society for Microbiology Distinguished Lecturer, 2014-2016, and was awarded an honorary PhD (*Honoris Causa*) from the National Kapodistrian University in Athens, Greece (2017) and from the Aristotle University in Thessaloniki, Greece (2020). Kontoyiannis is a fellow of the American College of Physicians, a fellow of the Infectious Diseases Society of America, a fellow elect of the American Academy of Microbiology, fellow of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), fellow of the Royal College of Physicians and an inaugural lifetime fellow of the ECMM. Kontoyiannis is the past president-elect of Immunocompromised Host Society (2016-2018). He is a fellow of the American Association for the Advancement of Science (AAAS), member in class II—Medicine of the European Academy of Sciences and Arts (*Academia Scientiarum et Artium Europaea*) and was recently elected in American Associations of Physicians (AAP). He is the recipient of Award for Excellence in Clinical Microbiology and Infectious Diseases of ESCMID for 2018, and the Rhoda Benham Award in MMSA (2019). In 2023, an award was named after him (*The Dimitrios P Kontoyiannis junior investigator award in Medical Mycology*) by the Hellenic Society in Medical Mycology. He is the leader of the ECMM Diamond Excellence in Mycology Center at MD Anderson Cancer Center, the only US center to receive such designation by ECMM). He is the president elect of The Mycoses Study Group Education Consortium (2024-2026). Kontoyiannis is considered among the 1-2 leading experts in mycology world-wide and among the 1-2 most highly cited investigators in the area of mycology with over 660 peer-reviewed publications and 65350 citations and an H index of 124 (Google Scholar, accessed March 30, 2023).







## CURRICULUM VITAE

**Dimitrios P. Kontoyiannis, MD, MS, ScD, PhD, FACP, FIDSA, FECMM, FAAM, FAAAS, AAP**

### PRESENT TITLE AND AFFILIATION

#### Primary Appointment

Deputy Head Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

#### Dual/Joint/Adjunct Appointment

Adjunct Professor, The University of Houston, Division of Pharmacology, Houston, TX

Adjunct Professor, Department of Infectious Diseases, Baylor College of Medicine, Houston, TX

Adjunct Professor, UT Health School of Public Health, Houston, TX

### CITIZENSHIP

United States

Greece

### OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center

1400 Pressler Street

Division of Internal Medicine, Unit 1463

Houston, TX 77030

Room Number: FCT12.5069

Phone: (713) 792-6517

Fax: (713) 563-3108

### EDUCATION

#### Degree-Granting Education

National and Kapodistrian University of Athens, Athens, Greece, MD, 1987, Medical Science

Harvard Medical School, Boston, MA, MS, 1997, Medical Sciences (MSc)

University of Crete, Crete, Greece, DSc, 1998, Medical Thesis: Transposon mutagenesis to study azole resistance in *S. cerevisiae*

#### Postgraduate Training

Second Lieutenant of the Medical Corp, Greek Army, Athens, Greece, 1987-1988

Internal Medicine Resident, Department of Internal Medicine, 401 General Army Hospital, Athens, Greece, 1988-1989

Clinical Research Fellow, Section of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX, Director: Gerald P. Bodey, MD, 1989-1991

Resident in Internal Medicine, Baylor College of Medicine, Houston, TX, Director: Antony Gotto, MD, 1991-1994

Fellow in Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Director: Steven B. Calderwood, MD, 1994-1998

Visiting Scientist, Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, Boston, MA, Director: Gerald R. Fink, PhD, 1995-1996



Fellow, Clinical Investigation Training Program, Division of Health Sciences and Technology-Beth Israel Deaconess Medical Center in collaboration with Pfizer, Inc., Harvard/MIT, Boston, MA, Director: Robert H. Rubin, MD, 1995-1998

Seminar in Advanced Molecular Cloning and Expression of Eukaryotic Genes, Cold Spring Harbor Laboratory, New York, NY, 7/1995-8/1995

Visiting Principal Research Investigator, Whitehead Institute for Biomedical Research/MIT, Boston, MA, Director: Gerald R. Fink, PhD, 1997-1998

MD Anderson Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2004-12/2005

Graduate Certificate in Health Care Management, Rice University, Houston, TX, 10/2013-3/2014

LEADing Others Core Curriculum, Coach2 Lead, LEADing Others Discover, Leadership Institute, Houston, TX, 2020-2020

LEADing Others Discover, Leadership Institute, Houston, TX, 2020-2020

Promoting Professionalism (Virtual Training), Vanderbilt Center for Patient and Professional Advocacy, Nashville, TN, 10/2020-10/2020

## **CREDENTIALS**

### **Board Certification**

Diplomate, American Board of Internal Medicine, 1994, Recertification Date: 2009

Diplomate, American Board of Infectious Diseases, 1996, Recertification Date: 2021

Diplomate, Greek Board of Internal Medicine, 1997

Diplomate, Greek Board of Infectious Diseases, 2001

### **Licensures**

#### **Active**

State of Texas, TX, #K6059, 1998

#### **Inactive**

Greek, #31231/97, 1987

MA, 7/1994-7/1998

## **EXPERIENCE/SERVICE**

### **Academic Appointments**

Assistant in Internal Medicine, Medical Walk-in Clinic, Division of Internal Medicine, Massachusetts General Hospital, Boston, MA, 1994-1998

Chief Medical Resident, VA Medical Center, Baylor College of Medicine, Houston, TX, 1994

Assistant Professor, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998-2002

Adjunct Assistant Professor, Pharmacology, The University of Houston, Houston, TX, 2001-2003

Associate Professor, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2002-8/2006

Adjunct Associate Professor, The University of Houston, Division of Pharmacology, Houston, TX, 2003-2006

Adjunct Professor, The University of Houston, Division of Pharmacology, Houston, TX, 2006-present

Professor, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-present

Adjunct Professor, Department of Infectious Diseases, Baylor College of Medicine, Houston, TX, 2008-present

Adjunct Faculty, Clinical Scientist Training Program (CSTP), Baylor College of Medicine, Houston, TX, 4/2015-present

Adjunct Professor, UT Health School of Public Health, Houston, TX, 3/2018-present

#### **Administrative Appointments/Responsibilities**

Chief Medical Resident, Baylor College of Medicine, Houston, TX, 1994

Coordinator, Infectious Diseases Research Conferences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000-2008

Deputy Department Chair, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008-6/2011

Deputy Head Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2011-present

#### **Other Appointments/Responsibilities**

Interviewer, Infectious Diseases Fellowship, MD Anderson Cancer Center, Houston, TX, 1998-present

#### **Endowed Positions**

Frances King Black Endowed Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2011-2017

The Texas 4000 Distinguished Endowed Professor For Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017-2020

Robert C Hickey Chair in Clinical Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2020-present

#### **Consultantships**

University of Houston, Department of Pharmacology, Houston, 1998-2001

Bacterial BarCodes, Inc. Scientific Advisory Board Member, Houston, TX, 2002-2004

Merck Sharp & Dohme Corp. Global Advisory Board, Whitehouse, NJ, 2008

Astellas, Inc., Illinois, 2013

Amplify Pharmaceuticals, Inc., San Diego, CA, 2016

Matinas BioPharma Holdings, Inc., Bedminster, NJ, 2017

Jazz Pharmaceuticals, San Francisco, CA, 2017

Mayne Pharmaceuticals, Durham, NC, 2018

Pulmocide, Washington DC, 2019

Volatylix, Inc., Cambridge, MA, 2020

AbbVie, Inc., Chicago, IL, 2020

Scynexis, New Jersey City, NJ, 2020

Cidara, San Diego, CA, 2021

AbbVie, Inc., Chicago, IL, 2021

CellChorus, Houston, TX, 2022

F2G, Inc., Manchester, UK, 2022

**Military or Other Governmental Service**

Greek Army, Second Lieutenant of Medical Corp, 1987-1989

**Institutional Committee Activities**

BCM, Internal Medicine resident's evaluation committee, Internal Medicine resident's curriculum committee, Core Clerkship in Internal Medicine Students curriculum committee, House Staff Association Council, VA Medical Center medical staff committee, 1994

MDACC Immunization Vaccination and Viral Prevention Ad Hoc Infection Control Subcommittee, Vice Chairman, 1999-2003

MDACC Ad Hoc Infection Control Subcommittee for Fungal Infections, Vice Chairman, 1999-2003

MDACC Division of Internal Medicine Research Committee, Chair, 2001-2002

MDACC CME Advisory Committee, Member (Alternate), 2001-2004

MDACC Infection Control Antibiotic Utilization Subcommittee, Member, 2001-present

MDACC Study Section Review Committee for Basic Research Projects, Member, 2002-2005

MDACC Pharmacy and Therapeutics Committee, Member, 2002-2008

MDACC Institutional Animal Care and Use Committee (IACUC), Member, 2003-2006

MDACC Bridge Grant/UCF Grant Review Committee, Member, 2004

MDACC Pharmaceutical Policy & Outcomes Research Antifungal Taskforce, member, 2005-2009

MDACC Trainee Recognition Day Faculty Judges Committee, Judge, 2005

MDACC Clinical Research Evaluation Committee, Member, 2006-2009

MDACC Faculty Senate, Member, 2006-2009

MDACC Faculty Focus Group, Member, 2006-2009

MDACC Clinical Research Impact Subcommittee of the Clinical Council, Member, 2006-2010

MDACC Faculty Achievement Awards Committee, Member, 2006

MDACC Division of Internal Medicine Research Committee, Chairman, 2008-2010

MDACC TRIUMPH (Translational Research in Multi-Disciplinary Program) Committee, Member, 2008

MDACC Division of Internal Medicine Task Force: Hospitalist Program, member, 2009

MDACC Mid Tenure Review Committee, Chair, 2009

MDACC Clinical Research Advisory Committee, member, 2011-2013

MDACC, Division of Internal Medicine Executive Council, Member, 2011-present

MDACC Research Council, Member, 2012-2017

MDACC Oncolog Editorial Board, Member, 2012-2018

MDACC Dept. of Infectious Diseases, Pulmonary, Nephrology, and Endocrine, Microbiology Search Committees, Member, 2012

MDACC Pneumonia in Adult Patients with Cancer and on Therapy Algorithm Committee, member, 4/2012-present

MDACC Promotion & Tenure Committee, Member, 9/2012-8/2013

MDACC Technology Task Force, Member, 9/2012-8/2015

MDACC Faculty Mentor Award Selection Committee, Member, 2014-2018

MDACC Study Section Review Committee for Basic Research Projects, Member, 2014-2020

MDACC Search Committee for Chair of Pathology, Member, 2014

MDACC Mid Tenure Review Committee, Chair, 2014  
MDACC Mentoring Advisory Committee, Member, 1/2014-present  
MDACC Science That Enables: The External Review Process and Criteria, Member, 9/2014-9/2015  
MDACC Molecular Testing Evaluation Committee, Member, 9/2014-9/2015  
MDACC Scientific Publication Advisory Board, Member, 2015-present  
BCM, Clinical Scientist Training Program, Member, 2015  
MDACC Subcommittee For Translational Research Strategic Planning, Member, 4/2015-8/2015  
MDACC International Advisory Board (IAB), Member, 9/2015-2017  
MDACC Prophylaxis and treatment of infections in patients on check point inhibitors trials, Special Advisor, 10/2015  
MDACC INTEREST - Internal Review Study Section, Member, 5/2016  
MDACC Rare Diseases Working Group, Member, 8/2016  
MDACC Clinical Innovator Awards, Reviewer, 10/2016  
MDACC Antifungal Stewardship Working Group, Member, 2017-present  
MDACC Mid Tenure CFA Review Committee, Member, 2017  
MDACC Education Task Force, Member, 9/2017  
MDACC Faculty Recruitment, Retention and Development Task Force, Member, 9/2017  
MDACC Research Task Force, Member, 9/2017  
MDACC Promotion & Tenure Committee, Member, 2018-2020  
MDACC Career Resiliency Enhancement Wellness Sustainability (CREWS) Task Force, Member, 1/2018  
MDACC Division of Pediatrics Mentoring Faculty, Member, 7/2018  
MDACC Senior Faculty Engagement Taskforce, Member, 2019-2021  
MDACC Division of Internal Medicine Educational Task Force, Co-Chair, 2019-present  
MDACC Global Academic Programs, Abstract Reviewer, 2019  
MDACC TT Mid-tenure Review Committee, Member, 2019  
LBJ Leukemia Tumor Board, Ad Hoc Member, 2019  
MDACC Working Group for Hyperbaric use for Infections, Member, 2019  
MDACC Clinical Program Assessment Subcommittee, Member, 4/2019-8/2020  
MDACC Academic Mentoring Advisory Committee, Member, 6/2019-2021  
MDACC Faculty Vitality Taskforce, Member, 2020-2021  
MDACC Division of Internal Medicine Research Committee, Member, 2020-present  
MDACC Mid Tenure Review Committee, Member, 2020-present  
COVID-19 Department of Infectious Diseases Journal Club, Coordinator, 3/2020-3/2022  
COVID-19 Management Algorithm Task Force, Member, 3/2020-present  
MDACC TMC3 Think Tank, Member, 4/2020-present  
MDACC Senior Faculty Committee, Chair, 8/2020-6/2021  
MDACC TMC3 Vivarium Think Tank, Member, 9/2020-3/2021  
MDACC Academic Leadership Team, Member, 11/2020-4/2021

MDACC Employee Engagement Council, Member, 12/2020-3/2021  
MDACC Cost of Care-Antifungals Working Group, Ad hoc expert, 2021-present  
MDACC Endemic COVID19 Optimization teams, Co-lead, Infection Control-Research, 2021-present  
MDACC Research COVID-19 Core Leadership Team (R-CCLT), Member, 2021-present  
MDACC Leukemia Antifungal Guidelines Working Group, Member, 2021-present  
MDACC, Yeast susceptibility working group, Ad hoc expert, 2021  
MDACC Selection Committee for LEADership Award Winners Committee, Member, 2021  
MDACC Academic Mentoring Council, Member, 2022-present  
MDACC Strategic Planning Subcommittee Invest in Research Excellence/Talent/Academic Mission, Member, 2022

#### **HONORS AND AWARDS**

Hellenic National Scholarship, Hellenic National Scholarships Foundation, 1981-1987  
Ranked 4th nationwide in the entrance examination, National and Kapodistrian University of Athens/Athens Medical School, 1981  
Valedictorian, Athens Medical School, 1981-1987  
Mavrokordatos Foundation Scholarship, Mavrokordatos Foundation, 1985-1987  
Graduated 1st "Summa Cum Laude," Athens, Medical School, 1987  
Kontoleontos Foundation Scholarship, Kontoleontos Foundation, 1989  
NATO Scholarship, 1989  
Certificate of Merit, The University of Texas MD Anderson Cancer Center, 1991  
Chief Medical Resident, Veterans Affairs Medical Center, Baylor College of Medicine, 1994  
Henry D McIntosh Outstanding Resident in Medicine Award, Baylor College of Medicine, 1994  
Ranked above the 99th percentile nationwide, Baylor College of Medicine, 1994  
Visiting Principal Research Investigator, Whitehead Institute for Biomedical Research/MIT, 1997  
Winner in Fellow Abstract Competition, Special Citation (2 abstracts), Infectious Diseases Society of America, 1998  
Invited Discussant, Clinico-Pathological Conference, Massachusetts General Hospital, Boston, MA, 2000, 2011  
Fellow, American College of Physicians-American Society of Internal Medicine (F.A.C.P.), 2001-present  
Award for outstanding abstract in Pathogenesis of Microbial Diseases (primary investigator), American Society of Microbiology/43th International Conference of Antimicrobial Agents and Chemotherapy Committee, 2003  
Nominated for the Julie & Ben Rogers Award for Excellence, 2003  
Faculty E. N Cobb Scholar Award (Research Endowment), The University of Texas MD Anderson Cancer Center, 2004-2007  
Fellow, Infectious Diseases Society of America (F.I.D.S.A.), 2004-present  
First place winner (mentor of Dr. M Lionakis), Bristol-Myers Squibb Trainee Recognition Day Award in Translational Research, The University of Texas MD Anderson Cancer Center for: "Drosophila melanogaster: A mini-host model to study Aspergillus virulence and the efficacy of antifungals in invasive aspergillosis", 2004  
Clinical Infectious Diseases Award for Outstanding Review, 2005, 2008

First place winner (mentor of Dr. M Lionakis), research poster competition for "Combinatorial selection of targeting peptides in a murine model of invasive pulmonary aspergillosis," Annual Meeting of the Texas Academy of Internal Medicine (TAIM), 2005

First place winner (mentor of Dr. M Lionakis), research poster competition for "Drosophila melanogaster as an alternative in vivo model to study candidiasis," Bristol-Myers Squibb Trainee Recognition Day Award in Translational Research, The University of Texas MD Anderson Cancer Center, 2005

Top Reviewer, Journal Infectious Diseases, 2005

Houston's Top Doctors, H Texas Magazine, 2006

Koenig Visiting Professor, Vanderbilt University, 2006

Nominee, Robert M Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center, 2006, 2008, 2010, 2014

Ranked among top reviewers, Annals Internal Medicine, 2006

The Kimberly Patterson Fellowship in Leukemia Research (mentor of Dr. G Chamilos), 2007

The University Cancer Foundation Faculty Achievement Award For Clinical Care, The University of Texas MD Anderson Cancer Center, 2007

America's Top Physicians, Consumers Research Council of America, 2008, 2009

Elected Member, Immunocompromised Host Society Council, 2008-present

First place winner (mentor of Dr. G. Hamilos), basic research poster competition for "Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis," 2nd Infections in Cancer Symposium, 2008

The Kimberly Patterson Fellowship in Leukemia Research (mentor for Dr. K. Leventakos), 2008

The Shannon Timmins Fellowship in Leukemia Research (mentor of Dr. R. Ben-Ami), 2008

IDSA Program Committee, IDSA, 2009-2012

Top Ten Papers in Medical Mycology, ICAAC Annual Meeting, 2009, 2010, 2015, 2016

Top Ten Papers in Medical Mycology, IDSA Annual Meeting, 2009, 2010, 2015

Award Winner for "Monitoring of Innate Cellular Immune Responses in Chronic Lymphocytic Leukemia-A Pilot Study," Hematologic Malignancies Conference, 2010

Featured as Innovative Researcher, *Microbe*, Official Journal of the American Society of Microbiology, 2010

Outstanding Intellectuals for the 21st Century, International Biographical Center, 2010

ASM/ICAAC fellow abstract travel award (mentor for Dr. Manuri), 2011

Fellow Abstract Travel Award (mentor for Dr. Chitasombat), IDSA, 2011

Frances King Black Endowed Professorship, The University of Texas MD Anderson Cancer Center, 2011

Invited Keynote Speaker, Golden Jubilee, German Mycology Society, 2011

Provost's Distinguished Clinical Faculty Mentor Award, The University of Texas MD Anderson Cancer Center, 2012

Billy H Cooper Memorial Award, Medical Mycology Society of Americas, 2013

Fellow Abstract Travel Award (mentor for Dr. Farmakiotis), IDSA, 2013

First place winner (Dr. F Shirazi), basic research poster competition, 3rd Infections in Cancer Symposium for "Azoles and hyperthermia induced apoptosis in *R. oryzae*," The University of Texas MD Anderson Cancer Center, 2013

Key Note Lecturer, Division F, Annual American Society of Microbiology Meeting, 2013



Second place winner (mentor for Dr. F. Shirazi), Amgen Trainee Recognition Award in Basic Research for "An obesity *Drosophila* model of mucormycosis," The University of Texas MD Anderson Cancer Center, 2013

American Society for Microbiology Distinguished Lecturer, 2014-2016

Clinical Research Mentor Category Winner (mentor of Dr. D. Farmakiotis), Medicine Housestaff Research Symposium, Baylor College of Medicine, 2014

Inaugural R. Lee Clark Fellowship, physician scientist category (mentor of Dr. Samuel Shelburne), The University of Texas MD Anderson Cancer Center, 2014-2016

Mycoses Study Group Steering Committee, 2014

President's Recognition for Faculty Excellence, 2014

Americas Top Doctors, 2015

DrouhetLife Time Achievement Award in Mycology, European Federation of Medical Mycology/EORTC, 2015

Faculty Educator of the Month, The University of Texas MD Anderson Cancer Center, 2015

A. Milton Huppert Graduate Student Award, Medical Mycology Society of America (Mentor of Alexander Tatara), 2016

Among the 100 Most Influential Scientists of Greek Descent,  
<https://www.yumpu.com/en/document/view/55602879/mostcitedgreekscientists/>, 2016

Award Winner, Best Poster for the Clinical Cyrus Scholar Award (Mentor of Alexander Tatara), Division of Internal Medicine Research Retreat, 2016

Elected Inaugural Member at Large on the Board of Directors, Mycoses Study Group Education and Research Consortium, 2016-present

Emeritus Member, Paul-Ehrlich-Society, 2016-present

Inaugural Emeritus Fellow, Academy of the European Confederation of Medical Mycology, 2016-present

Keynote Speaker, ICHS Meeting, 19th ICHS Santiago, Chile, 2016

Master Clinicians Panel, Difficult Cases in Infectious Diseases, ID Week, 2016

Maxwell Littman Award, Medical Society of New York, 2016

President Elect, Immunocompromised Host Society, 2016-2018

TJ Walsh Junior Faculty Award, Medical Mycology Society of America (Mentor of D. Farmakiotis, MD), 2016

Best Doctors In America, 2017-2018, 2019-2020

Fellow, American Academy of Microbiology, 2017

Fellow, American Association for the Advancement of Science, Elected for "Distinguished contributions to medical/ translational mycology through advances in antifungal pharmacology, study host defenses against fungi, novel diagnostics, clinical trials, professional service and life-saving patient care", 2017

Global Academic Programs Best Poster Award, The University of Texas M.D. Anderson Cancer Center, 2017

Honorary Doctorate (PhD, *honoris causa*), National and Kapodistrian University of Athens, 2017

Medical Scholar Award (Mentor of Alexander Tatara), IDSA Foundation, 2017

The Texas 4000 Distinguished Endowed Professor for Cancer Research, 2017

Top Mycology Expert Worldwide, Expertscape.com, 2017-present

Board of Directors, Secretary, Mycoses Study Group Executive Committee, 2018

Elected Member, in class II-Medicine, European Academy of Sciences and Arts (Academia Scientiarum et Artium Europaea), 2018-present

Keynote Speaker, 16th InFocus, Santiago de Cali, Colombia, 2018

Lifetime Award for Excellence in Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases, 2018

Program lead, MDACC Diamond Status of Excellence in Mycology, European Confederation of Medical Mycology, 2018

2019, Listed in the 1% of most highly cited and influential researchers world-wide, Web of Science Group, 2019-present

First place winner (mentor of Dr. S Wurster), Bristol-Myers Squibb Trainee Recognition Day Award in Translational Research, The University of MD Anderson Cancer Center for, "Establishment of a novel high-throughput fungal infection model in zebrafish larvae by controlled ablation of epithelial cells", 2019

ID Week 2019 Fellow Abstract Travel Award (Mentor for Dr. D. Axel-House), 2019

Invited Speaker, Leukemia Department Legends Series, The University of Texas MD Anderson Cancer Center, 2019

Nominated for the University of Texas System Kenneth I Shine, MD Academy of Health Science Education, 2019

Rhoda Benham Lifetime Achievement Award in Medical Mycology, Medical Mycology Society of the Americas, 2019

Senior chair, American Society of Transplantation and Cellular therapy guidelines for prevention and management of aspergillosis, 2019-2021

Senior lead, CDC/MSG ERC/EFMM consensus panel for guidance of the role of molecular techniques to identify fungi in tissues, 2019-2021

Top Mycology Expert in fungal lung disease, Expertscape/Medscape, 2019

"World Expert" in Mycology (top 0.1% of scholars writing about Mycoses over the past 10 years), Expertscape, 2020-present

2020 Excellence in LEADership award, MD Anderson Cancer Center, 2020

Aspergillosis Guidelines Chair, American Society for Transplantation & Cellular Therapy, 2020

Highly Cited Researchers (h>100) according to Google Scholar Citations public profiles, Webometrics.Info, 2020

Honorary Doctorate (PhD, *honoris causa*), Aristotle University of Thessaloniki, 2020

Honorary Fellow, European Society of Clinical Microbiology & Infectious Diseases, 2020

Robert F Gagel Lifetime Achievement Award, Division of Internal Medicine, MD Anderson Cancer Center, 2020

Top Doctor, Castle Connolly, 2020

2021, World Academy of Sciences, Member, 1st class (Medicine), 2021

Gerald P Bodey Sr Distinguished professorship award, 2021

Expert, WHO Global Antimicrobial Resistance Research Agenda on One Health, 2022

Expert, WHO Global Antimicrobial Resistance Research Agenda on One Health, 2022

Fellow, Royal College of Physicians, 2022

Elected Member, American Association of Physicians (AAP), 2023

Named award, The Dimitrios P Kontoyiannis junior investigator award in Medical Mycology, by the Hellenic Society in Medical Mycology, 2023



President-Elect, Mycoses Study Group Education and Research Consortium (MSGERC), 2024-2026

## RESEARCH

### Grants and Contracts

#### Funded

Principal Investigator, Redirected T Cell Therapy to Cure Invasive Fungal Infections (no-cost extension 11/2022), 4R33AI127381 (no-cost extension 11/2022), NIH/NIAID, 12/1/2018-11/30/2021, \$1,802,232

Principal Investigator, Post influenza aspergillosis and the effect of a liposomal amphotericin B and oseltamivir in a corticosteroid-immunosuppressed murine model of influenza., Gilead, Inc., 11/1/2020-11/1/2022, \$206,000

Principal Investigator, Direct and immune cell-mediated synergism of isavuconazole and micafungin against echinocandin-resistant *Candida glabrata*, echinocandin-resistant *Candida auris*, and azole-resistant *Aspergillus fumigatus*, Astellas, Inc., 11/2021-11/2023, \$128,061

Principal Investigator, Development of an acute myeloid leukemia murine model of invasive pulmonary aspergillosis to gain insights into the role of leukemia and its treatments in the pathobiology of aspergillosis, 1R03 AI 166285-01A1, NIH/NCRR, 1/2022-12/31/2023, \$162,000

#### Pending

Principal Investigator, Defining the isavuconazole dose escalation ceiling against Mucorales, 203, 278S, contract pending, Astellas, Inc. (\$203,278/year)

Principal Investigator, Exploring the synergy of isavuconazole and immunomodulators in a neutropenic mouse model of mucormycosis, contract pending, Astellas, Inc., \$171,642

#### Other

Faculty Member, Texas Medical Center Training Program in Antimicrobial Resistance, Faculty Member T35, T35-Training Grant, Texas Medical Center, PI - Cesar Arias, MD, 7/1/2019-7/1/2024, \$1,265,013

#### Completed

Co-Principal Investigator, 1%, Role of the Gastrointestinal Microbiome in Cancer Patient Care, LS-MRP-2015, Multidisciplinary Research Program (MRP), PI - Shpall/Kontoyiannis, 5/1/2015-4/30/2018, \$100,000

Principal Investigator, 1%, Comparative in vitro Pharmacodynamic of Isavuconazole with other clinically-used antifungals against clinical and laboratory strains of *Aspergillus*, *Zygomycetes*, *Fusarium*, *Scedosporium* and *phaeohyphomycetes*, CRES-15K02/03, Astellas, Inc., 8/1/2016-10/30/2018, \$97,167 (\$59,861/year)

Principal Investigator, Redirected T Cell Therapy to Cure Invasive Fungal Infections, 4R21AI127381-01, NIH, 12/5/2016-11/30/2018, \$272,631

Principal Investigator, 1%, Study of the check point inhibitors with or without antifungals on the natural history of invasive pulmonary aspergillosis, MD Anderson Cancer Center, Institutional Research Grant, 7/10/2017-7/10/2018, \$75,000

Principal Investigator, 1%, Study of the check point inhibitors with or without antifungals on the natural history of invasive pulmonary aspergillosis, RO3AI37754, NIH, 1/25/2018-12/31/2019, \$160,000

Principal Investigator, 0.6 months, Invasive Mold Infections at MD Anderson pre and post hurricane Harvey, CDC 75D30119C05279, Centers for Disease Control (CDC), 7/15/2019-11/14/2020, \$159,904

Principal Investigator, Hyperglycemic and obese *Drosophila melanogaster* flies as a model organism to study combined insulin sensitizing and antifungal therapy to mitigate invasive mucormycosis, Adverse Incidence Bridge Funding Committee, MDACC, 12/1/2020-12/1/2021, \$74,930

**Not Funded**

N/A

**Protocols**

**Funded**

Site Principal Investigator, An open label, non-comparative study of FK463 for the treatment of invasive aspergillosis, DM99-022, 1998-2001, \$70,000, Fujisawa Healthcare, Inc

Site Principal Investigator, An open label, non-comparative study of FK463 in the treatment of patients with candidemia or invasive candidiasis, DM99-027, 1998-2001, \$70,000, Fujisawa Healthcare, Inc

Site Principal Investigator, A Phase 3, randomized, double-blind, comparative trial of FK463 versus fluconazole for prophylaxis of fungal infections in patients undergoing a hematopoietic stem cell transplant, DM99-366, 1999-2000, \$175,000, Fujisawa Healthcare, Inc

Principal Investigator, A multi-center, open non-comparative study to estimate the safety, tolerability and efficacy of caspofungin acetate in combination with amphotericin B, lipid formulations of amphotericin B or azoles in the treatment of invasive Aspergillus infections in adults who are refractory to or intolerant of standard therapy, ID03-0093, 2003-2004, \$50,000, Merck & Co, Inc.

Principal Investigator, A phase 2, open label, non-comparative trial of micafungin (FK463) in combination with liposomal amphotericin B (ambisome®) as first-line therapy in the treatment of invasive aspergillosis, DM02-350, 2003, \$20,000, Fujisawa Healthcare, Inc

Site Principal Investigator, A multi-center, open, non-comparative study to estimate the safety, tolerability and efficacy of caspofungin acetate in the treatment of adults with invasive Candida infections (excluding patients with candidemia as the sole site of infection), 2004-0300, 2004-2006, \$48,000, Merck & Co, Inc

Site Principal Investigator, A phase 3, randomized, double-blind, comparative study of micafungin (FK463) vs. caspofungin as antifungal treatment in patients with invasive candidiasis or candidemia, 2004-0299, 2004-2006, \$21,000, Fujisawa Healthcare, Inc

Principal Investigator, A Multicentre, double blind, comparative, randomized study to evaluate the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (Ambisome) in the treatment of invasive candidiasis and candidemia, 2003-0417, 2004-present, \$75,000, Fujisawa Healthcare, Inc

Site Principal Investigator, DEFEAT Mucor phase I study of the combination of defrasirox with Ambisome, 2007-0188, 2007-2010, \$45,000 (\$45,000/year), Novartis, Inc

Principal Investigator, Evaluation of efficacy, tolerability and patient factors associated with posaconazole and voriconazole prophylactic use in patients with leukemia and hematopoietic stem cell transplantation, 2011-2012, \$47,000, Pfizer, Inc.

Principal Investigator, Weekly liposomal amphotericin B as seprimary or secondary prophylaxis in high risk patients with hematologic malignancy, 2011-2012, \$57,000, Astellas, Inc.

Co-Principal Investigator, Incidence of cutaneous squamous cell carcinoma and melanoma associated with prolonged use of voriconazole and posaconazole therapy at MD Anderson Cancer Center-5 year experience, 2011-2013, \$50,000, Merck & Co, Inc.

Micafungin treatment in candidemic patients with cancer: The MD Anderson Experience, 2013-2014 (\$57,000/year), Astellas, Inc.

Site Principal Investigator, T2 Biosystems, Detecting Infections Rapidly and Easily for Candidemia Trail (DIRECT Study) - Part 1 Prospective Collection and Freezing of Whole Blood Specimens, 2013-2015, \$100,000

Principal Investigator, Institutional Knowledge GAP Proposal, Integrated Program in Toxicity Genomics in Patients with Acute Myelogenous Leukemia/MDS, 2013-present, \$200,000

Co-Investigator, A Phase I Trial of a Conditionally Replication-Competent Adenovirus (Delta-24-RGD-4C) for Recurrent Malignant Gliomas, ID01-310, 2015

Co-Investigator, "A Phase Ib Investigation of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Treatment-Refractory Solid Tumors", 2017-0008, 2016

Principal Investigator, Open-Label Study for primary prophylaxis with Isavuconazole in patients with acute leukemia receiving remission-induction chemotherapy, 2017-2019, \$647,000, Astellas, Inc.

Principal Investigator, A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species, PA16-0975, 2018-2019, \$164,050, Astellas, Inc.

Co-Investigator, Monitoring detoxifying and rebalancing metals during AML and MDS therapy, PA 2017-0752, 2018

Co-Principal Investigator, An open-label single-arm Phase IIB study of F901318 as treatment of invasive fungal infections due to Lomentospora/Scedosporium spp., Aspergillus spp., and other resistant fungi in patients lacking suitable alternative treatment, 2019-0104, PI - Bruno Granwehr, MD, 2019, F2G Ltd.

**Unfunded**

N/A

**Patents and Technology Licenses**

**Patents**

UT MD Anderson Cancer Center, One of the Inventors in the Ziopharm/Lutrexon License Agreement. Manufacture of Clinical-grade T Cells Using Sleeping Beauty (SB) System and Artificial Antigen Presenting Cell (aAPC) Platform, United States, MDA13-113, 2/2015, Issued

Rice Tech ID (Rice Ref.: 2016-077-03), Polydiol Fumarates and Polydiol Fumarate Co-Succinate, United States, 16/146, 258, Issued

UT MD Anderson Cancer Center, Biopanning as an approach to study the pathogenesis of and invent novel treatment modalities for invasive aspergillosis, United States, 60/502, Filed

UT MD Anderson Cancer Center, Fungus-Specific Imaging Agents, United States, MDA 06-061, Filed

UH & UT MD Anderson Cancer Center, Theranostic Liposomes for invasive pulmonary aspergillosis, United States, Filed

**Technology Licenses**

N/A

**Grant Reviewer/Service on Study Sections**

National Institute of Allergy and Infectious Diseases (NIAID)/Mycoses Study Group, Member, 1999-2012

Mycoses Study Group/CDC TRANSNET Study, Data Review Committee, NIAID, Member, 2000-present

NIAID/NIH Division of Extramural Activities, NIAID/NIH, Reviewer, 2002

PO1 Grant Reviewer, National Cancer Institute (NCI/NIH), 2002

Research Steering Committee Member, NIAID Bacteriology and Mycology Study Group (Risk group 1), 2004-2008

Reviewer, Promotion and Tenure Committee, NIH/NCI, Ad Hoc Member, 2004

Centers of Disease Control and Prevention (CDC) National Center for Infectious Diseases/National Institute for Occupational Safety and Health, Ad Hoc Reviewer, "Prevention strategies and possible health effects in the aftermath of hurricanes Katrina and Rita", 2005

Consensus Panel Member, EORTC/BAMSG, "Defining responses to therapy and study outcomes in clinical trials of invasive fungal infections", EORTC/BAMSG, Member, 2005

Grant Reviewer, Cancer Research UK, 2005

Reviewer, Promotion and Tenure Committee, University of Buffalo, Ad Hoc Member, 2005

Reviewer, Promotion and Tenure Committee, The University of Chicago, Ad Hoc Member, 2005

Study Section Grant Reviewer, Italian Association for Cancer Research, 2005

Reviewer, Promotion and Tenure Committee, The University of Wisconsin, Ad Hoc Member, 2006

Reviewer, The Wellcome Trust, London, UK, 2006

ISHAM A. terreus working group (TerrNet), ISHAM, Member, 2006-present

Reviewer, Promotion and Tenure Committee, UCLA, Ad Hoc Member, 2007-2010

MSG/EORTC/Pfizer Protocol A881009, Protocol Committee, Member of the Steering Committee, A prospective, randomized trial comparing the efficacy of anidulafungin and voriconazole in combination to that of voriconazole alone when used for primary therapy of proven or probable invasive aspergillosis., 2007-2012

Reviewer, Promotion and Tenure Committee, Memorial Sloan-Kettering Cancer Center, Ad Hoc Member, 2007-2013

Executive Committee for "Interest Group" in Transplant Recipient and Immunocompromised Hosts, IDSA, Member, 2007-2014

Aspergillosis Guidelines Committee, Infectious Diseases Society of America, Member, 2007-2016

Reviewer, Health, Welfare and Food Bureau, Hong Kong SAR Government Research Fund, 2007

Reviewer, Promotion and Tenure Committee, Oregon Health & Science University, Ad Hoc Member, 2007

Reviewer, Promotion and Tenure Committee, Wayne State University, Ad Hoc Member, 2007

Educational Committee, Mycoses Study Group, Member, 2007-present

Reviewer, Promotion and Tenure Committee, University of Pennsylvania Children's Hospital, Ad Hoc Member, 2008

Reviewer, Promotion and Tenure Committee, Johns Hopkins University School of Medicine, Ad Hoc Member, 2009

Reviewer, Promotion and Tenure Committee, University of Minnesota, Ad Hoc Member, 2009

Reviewer, UK National Center for replacement, refinement and reduction of animals in research, Member, 2009

Reviewer, Promotion and Tenure Committee, Univ of Alabama/School of Medicine, Ad Hoc Member, 2010-2014

Reviewer, Promotion and Tenure Committee, Duke University, Ad Hoc Member, 2010-2014

NIH Study Section, Drug Discovery, 2010

Reviewer, Promotion and Tenure Committee, University of Michigan, Ad Hoc Member, 2010

Reviewer, Promotion and Tenure Committee, Sackler School of Medicine, Tel Aviv University, Ad Hoc Member, 2010

Reviewer, Promotion and Tenure Committee, Univ of California, San Diego/School of Medicine, Ad Hoc Member, 2010

Reviewer, Promotion and Tenure Committee, Univ of Minnesota, Ad Hoc Member, 2010

Reviewer, Promotion and Tenure Committee, UCLA, Ad Hoc Member, 2010

Reviewer, Promotion and Tenure Committee, University of Toronto, Member, 2010

Non-HIV Immunocompromised host development panel, IDSA, Member, 2010-present  
Working group on Zygomycetes, ECMM/ISHAM, Member, 2010-present  
Ad Hoc Reviewer, Hellenic Research Program Thalys, 2011-2012  
IDSA MOC Development Panel, Member, 2011-2012  
Ad Hoc clinical expert's panel; fungal meningitis epidemic treatment guidelines, MSG/CDC, 2012-2013  
DRC Group Leader, A phase 3 randomized, double-blind study of isavuconazole versus voriconazole for invasive aspergillosis, MSG/EORTC/Astellas, 2012-2013  
Reviewer, Promotion and Tenure Committee, University of Washington, Ad Hoc Member, Fred Hutchinson Research Cancer Center, 2012  
Reviewer, Promotion and Tenure Committee, Tufts University, Ad Hoc Member, 2012  
Reviewer, SSC grants pre-award, Research Council UK, 2012  
Steering Committee, Mycoses Study Group, Member, 2012-present  
Reviewer, Promotion and Tenure Committee, The University of Chicago, Ad Hoc Member, 2013-2014  
External review panelist, Department of Infectious Diseases, St. Jude Children's Research Hospital, 2013  
Reviewer, Australian Science Fund (FWF), 2013  
Reviewer, Promotion and Tenure Committee, Warren Alpert Medical School of Brown University, Ad Hoc Member, 2013  
Reviewer, Promotion and Tenure Committee, University of Virginia, Ad Hoc Member, 2013  
Reviewer, Promotion and Tenure Committee, Hellenic Research Program Aristeia, 2013  
Diagnosis Subcommittee, Mycoses Study Group, Co-Chair, 2013-present  
Reviewer, Promotion and Tenure Committee, McGill University, Ad Hoc Member, 2014  
Reviewer, Promotion and Tenure Committee, University of Patras (Patras, Greece), 2014  
Reviewer, Promotion and Tenure Committee, University of Thessaloniki Greece, 2014-present  
Reviewer, Promotion and Tenure Committee, University of Athens (Athens, Greece), 2014-present  
Reviewer, Award Committee, Medical Mycology Society of Americas, Member, 2015  
Reviewer, Promotion and Tenure Committee, Johns Hopkins University School of Medicine, Ad Hoc Member, 2015  
Reviewer, Promotion and Tenure Committee, University of Crete (Heraklion, Crete), 2015  
Advisory Board Member, Center for Clinical Epidemiology and Outcomes (CLEO), Athens, Greece, 2015-present  
Data Review Committee, International Pediatric Fungal Network, Member, 2016  
Reviewer, Dunn Collaborative Research Award Program, Ad Hoc Member, 2016  
Reviewer, Promotion and Tenure Committee, Baylor College of Medicine, 2016  
Reviewer, Promotion and Tenure Committee, University of New Mexico, 2016  
Reviewer, Translational Research Program, University of Patras, Greece, Unknown, 2016  
Special Advisor, CDC/Mycotic Diseases Branch, 2016  
Board of Directors, Mycoses Study Group Education and Research Consortium (MSGERC), Member, 2016-present



ESCMID Fungal Study Group, Member, 2016-present  
Founding Member, Mycoses Study Group Education and Research Consortium (MSGERC), 2016-present  
UT Center for Antimicrobial Resistance and Microbial Genomics, Member, 2016-present  
Reviewer, Promotion and Tenure Committee, American University of Beirut, Ad Hoc Member, 2017  
Reviewer, Promotion and Tenure Committee, Harvard Medical School, Ad Hoc Member, 2017  
Reviewer, Promotion and Tenure Committee, NIH, Ad Hoc Member, 2017  
Reviewer, Promotion and Tenure Committee, UT Health Sciences Center San Antonio, Ad Hoc Member, 2017  
Reviewer, Promotion and Tenure Committee, Yale University, Ad Hoc Member, 2017  
Reviewer, Promotion and Tenure Committee, Rutgers Cancer Institute, Ad Hoc Member, 2017  
Reviewer, Promotion and Tenure Committee, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, Ad Hoc Member, 2017  
ECCMM Working Group on Immunologic markers for diagnosis and treatment monitoring in invasive mold infections, Member, 2018  
Reviewer, NIAID R21/R33 Special Emphasis Review Study Section, Reviewer, 2018  
Reviewer, ZonMw Netherlands Awards in Science, Reviewer, 2018  
Texas Medical Center C. Auris Working Group, Member, 2018  
Mycoses Study Group Education and Research Consortium (MSGERC), Secretary and Member of the Executive Board, Member, 2019-2022  
Advisory Committee, CARMIG/McGovern Medical School, Member, 2019  
Reviewer, Promotion and Tenure Committee, Mayo Clinic College of Medicine, Ad Hoc Member, 2019  
Reviewer, Promotion and Tenure Committee, Ben Gurion University, Israel, Ad Hoc Member, 2019  
Reviewer, Promotion and Tenure Committee, Duke University, Ad Hoc Member, 2019  
Reviewer, Promotion and Tenure Committee, University of Alberta, Ad Hoc Member, 2019  
Reviewer, Promotion and Tenure Committee, San Antonio Military Medical Center, Brooke Army Medical Center, Ad Hoc Member, 2019  
Advisory Board, Center of Bio Medical Research and Education, Aristotle University of Thessaloniki, Greece, Member, 2019-present  
Chair, Data Review Committee, Mycoses Study Group #16 Nature - US Study, Chair, 2020  
Chair, Recommendations for antifungal stewardship, MSGERC writing team, Chair, 2020  
Data Review Committee, A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA), Verona, Member, 2020  
Reviewer, Promotion & Tenure Committee, University of California, San Diego, Ad Hoc Member, 2020  
Reviewer, Promotion and Tenure Committee, Tel Aviv Sourasky Medical Center, Ad Hoc Member, 2020  
Reviewer, Promotion and Tenure Committee, Memorial Sloan Kettering Cancer Center, Weill Corn, Ad Hoc Member, 2020

Scientific Advisory Board, Center for Clinical Epidemiology and Outcomes Research, National & Kapodistrian University of Athens, GR, Member, 2020

Advisory Board, Post Graduate Studies Program, University of Crete Medical School, Member, Heraklion, Greece, 2020-present

Data Review Committee, Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin vs Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Allogeneic Blood and Marrow Transplantation (ReSPECT Study), Member, 2020-present

Infectious Diseases and Immunology Study Section, NIH, Ad Hoc Reviewer, 2021

Reviewer, Canada Research Chair Nomination, McGill University, Canada, Member, 2021

Reviewer, Endowed Chair Committee, University of Virginia, Ad Hoc Member, 2021

Reviewer, Promotion and Tenure Committee, McGovern Medical School at UT Health, Ad Hoc Member, 2021

Reviewer, Promotion and Tenure Committee, University of Michigan, Ad Hoc Member, 2021

Reviewer, Promotion and Tenure Committee, Boston Children's Hospital/Harvard Medical School, Ad Hoc Member, 2021

Reviewer, Promotion and Tenure Committee, Baylor College of Medicine, Houston, TX, Ad Hoc Member, 2021

Reviewer, Promotion and Tenure Committee, Ben Gurion University at Negev, Israel, Ad Hoc Member, 2021

Reviewer, Rhoda Benham Lifetime Achievement Award Selection Committee, Medical Mycology Society of the Americas, Ad Hoc Member, 2021

Cystic Fibrosis Research Institute, Grant Reviewer, 2022

DynaMed, ACP topic reviewer, 2022

Expert reviewer, National Organization for Rare Disorders, Mucormycosis, Member, 2022

Reviewer, Clinical Research and Field Studies Special NIH Study Section, NIH, Reviewer, 2022

Reviewer, Etiology, Diagnostic, Intervention and Treatment of Infectious Diseases EDIT Study Section, NIH, Ad Hoc Member, 2022

Reviewer, Promotion and Tenure Committee, Harvard Medical School, Ad Hoc Member, 2023

Allergy, Immunology and Transplantation Research Committee Study Section, NIH, Ad Hoc Member, 2023

## PUBLICATIONS

### Peer-Reviewed Original Research Articles

1. Anaissie E, **Kontoyiannis DP**, Kantarjian H, Elting L, Robertson LE, Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. *Ann Intern Med* 117(6):466-9, 9/1992. PMID: 1354425.
2. Kantarjian, HM, Talpaz M, **Kontoyiannis DP**, Gutterman J, Keating MJ, Estey EH, O'Brien S, Rios MB, Beran M, Deisseroth A. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony stimulating factor. *J Clin Oncol.* 3:398-405, 1992.
3. Anaissie EJ, **Kontoyiannis DP**, Vartivarian S, Kantarjian HM, O'Brien S, Giralt SA, Andersson BS, Karl C, Champlin RE, Bodey GP. Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. *Clin Infect Dis* 17(6):1022-31, 12/1993. PMID: 8110925.
4. **Kontoyiannis DP**, Vartivarian S, Anaissie EJ, Samonis G, Rinaldi M, Bodey GP. *Cunninghamella bertholletiae* infections in patients with leukemia: Report of three cases and review. *Clin Infect Dis* 18:925-928, 1994.

5. Anaissie EJ, **Kontoyiannis DP**, Huls C, Vartivarian SE, Karl C, Prince RA, Bosso J, Bodey GP. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. *J Infect Dis* 172(2):599-602, 8/1995. PMID: 7622915.
6. **Kontoyiannis DP**, Calia KE, Basgoz N, Calderwood SB. Primary septicemia caused by *Vibrio cholerae* non-O1 acquired on Cape Cod, Massachusetts. *Clin Infect Dis* 21(5):1330-3, 11/1995. PMID: 8589171.
7. Anaissie EJ, Samonis G, **Kontoyiannis DP**, Raad I, Rosenbaum B, Sabharwal U, Costerton JW, Bodey GP. Biofilm and Central venous catheter-related infections: Evidence of universal colonization and low risk of hematogenous seeding. *Eur J Clin Microbiol* 14:134-137, 1995.
8. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, **Kontoyiannis DP**, Khoury P, Papadakis K, Gardner A, Raad II, Gilbreath J, Bodey GP. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. *Am J Med* 101(2):170-6, 8/1996. PMID: 8757357.
9. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, Williams T, **Kontoyiannis DP**, Karl CL, Bodey GP. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. *Clin Infect Dis* 23(5):964-72, 11/1996. PMID: 8922787.
10. **Kontoyiannis DP**, Ruoff K, Hooper DC. *Nocardia* bacteremia. Report of 4 cases and review of the literature. *Medicine (Baltimore)* 77(4):255-67, 7/1998. PMID: 9715730.
11. Anaissie EJ, **Kontoyiannis DP**, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. *Ann Intern Med* 129(7):559-66, 10/1998. PMID: 9758577.
12. **Kontoyiannis DP**. Genetic analysis of azole resistance by transposon mutagenesis in *Saccharomyces cerevisiae*. *Antimicrob Agents Chemother* 43(11):2731-5, 11/1999. PMID: PMC89561.
13. **Kontoyiannis DP**, Sagar N, Hirschi KD. Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in *Saccharomyces cerevisiae*. *Antimicrob Agents Chemother* 43(11):2798-800, 11/1999. PMID: PMC89564.
14. **Kontoyiannis DP**. Fluconazole inhibits pseudohyphal growth in *Saccharomyces cerevisiae*. *Chemother* 46(2):100-3, 3/2000. PMID: 10671759.
15. **Kontoyiannis DP**, Rupp S. Cyclic AMP and fluconazole resistance in *Saccharomyces cerevisiae*. *Antimicrob Agents Chemother* 44(6):1743-4, 6/2000. PMID: PMC89950.
16. **Kontoyiannis DP**, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. *Clin Infect Dis* 30(6):851-6, 6/2000. PMID: 10852735.
17. **Kontoyiannis DP**, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. *Clin Infect Dis* 31(1):188-9, 7/2000. PMID: 10913421.
18. **Kontoyiannis DP**, Jacobson KL, Whimbey EE, Rolston KV, Raad II. Central venous catheter-associated *Nocardia* bacteremia: an unusual manifestation of nocardiosis. *Clin Infect Dis* 31(2):617-8, 2000. PMID: 10987735.
19. **Kontoyiannis DP**. Efflux-mediated resistance to fluconazole could be modulated by sterol homeostasis in *Saccharomyces cerevisiae*. *J Antimicrob Chemother* 46(2):199-203, 2000. PMID: 10933641.
20. Tsiodras S, Samonis G, Keating MJ, **Kontoyiannis DP**. Infection and immunity in chronic lymphocytic leukemia. *Mayo Clin Proc* 75(10):1039-54, 2000. PMID: 11040852.
21. **Kontoyiannis DP**, Lewis RE, Sagar N, May G, Prince RA, Rolston KV. Itraconazole-amphotericin B antagonism in *Aspergillus fumigatus*: an E-test-based strategy. *Antimicrob Agents Chemother* 44(10):2915-8, 2000. PMID: 10991890.
22. **Kontoyiannis DP**. Modulation of fluconazole sensitivity by the interaction of mitochondria and erg3p in *Saccharomyces cerevisiae*. *J Antimicrob Chemother* 46(2):191-7, 2000. PMID: 10933640.
23. LaRosa A, Champlin RE, Gajewski J, Giral S, Rolston KVI, Raad I, Jacobson K, **Kontoyiannis DP**, Elting L, Whimbey E. Adenovirus infections in adult blood and marrow transplant recipients. *Clin Infect Dis* 32:871-876, 2001.
24. Mattiuzzi, GN Kantarjian H, Faderl S, Lim J, **Kontoyiannis DP**, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as



- prophylaxis in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. *Cancer* 100(3):581-589, 2001.
25. **Kontoyiannis DP**, Peitsch WK, Reddy BT, Whimbey EE, Han XY, Bodey GP, Rolston KV. Cryptococcosis in patients with cancer. *Clin Infect Dis* 32(11):E145-50, 2001. PMID: 11340547.
  26. **Kontoyiannis DP**, Tarrand J, Prince R, Samonis G, Rolston KV. Effect of fluconazole on agar invasion by *Candida albicans*. *J Med Microbiol* 50(1):78-82, 2001. PMID: 11192509.
  27. Samonis G, Maraki S, Hajjiioannou I, Chatzinikolaou I, Rolston KV, Bodey GP, **Kontoyiannis DP**. Effect of ketoconazole, itraconazole and fluconazole on the gastrointestinal colonization of mice by *Candida albicans*. *J Chemother* 13(1):66-9, 2001. PMID: 11233803.
  28. **Kontoyiannis DP**, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. *Mycoses* 44(5):125-35, 2001. PMID: 11486448.
  29. **Kontoyiannis DP**, Andersson BS, Lewis RE, Raad II. Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. *Clin Infect Dis* 32(5):E94-6, 2001. PMID: 11229866.
  30. Maraki S, Mouzas IA, **Kontoyiannis DP**, Chatzinikolaou I, Tselentis Y, Samonis G. Prospective evaluation of the impact of amoxicillin, clarithromycin and their combination on human gastrointestinal colonization by *Candida* species. *Chemotherapy* 47(3):215-8, 2001. PMID: 11306791.
  31. Oshervov N, **Kontoyiannis DP**, Romans A, May GS. Resistance to itraconazole in *Aspergillus nidulans* and *Aspergillus fumigatus* is conferred by extra copies of the A. nidulans P-450 14 $\alpha$ -demethylase gene, pdmA. *J Antimicrob Chemother* 48(1):75-81, 2001. PMID: 11418514.
  32. **Kontoyiannis DP**, Vaziri I, Hanna HA, Boktour M, Thornby J, Hachem R, Bodey GP, Raad II. Risk factors for *Candida tropicalis* fungemia in patients with cancer. *Clin Infect Dis* 33(10):1676-81, 2001. PMID: 11568858.
  33. Ghosh, S, Champlin R, Ueno N, Anderlini P, Rolston K, Raad I, **Kontoyiannis DP**, Jacobson K, Luna M, Tarrand J, Whimbey E. RSV infections in autologous blood and marrow transplant (BMT) recipients with breast cancer: combination therapy with aerosolized ribavirin and immunotherapy. *Bone Marrow Transplant* 28:271-275, 2001.
  34. Mavromanolakis E, Maraki S, Cranidis A, Tselentis Y, **Kontoyiannis DP**, Samonis G. The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by *Candida albicans*. *Scand J Infect Dis* 33(6):477-8, 2001. PMID: 11450873.
  35. **Kontoyiannis DP**, Reddy BT, Torres HA, Luna M, Lewis RE, Tarrand J, Bodey GP, Raad II. Pulmonary candidiasis in patients with cancer: an autopsy study. *Clin Infect Dis* 34(3):400-3, 2/2002. PMID: 11774088.
  36. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, Hachem RY, **Kontoyiannis DP**, Raad II. The epidemiology of *Candida glabrata* and *Candida albicans* fungemia in immunocompromised patients with cancer. *Am J Med* 112(5):380-5, 4/2002. PMID: 11904112.
  37. Lewis RE, **Kontoyiannis DP**, Darouiche RO, Raad II, Prince RA. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of *Candida* catheter-related bloodstream infection. *Antimicrob Agents Chemother* 46(11):3499-505, 2002. PMID: 12384356.
  38. **Kontoyiannis DP**, Lewis RE. Antifungal drug resistance of pathogenic fungi. *Lancet* 359(9312):1135-44, 2002. PMID: 11943280.
  39. **Kontoyiannis DP**, Reddy BT, Hanna H, Bodey GP, Tarrand J, Raad II. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and *Candida* species but not intensity. *Infect Control Hosp Epidemiol* 23(9):542-5, 2002. PMID: 12269454.
  40. Reddy BT, Torres HA, **Kontoyiannis DP**. Breast implant infection caused by *Trichosporon beigelii*. *Scand J Infect Dis* 34(2):143-4, 2002. PMID: 11928852.
  41. Samonis G, Maraki S, Anatoliotakis N, Anatoliotaki M, Apostolou H, Margioris AN, Tselentis Y, **Kontoyiannis DP**. Effects of erythromycin, clarithromycin, roxithromycin and

- azithromycin on murine gut colonization by *Candida albicans*. *Med Mycol* 40(2):139-42, 2002. PMID: 12058726.
42. Torres HA, Rivero GA, **Kontoyiannis DP**. Endemic mycoses in a cancer hospital. *Medicine (Baltimore)* 81(3):201-12, 2002. PMID: 11997717.
  43. Raad I, Tarrand J, Hanna H, Albitar M, Janssen E, Boktour M, Bodey G, Mardani M, Hachem R, **Kontoyiannis DP**, Whimbey E, Rolston K. Epidemiology, molecular mycology and environmental sources of *Fusarium* infection in cancer patients. *Infect Control Hosp Epidemiol* 23:532-537, 2002.
  44. Lewis RE, Prince RA, Chi J, **Kontoyiannis DP**. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. *Antimicrob Agents Chemother* 46(10):3208-14, 2002. PMID: 12234846.
  45. Lewis RE, Lo HJ, Raad II, **Kontoyiannis DP**. Lack of catheter infection by the *efg1/efg1 cph1/cph1* double-null mutant, a *Candida albicans* strain that is defective in filamentous growth. *Antimicrob Agents Chemother* 46(4):1153-5, 2002. PMID: 11897612.
  46. Torres HA, Reddy BT, Raad II, Tarrand J, Bodey GP, Hanna HA, Rolston KV, **Kontoyiannis DP**. Nocardiosis in cancer patients. *Medicine (Baltimore)* 81(5):388-97, 2002. PMID: 12352633.
  47. Shaikh ZH, Torres HA, Walsh GL, Champlin RE, **Kontoyiannis DP**. Open lung biopsy in bone marrow transplant recipients has a poor diagnostic yield for a specific diagnosis. *Transpl Infect Dis* 4(2):80-4, 2002. PMID: 12220244.
  48. Oshero N, May GS, Albert ND, **Kontoyiannis DP**. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in *Saccharomyces cerevisiae*. *Antimicrob Agents Chemother* 46(8):2462-9, 2002. PMID: 12121919.
  49. Keating MJ, O'Brien S, **Kontoyiannis DP**, Plunkett W, Koller C, Beran M, Lerner S, Kantarjian H. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. *Leukemia and Lymphoma* 43:1755-62, 2002.
  50. Bodey GP, Boktour M, Mays S, Duvic M, **Kontoyiannis DP**, Hachem R, Raad II. Skin lesions associated with *Fusarium* infection. *Journal of the American Academy of Dermatology* 47:659-666, 2002.
  51. Nannini EC, Keating M, Binstock P, Samonis G, **Kontoyiannis DP**. Successful treatment of refractory disseminated *Mycobacterium avium* complex infection with the addition of linezolid and mefloquine. *J Infect* 44(3):201-3, 2002. PMID: 12099753.
  52. Torres HA, Rivero GA, Lewis RE, Hachem R, Raad II, **Kontoyiannis DP**. Aspergillosis caused by non-*fumigatus* *Aspergillus* species: risk factors and in vitro susceptibility compared with *Aspergillus fumigatus*. *Diagn Microbiol Infect Dis* 46(1):25-8, 5/2003. PMID: 12742315.
  53. Hicks KL, Chemaly RF, **Kontoyiannis DP**. Common community respiratory viruses in patients with cancer: more than just "common colds". *Cancer* 97(10):2576-87, 5/2003. PMID: 12733157.
  54. Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, **Kontoyiannis DP**, Keating MJ. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. *Cancer* 98(4):773-8, 8/2003. PMID: 12910522.
  55. Liu W, Lionakis MS, Lewis RE, Wiederhold N, May GS, **Kontoyiannis DP**. Attenuation of itraconazole fungicidal activity following preexposure of *Aspergillus fumigatus* to fluconazole. *Antimicrob Agents Chemother* 47(11):3592-7, 2003. PMID: 14576123.
  56. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, Han XY, Rolston KV, Safdar A, Raad II, **Kontoyiannis DP**. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. *Medicine (Baltimore)* 82(5):309-21, 2003. PMID: 14530780.
  57. **Kontoyiannis DP**, Lewis RE, Oshero N, Albert ND, May GS. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in *Aspergillus* species. *J Antimicrob Chemother* 51(2):313-6, 2003. PMID: 12562696.
  58. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, **Kontoyiannis DP**, Giles FJ, Raad II, Verstovsek S, Ferrajoli A, Kantarjian H. Development of varicella-zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. *Clin Cancer Res* 9:976-980, 2003.

59. Pham AS, Tarrand JJ, May GS, Lee MS, **Kontoyiannis DP**, Han XY. Diagnosis of invasive mold infection by real-time quantitative PCR. *Am J Clin Pathol* 119(1):38-44, 2003. PMID: 12520695.
60. Tarrand JJ, Lichterfeld M, Warraich I, Luna M, Han XY, May GS, **Kontoyiannis DP**. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. *Am J ClinPathol* 119(6):854-8, 2003. PMID: 12817433.
61. Maraki S, Margioris AN, Orfanoudaki E, Tselentis Y, Koumantakis E, **Kontoyiannis DP**, Rovithi M, Samonis G. Effects of doxycycline, metronidazole and their combination on *Candida* species colonization of the human oropharynx, intestinal lumen and vagina. *J Chemother* 15(4):369-73, 2003. PMID: 12962365.
62. **Kontoyiannis DP**, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. *Cancer* 98(2):292-9, 2003. PMID: 12872348.
63. Han XY, Weinberg JS, Prabhu SS, Hassenbusch SJ, Fuller GN, TarrandJJ,**Kontoyiannis DP**. Fusobacterial brain abscess: a review of five cases and an analysis of possible pathogenesis. *J Neurosurg* 99(4):693-700, 2003. PMID: 14567605.
64. Lionakis MS, **Kontoyiannis DP**. Glucocorticoids and invasive fungal infections. *Lancet* 362(9398):1828-38, 2003. PMID: 14654323.
65. Torres HA, Bodey GP, Rolston KV, Kantarjian HM, Raad II, **Kontoyiannis DP**. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. *Cancer* 98(1):86-93, 2003. PMID: 12833460.
66. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, **Kontoyiannis DP**, Koller C, Munsell M, Beran M, Kantarjian H. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. *Cancer* 97(2):450-6, 2003. PMID: 12518369.
67. Rivero GA, Torres HA, Rolston KV, **Kontoyiannis DP**. *Listeria monocytogenes* infection in patients with cancer. *Diagn Microbiol Infect Dis* 47(2):393-8, 2003. PMID: 14522512.
68. Lionakis MS, Lewis RE, Samonis G, **Kontoyiannis DP**. Pentamidine is active in vitro against *Fusarium* species. *Antimicrob Agents Chemother* 47(10):3252-9, 2003. PMID: 14506038.
69. Torres HA, Bodey GP, Tarrand JJ, **Kontoyiannis DP**. Protothecosis in patients with cancer: case series and literature review. *Clin Microbiol Infect* 9(8):786-92, 2003. PMID: 14616698.
70. **Kontoyiannis DP**, Lewis RE, Lionakis MS, Albert ND, May GS, Raad II. Sequential exposure of *Aspergillus fumigatus* to itraconazole and caspofungin: evidence of enhanced in vitro activity. *Diagn Microbiol Infect Dis* 47(2):415-9, 2003. PMID: 14522515.
71. Raad, II, Escalante C, Hachem RY, Hanna HA, Husni R, Afif C, Boktour MR, Whimbey E, **Kontoyiannis DP**, Jacobson K, Kantarjian H Levett LM, Rolston KVI. Treatment of febrile neutropenic cancer patients requiring hospitalization: a prospective, randomized study comparing imipenem and cefepime. *Cancer* 98:1039-1047, 2003.
72. Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, Mavroudis D, Georgoulas V, Rolston KV, **Kontoyiannis DP**, Galanakis E, Samonis G. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. *Infection* 32(2):65-71, 4/2004. PMID: 15057569.
73. Hachem RY, **Kontoyiannis DP**, Boktour MR, Afif C, Cooksley C, Bodey GP, Chatzinikolaou I, Perego C, Kantarjian HM, Raad II. *Aspergillus terreus*: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. *Cancer* 101(7):1594-600, 10/2004. PMID: 15378491.
74. Xue T, Nguyen CK, Romans A, **Kontoyiannis DP**, May GS. Isogenic auxotrophic mutant strains in the *Aspergillus fumigatus* genome reference strain AF293. *Arch Microbiol* 182(5):346-53, 11/2004. PMID: 15365692.
75. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, **Kontoyiannis DP**, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. *Cancer* 100(3):581-9, 2004. PMID: 14745876.

76. Liu W, May GS, Lionakis MS, Lewis RE, **Kontoyiannis DP**. Extra copies of the *Aspergillus fumigatus* squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in *A. fumigatus*. *Antimicrob Agents Chemother* 48(7):2490-6, 2004. PMID: 15215099.
77. Torres HA, **Kontoyiannis DP**, Rolston KV. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study. *Support Care Cancer* 12(7):511-6, 2004. PMID: 14986077.
78. Healy M, Reece K, Walton D, Huong J, Shah K, **Kontoyiannis DP**. Identification to the species level and differentiation between strains of *Aspergillus* clinical isolates by automated repetitive-sequence-based PCR. *J Clin Microbiol* 42(9):4016-24, 2004. PMID: 15364984.
79. Safdar A, Hanna HA, Boktour M, **Kontoyiannis DP**, Hachem R, Lichtiger B, Freireich EJ, Raad II. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of *Candida* species bloodstream infections. *Cancer* 101(12):2859-65, 2004. PMID: 15529309.
80. Steinbach WJ, Benjamin DK, **Kontoyiannis DP**, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to *Aspergillus terreus*: a multicenter retrospective analysis of 83 cases. *Clin Infect Dis* 39(2):192-8, 2004. PMID: 15307028.
81. Mattiuzzi GN, Kantarjian H, O'Brien S, **Kontoyiannis DP**, Giles F, Zhou X, Lim J, Bekele BN, Faderl S, Cortes J, Pierce S, Leitz GJ, Raad I, Estey E. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. *Cancer* 100(3):568-73, 2004. PMID: 14745874.
82. Ohmagari N, Raad II, Hachem R, **Kontoyiannis DP**. Invasive aspergillosis in patients with solid tumors. *Cancer* 101(10):2300-2, 2004. PMID: 15452832.
83. Raad I, Hanna H, Boktour M, Girgawy E, Danawi H, Mardani M, **Kontoyiannis DP**, Darouiche R, Hachem R, Bodey GP. Management of central venous catheters in patients with cancer and candidemia. *Clin Infect Dis* 38:1119-1127, 2004.
84. Boktour MR, **Kontoyiannis DP**, Hanna HA, Hachem RY, Girgawy E, Bodey GP, Raad II. Multiple-species candidemia in patients with cancer. *Cancer* 101(8):1860-5, 2004. PMID: 15386338.
85. De La Rosa GR, Jacobson KL, Rolston KV, Raad II, **Kontoyiannis DP**, Safdar A. *Mycobacterium tuberculosis* at a comprehensive cancer centre: active disease in patients with underlying malignancy during 1990-2000. *Clin Microbiol Infect* 10(8):749-52, 2004. PMID: 15301678.
86. **Kontoyiannis DP**, Bodey GP, Hanna H, Hachem R, Boktour M, Girgaway E, Mardani M, Raad II. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. *Leuk Lymphoma* 45(1):139-41, 2004. PMID: 15061210.
87. Wiederhold NP, **Kontoyiannis DP**, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. *J Infect Dis* 190(8):1464-71, 2004. PMID: 15378439.
88. Lionakis MS, Bodey GP, Tarrand JJ, Raad II, **Kontoyiannis DP**. The significance of blood cultures positive for emerging saprophytic moulds in cancer patients. *Clin Microbiol Infect* 10(10):922-5, 2004. PMID: 15373888.
89. Lionakis MS, **Kontoyiannis DP**. The significance of isolation of saprophytic molds from the lower respiratory tract in patients with cancer. *Cancer* 100(1):165-72, 2004. PMID: 14692037.
90. **Kontoyiannis DP**, Torres HA, Chagua M, Hachem R, Tarrand JJ, Bodey GP, Raad II. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. *Scand J Infect Dis* 36(8):564-9, 2004. PMID: 15370667.
91. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, **Kontoyiannis DP**, Cohen A, Martin T, Giral S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. *Blood* 104(3):649-54, 2004. PMID: 15069017.
92. Lewis RE, Wiederhold NP, Lionakis MS, Prince RA, **Kontoyiannis DP**. Frequency and species distribution of gliotoxin-producing *Aspergillus* isolates recovered from patients at a tertiary-care cancer center. *J Clin Microbiol* 43(12):6120-2, 12/2005. PMID: 161317213.



93. Torres HA, Hachem RY, Chemaly RF, **Kontoyiannis DP**, Raad II. Posaconazole: a broad-spectrum triazole antifungal. *Lancet Infect Dis* 5(12):775-85, 12/2005. PMID: 16310149.
94. Stanzani M, Orciuolo E, Lewis R, **Kontoyiannis DP**, Martins SL, St John LS, Komanduri KV. *Aspergillus fumigatus* suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. *Blood* 105(6):2258-65, 2005. PMID: 15546954.
95. Tarrand JJ, Han XY, **Kontoyiannis DP**, May GS. *Aspergillus* hyphae in infected tissue: evidence of physiologic adaptation and effect on culture recovery. *J Clin Microbiol* 43(1):382-6, 2005. PMID: PMC540129.
96. Lionakis MS, Lewis RE, Chamilos G, **Kontoyiannis DP**. *Aspergillus* susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. *Pharmacotherapy* 25(9):1174-80, 2005. PMID: 16164392.
97. Wiederhold NP, **Kontoyiannis DP**, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against *Candida albicans*: possible role of cell wall integrity and calcineurin pathways. *Antimicrob Agents Chemother* 49(12):5146-8, 2005. PMID: 16304189.
98. Lewis RE, Wiederhold NP, Chi J, Han XY, Komanduri KV, **Kontoyiannis DP**, Prince RA. Detection of gliotoxin in experimental and human aspergillosis. *Infect Immun* 73(1):635-7, 2005. PMID: 15618207.
99. Lionakis MS, Lahdenranta J, Sun J, Liu W, Lewis RE, Albert ND, Pasqualini R, Arap W, **Kontoyiannis DP**. Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis. *Infect Immun* 73(11):7747-58, 2005. PMID: 16239579.
100. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, **Kontoyiannis DP**, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis* 41(5):634-53, 2005. PMID: 16080086.
101. Torres HA, **Kontoyiannis DP**, Bodey GP, Adachi JA, Luna MA, Tarrand JJ, Nogueras GM, Raad II, Chemaly RF. Gastrointestinal cytomegalovirus disease in patients with cancer: a two decade experience in a tertiary care cancer center. *Eur J Cancer* 41(15):2268-79, 2005. PMID: 16143517.
102. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, **Kontoyiannis DP**. Increased frequency of non-*fumigatus* *Aspergillus* species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. *Diagn Microbiol Infect Dis* 52(1):15-20, 2005. PMID: 15878437.
103. Ostrosky-Zeichner L, **Kontoyiannis D**, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. *Eur J Clin Microbiol Infect Dis* 24(10):654-61, 2005. PMID: 16261306.
104. **Kontoyiannis DP**, Boktour M, Hanna H, Torres HA, Hachem R, Raad II. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. *Cancer* 103(11):2334-7, 2005. PMID: 15844093.
105. Lewis RE, **Kontoyiannis DP**. Micafungin in combination with voriconazole in *Aspergillus* species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. *J Antimicrob Chemother* 56(5):887-92, 2005. PMID: 16188916.
106. Rolston KV, **Kontoyiannis DP**, Yadegarynia D, Raad II. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. *Diagn Microbiol Infect Dis* 51(3):215-8, 2005. PMID: 15766609.
107. Sipsas NV, Bodey GP, **Kontoyiannis DP**. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. *Cancer* 103(6):1103-13, 2005. PMID: 15666328.
108. Chamilos G, Marom EM, Lewis RE, Lionakis MS, **Kontoyiannis DP**. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. *Clin Infect Dis* 41(1):60-6, 2005. PMID: 15937764.

109. Lionakis MS, Lewis RE, Chamilos G, **Kontoyiannis DP**. Problems in correlation of the in vitro susceptibility testing of *Aspergillus* to amphotericin B with outcome of initial amphotericin B therapy in cancer patients with invasive aspergillosis. *Pharmacotherapy* 9:1174-1180, 2005.
110. Torres HA, Prieto VG, Raad II, **Kontoyiannis DP**. Proven pulmonary cryptococcosis due to capsule-deficient *Cryptococcus neoformans* does not differ clinically from proven pulmonary cryptococcosis due to capsule-intact *C. neoformans*. *Mycoses* 48(1):21-4, 2005. PMID: 15679661.
111. Safdar A, Rodriguez G, Ohmagari N, **Kontoyiannis DP**, Rolston KV, Raad II, Champlin RE. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. *Cancer* 103(4):731-9, 2005. PMID: 15641032.
112. Lionakis MS, Lewis RE, May GS, Wiederhold NP, Albert ND, Halder G, **Kontoyiannis DP**. Toll-deficient *Drosophila* flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and *Aspergillus* virulence. *J Infect Dis* 191(7):1188-95, 2005. PMID: 15747256.
113. Healy M, Reece K, Walton D, Huong J, Frye S, Raad II, **Kontoyiannis DP**. Use of the Diversi Lab System for species and strain differentiation of *Fusarium* species isolates. *J Clin Microbiol* 43(10):5278-80, 2005. PMID: 16207996.
114. **Kontoyiannis DP**, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II. Zygomycosis in a tertiary-care cancer center in the era of *Aspergillus*-active antifungal therapy: a case-control observational study of 27 recent cases. *J Infect Dis* 191(8):1350-60, 2005. PMID: 15776383.
115. Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, **Kontoyiannis DP**, Freireich EJ, Shpall EJ, Raad II, Kantarjian HM, Champlin RE. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. *Cancer* 106(12):2664-71, 6/2006. PMID: 16691620.
116. Sipsas NV, **Kontoyiannis DP**. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. *Clin Infect Dis* 42(11):1584-91, 2006. PMID: 16652316.
117. Singh N, Limaye AP, Forrest G, Safdar N, Muñoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del Busto R, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, **Kontoyiannis DP**, Husain S. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. *Transplantation* 81(3):320-6, 2006. PMID: 16477215.
118. Yusuf SW, Ali SS, Swafford J, Durand JB, Bodey GP, Chemaly RF, **Kontoyiannis DP**, Tarrand J, Rolston KV, Yeh E, Raad II, Safdar A. Culture-positive and culture-negative endocarditis in patients with cancer: a retrospective observational study, 1994-2004. *Medicine (Baltimore)* 85(2):86-94, 2006. PMID: 16609347.
119. Torres HA, **Kontoyiannis DP**, Aguilera EA, Younes A, Luna MA, Tarrand JJ, Nogueras GM, Raad II, Chemaly RF. Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality. *Clin Lymphoma Myeloma* 6(5):393-8, 2006. PMID: 16640816.
120. Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, **Kontoyiannis DP**. *Drosophila melanogaster* as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in *Candida* species. *J Infect Dis* 193(7):1014-22, 2006. PMID: 16518764.
121. Garey KW, Neuhauser MM, Bearden DT, Cannon JP, Lewis RE, Gentry LO, **Kontoyiannis DP**. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. *Mycoses* 49(3):226-31, 2006. PMID: 16681815.
122. Kumashi PR, Safdar A, Chamilos G, Chemaly RF, Raad II, **Kontoyiannis DP**. Fungal osteoarticular infections in patients treated at a comprehensive cancer centre: a 10-year retrospective review. *Clin Microbiol Infect* 12(7):621-6, 2006. PMID: 16774557.
123. Lewis RE, Wiederhold NP, Prince RA, **Kontoyiannis DP**. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against *Candida* species in the

- presence of human serum albumin. *J Antimicrob Chemother* 57(2):288-93, 2006. PMID: 16387749.
124. Torres HA, Chemaly RF, Storey R, Aguilera EA, Noguerras GM, Safdar A, Rolston KV, Raad II, **Kontoyiannis DP**. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of *Pneumocystis jiroveci* pneumonia in cancer patients. *Eur J Clin Microbiol Infect Dis* 25(6):382-8, 2006. PMID: 16767486.
  125. Chamilos G, Lewis RE, **Kontoyiannis DP**. Inhibition of *Candida parapsilosis* mitochondrial respiratory pathways enhances susceptibility to caspofungin. *Antimicrob Agents Chemother* 50(2):744-7, 2006. PMID: 16436735.
  126. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, **Kontoyiannis DP**. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). *Haematologica* 91(7):986-9, 2006. PMID: 16757415.
  127. Almyroudis NG, **Kontoyiannis DP**, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. *Clin Infect Dis* 43(11):1449-55, 2006. PMID: 17083020.
  128. Chamilos G, Lewis RE, **Kontoyiannis DP**. Lovastatin has significant activity against *Zygomycetes* and interacts synergistically with voriconazole. *Antimicrob Agents Chemother* 50(1):96-103, 2006. PMID: 16377673.
  129. Lionakis MS, Chamilos G, Lewis RE, Wiederhold NP, Raad II, Samonis G, **Kontoyiannis DP**. Pentamidine is active in a neutropenic murine model of acute invasive pulmonary fusariosis. *Antimicrob Agents Chemother* 50(1):294-7, 2006. PMID: 16377700.
  130. Wiederhold NP, Tam VH, Chi J, Prince RA, **Kontoyiannis DP**, Lewis RE. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. *Antimicrob Agents Chemother* 50(2):469-73, 2006. PMID: 16436698.
  131. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, **Kontoyiannis DP**, Töpelt K, Courtney R, Wexler D, Krishna G, Martinho M, Corcoran G, Raad I. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. *Antimicrob Agents Chemother* 50(2):658-66, 2006. PMID: 16436724.
  132. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, **Kontoyiannis DP**. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. *Clin Infect Dis* 42(10):1398-403, 2006. PMID: 16619151.
  133. van Burik JA, Hare RS, Solomon HF, Corrado ML, **Kontoyiannis DP**. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. *Clin Infect Dis* 42(7):e61-5, 2006. PMID: 16511748.
  134. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, **Kontoyiannis DP**. *Scedosporium* infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. *Clin Infect Dis* 43(12):1580-4, 2006. PMID: 17109292.
  135. Rolston KV, Yadegarynia D, **Kontoyiannis DP**, Raad II, Ho DH. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients. *Int J Infect Dis* 10(3):223-30, 2006. PMID: 16439177.
  136. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, **Kontoyiannis DP**. A comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. *Antimicrob Agents Chemother* 51(4):1253-8, 2007. PMID: 17261624.
  137. Qiao J, **Kontoyiannis DP**, Wan Z, Li R, Liu W. Antifungal activity of statins against *Aspergillus* species. *Med Mycol* 45(7):589-93, 2007. PMID: 18033614.
  138. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, Chamilos G, Palella F, Kennedy L, Mullane K, Tallman MS, Evens A, Scheetz MH, Blum W, **Kontoyiannis DP**. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. *Bone Marrow Transplant* 39(7):425-9, 2007. PMID: 17310132.

139. Chou LS, Lewis RE, Ippoliti C, Champlin RE, **Kontoyiannis DP**. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. *Pharmacotherapy* 27(12):1644-50, 2007. PMID: 18041885.
140. Chamilos G, Luna M, Lewis RE, Chemaly R, Raad II, **Kontoyiannis DP**. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. *Clin Ther* 29(9):1980-6, 2007. PMID: 18035197.
141. Safdar A, Rodriguez G, Rolston KV, O'Brien S, Khouri IF, Shpall EJ, Keating MJ, Kantarjian HM, Champlin RE, Raad II, **Kontoyiannis DP**. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. *Bone Marrow Transplant* 39(3):157-64, 2007. PMID: 17245424.
142. **Kontoyiannis DP**, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II, Manning JT, Han X. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. *Cancer* 110(6):1303-6, 2007. PMID: 17614303.
143. **Kontoyiannis DP**, Chamilos G, Hassan SA, Lewis RE, Albert ND, Tarrand JJ. Increased culture recovery of Zygomycetes under physiologic temperature conditions. *Am J Clin Pathol* 127(2):208-12, 2007. PMID: 17210526.
144. Lass-Flörl C, Grif K, **Kontoyiannis DP**. Molecular typing of *Aspergillus terreus* isolates collected in Houston, Texas, and Innsbruck, Austria: evidence of great genetic diversity. *J Clin Microbiol* 45(8):2686-90, 2007. PMID: 17581930.
145. Chamilos G, Lewis RE, **Kontoyiannis DP**. Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: A hypothesis. *Fungal Genet Biol* 44(2):88-92, 2007. PMID: 16990037.
146. Chamilos G, Lewis RE, Albert N, **Kontoyiannis DP**. Paradoxical effect of echinocandins across *Candida* species in vitro: evidence for echinocandin-specific and *Candida* species-related differences. *Antimicrob Agents Chemother* 51(6):2257-9, 2007. PMID: 17438060.
147. Lewis RE, Chamilos G, Prince RA, **Kontoyiannis DP**. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. *Antimicrob Agents Chemother* 51(3):1078-81, 2007. PMID: 17194825.
148. Mulanovich V, Lewis RE, Raad II, **Kontoyiannis DP**. Random plasma concentrations of voriconazole decline over time. *J Infect* 55(5):e129-30, 2007. PMID: 17804077.
149. Chamilos G, Lionakis MS, Lewis RE, **Kontoyiannis DP**. Role of mini-host models in the study of medically important fungi. *Lancet Infect Dis* 7(1):42-55, 2007. PMID: 17182343.
150. Wise MG, Healy M, Reece K, Smith R, Walton D, Dutch W, Renwick A, Huang J, Young S, Tarrand J, **Kontoyiannis DP**. Species identification and strain differentiation of clinical *Candida* isolates using the DiversiLab system of automated repetitive sequence-based PCR. *J Med Microbiol* 56(Pt 6):778-87, 2007. PMID: 17510263.
151. Aisenberg G, Rolston KV, Dickey BF, **Kontoyiannis DP**, Raad II, Safdar A. *Stenotrophomonas maltophilia* pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. *Eur J Clin Microbiol Infect Dis* 26(1):13-20, 2007. PMID: 17200840.
152. Lamaris GA, Chamilos G, Lewis RE, **Kontoyiannis DP**. Virulence studies of *Scedosporium* and *Fusarium* species in *Drosophila melanogaster*. *J Infect Dis* 196(12):1860-4, 2007. PMID: 18190268.
153. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, **Kontoyiannis DP**, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis* 46(3):327-60, 2/2008. PMID: 18177225.
154. Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, **Kontoyiannis DP**, Raad II. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. *Cancer* 112(6):1282-7, 3/2008. PMID: 18224662.



155. Chamilos G, Lewis RE, **Kontoyiannis DP**. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. *Clin Infect Dis* 47(4):503-9, 8/2008. PMID: 18611163.
156. Atkinson BJ, Lewis RE, **Kontoyiannis DP**. *Candida lusitanae* fungemia in cancer patients: risk factors for amphotericin B failure and outcome. *Med Mycol* 46(6):541-6, 9/2008. PMID: 19180749.
157. Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, **Kontoyiannis DP**, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. *Clin Infect Dis* 47(5):674-83, 9/2008. PMID: PMC2671230.
158. Lamaris GA, Ben-Ami R, Lewis RE, **Kontoyiannis DP**. Does pre-exposure of *Aspergillus fumigatus* to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. *J Antimicrob Chemother* 62(3):539-42, 9/2008. e-Pub 6/2008. PMID: 18544603.
159. Lionakis MS, Samonis G, **Kontoyiannis DP**. Endocrine and metabolic manifestations of invasive fungal infections and systemic antifungal treatment. *Mayo Clin Proc* 83(9):1046-60, 9/2008. PMID: 18775205.
160. Ibrahim AS, Gebremariam T, Liu M, Chamilos G, **Kontoyiannis D**, Mink R, Kwon-Chung KJ, Fu Y, Skory CD, Edwards JE, Spellberg B. Bacterial endosymbiosis is widely present among Zygomycetes but does not contribute to the pathogenesis of mucormycosis. *J Infect Dis* 198(7):1083-90, 10/2008. PMID: PMC2729545.
161. Garcia-Effron G, **Kontoyiannis DP**, Lewis RE, Perlin DS. Caspofungin-resistant *Candida tropicalis* strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. *Antimicrob Agents Chemother* 52(11):4181-3, 11/2008. e-Pub 9/2008. PMID: PMC2573122.
162. Kasai M, Harrington SM, Francesconi A, Petraitis V, Petraitiene R, Beveridge MG, Knudsen T, Milanovich J, Cotton MP, Hughes J, Schaufele RL, Sein T, Bacher J, Murray PR, **Kontoyiannis DP**, Walsh TJ. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. *J Clin Microbiol* 46(11):3690-702, 11/2008. e-Pub 9/2008. PMID: PMC2576616.
163. Lewis RE, Albert ND, **Kontoyiannis DP**. Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. *Antimicrob Agents Chemother* 52(11):4178-80, 11/2008. e-Pub 8/2008. PMID: PMC2573155.
164. Qiao J, **Kontoyiannis DP**, Calderone R, Li D, Ma Y, Wan Z, Li R, Liu W. Afp1, encoding a bZip transcriptional factor of *Aspergillus fumigatus*, contributes to oxidative stress response but is not essential to the virulence of this pathogen in mice immunosuppressed by cyclophosphamide and triamcinolone. *Med Mycol* 46(8):1-10, 12/2008. PMID: 18608886.
165. Torres HA, Aguilera E, Safdar A, Rohatgi N, Raad II, Sepulveda C, Luna M, **Kontoyiannis DP**, Chemaly RF. Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study. *Clin Microbiol Infect* 14(12):1160-6, 12/2008. e-Pub 11/2008. PMID: 19046167.
166. Sipsas NV, **Kontoyiannis DP**. Occupation, lifestyle, diet, and invasive fungal infections. *Infection* 36(6):515-25, 12/2008. e-Pub 11/2008. PMID: 18998051.
167. Raad II, Hachem RY, Hanna HA, Fang X, Jiang Y, Dvorak T, Sherertz RJ, **Kontoyiannis DP**. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against *Candida* embedded in biofilm. *Int J Antimicrob Agents* 32(6):515-8, 12/2008. e-Pub 9/2008. PMID: 18783924.
168. **Kontoyiannis DP**, Lewis RE, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, Del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP,

- Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Albert ND, Wagener MM, Singh N. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against *Cryptococcus neoformans* isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. *Antimicrob Agents Chemother* 52(2):735-8, 2008. PMID: 18070977.
169. Lamaris GA, Lewis RE, Chamilos G, May GS, Safdar A, Walsh TJ, Raad II, **Kontoyiannis DP**. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against *Aspergillus* and non-*Aspergillus* hyphae. *J Infect Dis* 198(2):186-92, 2008. PMID: 18500936.
170. Lewis RE, Albert ND, **Kontoyiannis DP**. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. *J Antimicrob Chemother* 61(5):1140-4, 2008. PMID: 18305201.
171. Chamilos G, Lewis RE, Hu J, Xiao L, Zal T, Gilliet M, Halder G, **Kontoyiannis DP**. *Drosophila melanogaster* as a model host to dissect the immunopathogenesis of zygomycosis. *Proc Natl Acad Sci U S A* 105(27):9367-72, 2008. PMID: 18583479.
172. Lamaris GA, Esmaeli B, Chamilos G, Desai A, Chemaly RF, Raad II, Safdar A, Lewis RE, **Kontoyiannis DP**. Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases. *Eur J Clin Microbiol Infect Dis* 27(5):343-7, 2008. PMID: 18183439.
173. Tsiodras S, Samonis G, Boumpas DT, **Kontoyiannis DP**. Fungal infections complicating tumor necrosis factor alpha blockade therapy. *Mayo Clin Proc* 83(2):181-94, 2008. PMID: 18241628.
174. Chamilos G, Lewis RE, Lamaris GA, Albert ND, **Kontoyiannis DP**. Genomewide screening for genes associated with gliotoxin resistance and sensitivity in *Saccharomyces cerevisiae*. *Antimicrob Agents Chemother* 52(4):1325-9, 2008. PMID: PMC2292559.
175. Spikes S, Xu R, Nguyen CK, Chamilos G, **Kontoyiannis DP**, Jacobson RH, Ezykowitz DE, Chiang LY, Filler SG, May GS. Gliotoxin production in *Aspergillus fumigatus* contributes to host-specific differences in virulence. *J Infect Dis* 197(3):479-86, 2008. PMID: 18199036.
176. Chemaly RF, Torres HA, Hachem R, **Kontoyiannis DP**, Safdar A, Raad II. Human herpesvirus-6 DNAemia in immunosuppressed adult patients with leukemia at risk for mold infection. *Haematologica* 93(1):157-8, 2008. PMID: 18166808.
177. Marom EM, Holmes AM, Bruzzi JF, Truong MT, O'Sullivan PJ, **Kontoyiannis DP**. Imaging of pulmonary fusariosis in patients with hematologic malignancies. *AJR Am J Roentgenol* 190(6):1605-9, 2008. PMID: 18492913.
178. Quezada G, Koshkina NV, Zweidler-McKay P, Zhou Z, **Kontoyiannis DP**, Kleiner ES. Intranasal granulocyte-macrophage colony-stimulating factor reduces the *Aspergillus* burden in an immunosuppressed murine model of pulmonary aspergillosis. *Antimicrob Agents Chemother* 52(2):716-8, 2008. PMID: PMC2224773.
179. Jacobson KL, Miceli MH, Tarrand JJ, **Kontoyiannis DP**. Legionella pneumonia in cancer patients. *Medicine (Baltimore)* 87(3):152-9, 2008. PMID: 18520324.
180. Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, **Kontoyiannis DP**, Hachem RY. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. *Leukemia* 22(3):496-503, 2008. PMID: 18094720.
181. Awais A, Tam CS, **Kontoyiannis D**, Ferrajoli A, Duvic M, Cortes J, Keating MJ. Rapid resolution of *Mycobacterium marinum* chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. *Clin Infect Dis* 46(7):e69-71, 2008. PMID: 18444808.
182. Wahba H, Truong MT, Lei X, **Kontoyiannis DP**, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. *Clin Infect Dis* 46(11):1733-7, 2008. PMID: 18419427.
183. Hachem R, Hanna H, **Kontoyiannis D**, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: *Candida glabrata* and *Candida krusei* as the leading causes of candidemia in hematologic malignancy. *Cancer* 112(11):2493-9, 2008. PMID: 18412153.
184. Chamilos G, Macapinlac HA, **Kontoyiannis DP**. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. *Med Mycol* 46(1):23-9, 2008. PMID: 18297544.

185. Chamilos G, Lewis RE, Lamaris G, Walsh TJ, **Kontoyiannis DP**. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. *Antimicrob Agents Chemother* 52(2):722-4, 2008. PMID: PMC2224765.
186. Hachem RY, **Kontoyiannis DP**, Chemaly RF, Jiang Y, Reitzel R, Raad I. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for *Aspergillus fumigatus* infection in hematologic malignancy patients. *J Clin Microbiol* 47(1):129-33, 1/2009. e-Pub 11/2008. PMID: PMC2620882.
187. **Kontoyiannis DP**, Ratanatharathorn V, Young JA, Raymond J, Laverdière M, Denning DW, Patterson TF, Facklam D, Kovanda L, Arnold L, Lau W, Buell D, Marr KA. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. *Transpl Infect Dis* 11(1):89-93, 2/2009. e-Pub 10/2008. PMID: 18983417.
188. Yang Z, **Kontoyiannis DP**, Wen X, Xiong C, Zhang R, Albert ND, Li C. Gamma scintigraphy imaging of murine invasive pulmonary aspergillosis with a (111)In-labeled cyclic peptide. *Nucl Med Biol* 36(3):259-66, 4/2009. PMID: 19324271.
189. Ben-Ami R, Lewis RE, Raad II, **Kontoyiannis DP**. Phaeohyphomycosis in a tertiary care cancer center. *Clin Infect Dis* 48(8):1033-41, 4/2009. PMID: 19267655.
190. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, **Kontoyiannis DP**. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. *J Infect Dis* 199(9):1399-406, 5/2009. PMID: 19358672.
191. Spellberg B, Walsh TJ, **Kontoyiannis DP**, Edwards J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. *Clin Infect Dis* 48(12):1743-51, 6/2009. PMID: PMC2809216.
192. Chamilos G, Nobile CJ, Bruno VM, Lewis RE, Mitchell AP, **Kontoyiannis DP**. *Candida albicans* Cas5, a Regulator of Cell Wall Integrity, Is Required for Virulence in Murine and Toll Mutant Fly Models. *J Infect Dis* 200(1):152-7, 7/2009. PMID: 19463063.
193. Sipsas NV, Lewis RE, Raad II, **Kontoyiannis DP**. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study. *Int J Antimicrob Agents* 34(1):95-8, 7/2009. e-Pub 2/2009. PMID: 19251404.
194. Ben-Ami R, Luna M, Lewis RE, Walsh TJ, **Kontoyiannis DP**. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. *J Infect* 59(2):134-8, 8/2009. e-Pub 6/2009. PMID: 19576639.
195. Roussos P, Lewis RE, **Kontoyiannis DP**. Azoles and antidepressants: a mini-review of the tolerability of co-administration. *Mycoses* 52(5):433-9, 9/2009. e-Pub 1/2009. PMID: 19207836.
196. Granger JM, **Kontoyiannis DP**. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. *Cancer* 115(17):3919-23, 9/2009. e-Pub 6/2009. PMID: 19551882.
197. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, **Kontoyiannis DP**. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. *Cancer* 115(20):4745-52, 10/2009. PMID: 19634156.
198. Pongas GN, Ben-Ami R, Lewis RE, Walsh TJ, **Kontoyiannis DP**. Culture medium composition affects the lethality of *Cunninghamella bertholletiae* in a fly model of mucormycosis. *Antimicrob Agents Chemother* 53(10):4569, 10/2009. e-Pub 7/2009. PMID: PMC2764152.
199. Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, Alexander BD, Andes D, **Kontoyiannis DP**, Perrone G, Peterson S, Brandt ME, Pappas PG, Chiller T. Molecular identification of *Aspergillus* species collected for the Transplant-Associated Infection Surveillance Network. *J Clin Microbiol* 47(10):3138-41, 10/2009. e-Pub 8/2009. PMID: PMC2756904.
200. Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, **Kontoyiannis DP**, Ito JI, Balajee SA, Pappas PG, Moser SA. Patterns of susceptibility of *Aspergillus* isolates recovered from patients enrolled in the transplant-associated infection surveillance network. *J Clin Microbiol* 47(10):3271-5, 10/2009. e-Pub 8/2009. PMID: PMC2756905.



201. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, **Kontoyiannis D**, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. *J Clin Oncol* 27(32):5425-30, 11/2009. e-Pub 10/2009. PMID: 19805674.
202. Ben-Ami R, Lewis RE, Leventakos K, **Kontoyiannis DP**. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. *Blood* 114(26):5393-9, 12/2009. e-Pub 10/2009. PMID: PMC2925388.
203. Ben-Ami R, Lewis RE, Tarrand J, Leventakos K, **Kontoyiannis DP**. Antifungal activity of colistin against Mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. *Antimicrob Agents Chemother* 54(1):484-90, 1/2010. e-Pub 10/2009. PMID: PMC2798530.
204. Evans SE, Scott BL, Clement CG, Larson DT, **Kontoyiannis DP**, Lewis RE, Lasala PR, Pawlik J, Peterson JW, Chopra AK, Klimpel G, Bowden G, Höök M, Xu Y, Tuvim MJ, Dickey BF. Stimulated Innate Resistance of Lung Epithelium Protects Mice Broadly Against Bacteria and Fungi. *Am J Respir Cell Mol Biol* 42(1):40-50, 1/2010. e-Pub 3/2009. PMID: PMC2809220.
205. Kofteridis DP, Lewis RE, **Kontoyiannis DP**. Caspofungin-non-susceptible Candida isolates in cancer patients. *J Antimicrob Chemother* 65(2):293-5, 2/2010. e-Pub 12/2009. PMID: 20016020.
206. Vigil KJ, Johnson JR, Johnston BD, **Kontoyiannis DP**, Mulanovich VE, Raad II, Dupont HL, Adachi JA. Escherichia coli pyomyositis: an emerging infectious disease among patients with hematologic malignancies. *Clin Infect Dis* 50(3):374-80, 2/2010. PMID: 20038242.
207. Ben-Ami R, Lasala PR, Lewis RE, **Kontoyiannis DP**. Lack of galactomannan reactivity in dematiaceous molds recovered from cancer patients with phaeohyphomycosis. *Diagn Microbiol Infect Dis* 66(2):200-3, 2/2010. e-Pub 10/2009. PMID: 19836185.
208. Lewis RE, Albert ND, Liao G, Hou J, Prince RA, **Kontoyiannis DP**. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. *Antimicrob Agents Chemother* 54(3):1298-304, 3/2010. e-Pub 12/2009. PMID: PMC2826015.
209. Ben-Ami R, Lamaris GA, Lewis RE, **Kontoyiannis DP**. Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis. *Med Mycol* 48(2):1-9, 3/2010. e-Pub 7/2009. PMID: 19642052.
210. Tan CH, **Kontoyiannis DP**, Viswanathan C, Iyer RB. Tuberculosis: a benign impostor. *AJR Am J Roentgenol* 194(3):555-61, 3/2010. PMID: 20173128.
211. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, **Kontoyiannis DP**, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). *Clin Infect Dis* 50(8):1101-11, 4/2010. PMID: 20218876.
212. **Kontoyiannis DP**, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clin Infect Dis* 50(8):1091-100, 4/2010. PMID: 20218877.
213. Shannon VR, Andersson BS, Lei X, Champlin RE, **Kontoyiannis DP**. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. *Bone Marrow Transplant* 45(4):647-55, 4/2010. e-Pub 8/2009. PMID: 19684637.
214. Ben-Ami R, Lewis RE, Leventakos K, Latgé JP, **Kontoyiannis DP**. A Cutaneous model of invasive aspergillosis. *Antimicrob Agents Chemother* 54(5):1848-54, 5/2010. e-Pub 2/2010. PMID: PMC2863682.

215. Ben-Ami R, Varga V, Lewis RE, May GS, Nierman WC, **Kontoyiannis DP**. Characterization of a 5-azacytidine-induced developmental *Aspergillus fumigatus* variant. *Virulence* 1(3):164-73, May-Jun, 5/2010. PMID: PMC3265789.
216. Chamilos G, Bignell EM, Schrettl M, Lewis RE, Leventakos K, May GS, Haas H, **Kontoyiannis DP**. Exploring the concordance of *Aspergillus fumigatus* pathogenicity in mice and Toll-deficient flies. *Med Mycol* 48(3):506-10, 5/2010. PMID: 20370364.
217. Campo M, Lewis RE, **Kontoyiannis DP**. Invasive Fusariosis in Patients with Hematologic Malignancies at a Cancer Center: 1998-2009. *J Infect* 60(5):331-7, 5/2010. e-Pub 2/2010. PMID: 20138081.
218. Baddley JW, Andes DR, Marr KA, **Kontoyiannis DP**, Alexander BD, Kauffman CA, Oster RA, Anaissie EJ, Walsh TJ, Schuster MG, Wingard JR, Patterson TF, Ito JI, Williams OD, Chiller T, Pappas PG. Factors associated with mortality in transplant patients with invasive aspergillosis. *Clin Infect Dis* 50(12):1559-67, 6/2010. PMID: PMC2874071.
219. Panackal AA, Li H, **Kontoyiannis DP**, Mori M, Perego CA, Boeckh M, Marr KA. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. *Clin Infect Dis* 50(12):1588-97, 6/2010. PMID: PMC3024009.
220. Oxman DA, Chow JK, Frendl G, Hadley S, Hershkovitz S, Ireland P, McDermott LA, Tsai K, Marty FM, **Kontoyiannis DP**, Golan Y. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? *J Antimicrob Chemother* 65(7):1460-5, 7/2010. e-Pub 4/2010. PMID: 20430790.
221. Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, **Kontoyiannis DP**, Rolston KV, Walsh TJ, Champlin RE, Raad II. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. *Medicine (Baltimore)* 89(4):236-44, 7/2010. PMID: 20616663.
222. Feldman EM, **Kontoyiannis DP**, Sharabi SE, Lee E, Kaufman Y, Heller L. Breast implant infections: is cefazolin enough? *Plast Reconstr Surg* 126(3):779-85, 9/2010. PMID: 20811212.
223. Milito MA, **Kontoyiannis DP**, Lewis RE, Liu P, Mawlawi OR, Truong MT, Marom EM. Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis. *Med Mycol* 48(6):817-23, 9/2010. e-Pub 1/2010. PMID: 20109093.
224. Nguyen MH, Husain S, Clancy CJ, Peacock JE, Hung CC, **Kontoyiannis DP**, Morris AJ, Heath CH, Wagener M, Yu VL. Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. *J Infect* 61(5):419-26, 11/2010. e-Pub 8/2010. PMID: 20732350.
225. Evans SE, Leventakos K, Ben-Ami R, You D, Thakkar SG, Lewis RE, **Kontoyiannis DP**. Toll-deficient *Drosophila* are resistant to infection by *Pneumocystis* spp.: additional evidence of specificity to mammalian hosts. *Virulence* 1(6):523-5, Nov-Dec, 11/2010. e-Pub 11/2010. PMID: 21178507.
226. Chamilos G, Ganguly D, Lande R, Gregorio J, Meller S, Goldman WE, Gilliet M, **Kontoyiannis DP**. Generation of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of T(H)-17 responses. *PLoS One* 5(9):e12955, 2010. e-Pub 9/2010. PMID: PMC2944889.
227. Lewis RE, Pongas GN, Albert N, Ben-Ami R, Walsh TJ, **Kontoyiannis DP**. Activity of deferasirox in Mucorales: Influences of species and exogenous iron. *Antimicrob Agents Chemother* 55(1):411-3, 1/2011. e-Pub 10/2010. PMID: PMC3019624.
228. Mulanovich VE, Ahmed SI, Öztürk T, Khokhar FA, **Kontoyiannis DP**, de Lima M. Toxoplasmosis in allo-SCT patients: risk factors and outcomes at a transplantation center with a low incidence. *Bone Marrow Transplant* 46(2):273-7, 2/2011. e-Pub 5/2010. PMID: 20436521.
229. Ben-Ami R, Lewis RE, **Kontoyiannis DP**. In vitro interactions among echinocandins against *Aspergillus fumigatus*: lack of concordance among methods. *Med Mycol* 49(3):285-8, 4/2011. e-Pub 10/2010. PMID: 21028945.
230. Al Akhrass F, Debiante L, Abdallah L, Best L, Mulanovich V, Rolston K, **Kontoyiannis DP**. Palatal mucormycosis in patients with hematologic malignancy and stem cell transplantation. *Med Mycol* 49(4):400-5, 5/2011. e-Pub 11/2010. PMID: 21077735.



231. Lewis RE, Liao G, Hou J, Prince RA, **Kontoyiannis DP**. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant *Aspergillus fumigatus*. *J Antimicrob Chemother* 66(6):1324-31, 6/2011. e-Pub 4/2011. PMID: 21486855.
232. Lewis RE, Leventakos K, Liao G, **Kontoyiannis DP**. Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. *Antimicrob Agents Chemother* 55(7):3584-7, 7/2011. e-Pub 5/2011. PMCID: PMC3122398.
233. Lewis RE, Liao G, Wang W, Prince RA, **Kontoyiannis DP**. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of *Aspergillus fumigatus*-*Rhizopus oryzae* pulmonary infection. *Virulence* 2(4):348-55, Jul-Aug, 7/2011. e-Pub 7/2011. PMID: 21788730.
234. Ben-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, Perlin DS, **Kontoyiannis DP**. Fitness and Virulence Costs of *Candida albicans* FKS1 Hot Spot Mutations Associated With Echinocandin Resistance. *J Infect Dis* 204(4):626-35, 8/2011. PMCID: PMC3144175.
235. Rizos EC, Salanti G, **Kontoyiannis DP**, Ioannidis JP. Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents. *J Clin Epidemiol* 64(8):830-42, 8/2011. e-Pub 3/2011. PMID: 21411286.
236. Lockhart SR, Zimbeck AJ, Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, **Kontoyiannis DP**, Ito JI, Pappas PG, Chiller T. In vitro echinocandin susceptibility of *Aspergillus* isolates from patients enrolled in the transplant-associated infection surveillance network. *Antimicrob Agents Chemother* 55(8):3944-6, 8/2011. e-Pub 6/2011. PMCID: PMC3147660.
237. Sampsonas F, **Kontoyiannis DP**, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: A Prospective 2-Year Study. *Cancer* 117(15):3424-33, 8/2011. PMCID: PMC3457647.
238. Al Akhrass F, Hachem R, Mohamed JA, Tarrand J, **Kontoyiannis DP**, Chandra J, Ghannoum M, Haydoura S, Chaftari AM, Raad I. Central venous catheter-associated *Nocardia* bacteremia in cancer patients. *Emerg Infect Dis* 17(9):1651-8, 9/2011. PMCID: PMC3322064.
239. Perfect JR, Pfaller MA, Ostrosky-Zeichner L, **Kontoyiannis DP**. Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity). *Am J Med* 124(10):S2-3, 10/2011. PMID: 21962326.
240. Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt L, Ito JI, Kauffman CA, Lyon GM, Marr KA, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wingard JR, Walsh TJ, **Kontoyiannis DP**. Invasive non-*Aspergillus* mold infections in transplant recipients, United States, 2001-2006. *Emerg Infect Dis* 17(10):1855-64, 10/2011. PMCID: PMC3311117.
241. Khan H, Oberoi S, Mahvash A, Sharma M, Rondon G, Alousi A, Shpall EJ, **Kontoyiannis DP**, Champlin RE, Ciurea SO. Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. *Biol Blood Marrow Transplant* 17(10):1551-5, 10/2011. e-Pub 3/2011. PMID: 21396475.
242. Ramos ER, Jiang Y, Hachem R, Kassis C, **Kontoyiannis DP**, Raad I. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. *Oncologist* 16(7):1049-60, 2011. e-Pub 6/2011. PMCID: PMC3228136.
243. Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, **Kontoyiannis DP**. Rare opportunistic (non-*Candida*, non-*Cryptococcus*) yeast bloodstream infections in patients with cancer. *J Infect* 64(1):68-75, 1/2012. e-Pub 11/2011. PMID: 22101079.
244. Pongas G, Hamilos G, Rolston KV, **Kontoyiannis DP**. Formal adult infectious disease specialist consultations in the outpatient setting at a comprehensive cancer center (1998-2008): Diverse and impactful. *Support Care Cancer* 20(2):261-5, 2/2012. e-Pub 12/2010. PMID: 21191800.
245. Spellberg B, Ibrahim AS, Chin-Hong PV, **Kontoyiannis DP**, Morris MI, Perfect JR, Fredricks D, Brass EP. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study:

- a randomized, double-blinded, placebo-controlled trial. *J Antimicrob Chemother* 67(3):715-22, 3/2012. e-Pub 9/2011. PMID: PMC3383100.
246. Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, Wiener-Well Y, Weinberger M, Zimhony O, Chowers M, Weber G, Potasman I, Chazan B, Kassis I, Shalit I, Block C, Keller N, **Kontoyiannis DP**, Giladi M, Israeli Candidemia Study Group. Antibiotic exposure as a risk factor for fluconazole-resistant *Candida* bloodstream infection. *Antimicrob Agents Chemother* 56(5):2518-23, 5/2012. e-Pub 2/2012. PMID: PMC3346668.
247. Tarrand JJ, LaSala PR, Han XY, Rolston KV, **Kontoyiannis DP**. Dimethyl sulfoxide enhances effectiveness of skin antiseptics and reduces contamination rates of blood cultures. *J Clin Microbiol* 50(5):1552-7, 5/2012. e-Pub 2/2012. PMID: PMC3347107.
248. Georgiadou SP, Pongas G, Fitzgerald NE, Lewis RE, Rytting M, Marom EM, **Kontoyiannis DP**. Invasive mold infections in pediatric cancer patients reflect heterogeneity in etiology, presentation, and outcome: a 10-year, single-institution, retrospective study. *J Pediatric Infect Dis Soc* 1(2):125-35, 6/2012. e-Pub 5/2012. PMID: 26619165.
249. Lanternier F, Sun HY, Ribaud P, Singh N, **Kontoyiannis DP**, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. *Clin Infect Dis* 54(11):1629-36, 6/2012. e-Pub 3/2012. PMID: 22431807.
250. Torres HA, Nevah MI, Barnett BJ, Mahale P, **Kontoyiannis DP**, Hassan MM, Raad II. Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: a retrospective multicenter study. *J Clin Virol* 54(3):218-22, 7/2012. e-Pub 3/2012. PMID: 22459004.
251. Cahuayme-Zuniga L, Lewis RE, Mulanovich VE, **Kontoyiannis DP**. Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies. *Med Mycol* 50(5):543-8, 7/2012. e-Pub 11/2011. PMID: 22103347.
252. Spellberg B, **Kontoyiannis DP**, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, Ibrahim AS, Brass EP. Risk factors for mortality in patients with mucormycosis. *Med Mycol* 50(6):611-8, 8/2012. e-Pub 3/2012. PMID: 22435877.
253. Georgiadou SP, **Kontoyiannis DP**. Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the *Aspergillus* diagnosis? *J Infect* 65(3):262-8, 9/2012. e-Pub 5/2012. PMID: 22580034.
254. Gamaletsou MN, **Kontoyiannis DP**, Sipsas NV, Moriyama B, Alexander E, Roilides E, Brause B, Walsh TJ. *Candida* osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). *Clin Infect Dis* 55(10):1338-51, 11/2012. e-Pub 8/2012. PMID: 22911646.
255. Chamilos G, Gregorio J, Meller S, Lande R, **Kontoyiannis DP**, Modlin RL, Gilliet M. Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. *Blood* 120(18):3699-707, 11/2012. e-Pub 8/2012. PMID: PMC3488884.
256. Mahale P, **Kontoyiannis DP**, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. *J Hepatol* 57(6):1177-85, 12/2012. e-Pub 8/2012. PMID: 22871500.
257. Gamaletsou MN, Sipsas NV, **Kontoyiannis DP**, Tsiakalos A, Kontos AN, Stefanoul, Kordossis T. Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon- $\gamma$ . *Diagn Microbiol Infect Dis* 74(4):409-11, 12/2012. e-Pub 9/2012. PMID: 22975207.
258. Petraitis V, Petraitiene R, Antachopoulos C, Hughes JE, Cotton MP, Kasai M, Harrington S, Gamaletsou MN, Bacher JD, **Kontoyiannis DP**, Roilides E, Walsh TJ. Increased virulence of *Cunninghamella bertholletiae* in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism. *Med Mycol* 51(1):72-82, 1/2013. e-Pub 6/2012. PMID: 22686246.
259. Georgiadou SP, Sampsonas FL, Rice D, Granger JM, Swisher S, **Kontoyiannis DP**. Open-lung biopsy in patients with undiagnosed lung lesions referred at a tertiary cancer center is safe and reveals noncancerous, noninfectious entities as the most common diagnoses. *Eur J Clin Microbiol Infect Dis* 32(1):101-5, 1/2013. e-Pub 8/2012. PMID: 22895891.
260. Georgiadou SP, Lewis RE, Best L, Torres HA, Champlin RE, **Kontoyiannis DP**. The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of

- triazole-based secondary prophylaxis. *Bone Marrow Transplant* 48(1):141-3, 1/2013. e-Pub 5/2012. PMID: 22635244.
261. Baddley JW, Andes DR, Marr KA, Kauffman CA, **Kontoyiannis DP**, Ito JI, Schuster MG, Brizendine KD, Patterson TF, Lyon GM, Boeckh M, Oster RA, Chiller T, Pappas PG. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. *Med Mycol* 51(2):128-35, 2/2013. e-Pub 6/2012. PMID: 22680976.
262. Ben-Ami R, Watson CC, Lewis RE, Albert ND, Arias CA, Raad II, **Kontoyiannis DP**. *Drosophila melanogaster* as a model to explore the effects of methicillin-resistant *Staphylococcus aureus* strain type on virulence and response to linezolid treatment. *MicrobPathog* 55:16-20, 2/2013. e-Pub 12/2012. PMID: 23232438.
263. McGrath DM, Barbu EM, Driessen WH, Lasco TM, Tarrand JJ, Okhuysen PC, **Kontoyiannis DP**, Sidman RL, Pasqualini R, Arap W. Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimetic. *Proc Natl Acad Sci U S A* 110(9):3477-82, 2/2013. e-Pub 1/2013. PMCID: PMC3587187.
264. Lewis RE, Ben-Ami R, Best L, Albert N, Walsh TJ, **Kontoyiannis DP**. Tacrolimus enhances the potency of posaconazole against *Rhizopus oryzae* in vitro and in an experimental model of mucormycosis. *J Infect Dis* 207(5):834-41, 3/2013. e-Pub 12/2012. PMCID: PMC3563310.
265. Farmakiotis D, Tverdek FP, **Kontoyiannis DP**. The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B. *Clin Infect Dis* 56(5):701-3, 3/2013. e-Pub 11/2012. PMID: 23166189.
266. Berthier E, Lim FY, Deng Q, Guo CJ, **Kontoyiannis DP**, Wang CC, Rindy J, Beebe DJ, Huttenlocher A, Keller NP. Low-Volume Toolbox for the Discovery of Immunosuppressive Fungal Secondary Metabolites. *PLoSPathog* 9(4):e1003289, 4/2013. e-Pub 4/2013. PMID: 23592999.
267. Ben-Ami R, Albert ND, Lewis RE, **Kontoyiannis DP**. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. *J Infect Dis* 207(7):1066-74, 4/2013. e-Pub 1/2013. PMCID: PMC3583270.
268. Georgiadou SP, Tarrand J, Sipsas NV, **Kontoyiannis DP**. Candiduria in haematologic malignancy patients without a urinary catheter: nothing more than a frailty marker? *Mycoses* 56(3):311-4, 5/2013. e-Pub 11/2012. PMCID: PMC3883107.
269. Lewis RE, Albert NP, Liao G, Wang W, Prince RA, **Kontoyiannis DP**. High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental *Aspergillus terreus* pneumonia. *J Antimicrob Chemother* 68(5):1148-51, 5/2013. e-Pub 1/2013. PMID: 23349440.
270. Zanette RA, **Kontoyiannis DP**. Pre-exposure of *Candida* species to cytarabine and daunorubicin does not affect their in vitro antifungal susceptibility and virulence in flies. *Virulence* 4(4):344-6, 5/2013. e-Pub 4/2013. PMCID: PMC3710338.
271. Diaz L, **Kontoyiannis DP**, Panesso D, Albert ND, Singh KV, Tran TT, Munita JM, Murray BE, Arias CA. Dissecting the Mechanisms of Linezolid Resistance in a *Drosophila melanogaster* Infection Model of *Staphylococcus aureus*. *J Infect Dis* 208(1):83-91, 7/2013. e-Pub 4/2013. PMCID: PMC3666140.
272. Kyrnizi I, Gresnigt MS, Akoumianaki T, Samonis G, Sidiropoulos P, Boumpas D, Netea MG, van de Veerdonk FL, **Kontoyiannis DP**, Chamilos G. Corticosteroids Block Autophagy Protein Recruitment in *Aspergillus fumigatus* Phagosomes via Targeting Dectin-1/Syk Kinase Signaling. *J Immunol* 191(3):1287-99, 8/2013. e-Pub 7/2013. PMCID: PMC3883106.
273. Ben-Ami R, Rahav G, Elinav H, Kassis I, Shalit I, Gottesman T, Megged O, Weinberger M, Ciobotaro P, Shitrit P, Weber G, Paz A, Miron D, Oren I, Bishara J, Block C, Keller N, **Kontoyiannis DP**, Giladi M, Israeli Candidaemia Study Group. Distribution of fluconazole-resistant *Candida* bloodstream isolates among hospitals and inpatient services in Israel. *Clin Microbiol Infect* 19(8):752-756, 8/2013. e-Pub 9/2012. PMID: 23005038.
274. **Kontoyiannis DP**, Georgiadou SP, Wierda WG, Wright S, Albert ND, Ferrajoli A, Keating M, Lewis RE. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. *Leuk Lymphoma* 54(8):1730-3, 8/2013. e-Pub 2/2013. PMCID: PMC3858983.



275. Zanette RA, **Kontoyiannis DP**. Paradoxical effect to caspofungin in *Candida* species does not confer survival advantage in a *Drosophila* model of candidiasis. *Virulence* 4(6):497-8, 8/2013. e-Pub 6/2013. PMID: 23863608.
276. Kaluarachchi WD, Cisneros BT, Corr SJ, Albert ND, Curley SA, **Kontoyiannis DP**. *Aspergillus fumigatus* hyphal damage caused by noninvasive radiofrequency field hyperthermia. *Antimicrob Agents Chemother* 57(9):4444-8, 9/2013. e-Pub 7/2013. PMID: PMC3754314.
277. Shirazi F, Pontikos MA, Walsh TJ, Albert N, Lewis RE, **Kontoyiannis DP**. Hyperthermia Sensitizes *Rhizopus oryzae* To Posaconazole And Itraconazole Action Through Apoptosis. *Antimicrob Agents Chemother* 57(9):4360-8, 9/2013. e-Pub 7/2013. PMID: PMC3754336.
278. Shirazi F, **Kontoyiannis DP**. The Calcineurin Pathway Inhibitor Tacrolimus Enhances The In Vitro Activity Of Azoles Against Mucorales Via Apoptosis. *Eukaryot Cell* 12(9):1225-34, 9/2013. e-Pub 7/2013. PMID: PMC3811568.
279. Farmakiotis D, Ciurea AM, Cahuayme-Zuniga L, **Kontoyiannis DP**. The diagnostic yield of skin biopsy in patients with leukemia and suspected infection. *J Infect* 67(4):265-72, 10/2013. e-Pub 6/2013. PMID: 23769840.
280. Zanette RA, Santurio JM, Loreto ES, Alves SH, **Kontoyiannis DP**. Toll-deficient *Drosophila* is susceptible to *Pythium insidiosum* infection. *Microbiol Immunol* 57(10):732-5, 10/2013. e-Pub 7/2013. PMID: 23865688.
281. Lewis RE, Cahuayme-Zuniga L, Leventakos K, Chamilos G, Ben-Ami R, Tamboli P, Tarrand J, Bodey GP, Luna M, **Kontoyiannis DP**. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. *Mycoses* 56(6):638-45, 11/2013. e-Pub 4/2013. PMID: 23551865.
282. Barbu EM, Shirazi F, McGrath DM, Albert N, Sidman RL, Pasqualini R, Arap W, **Kontoyiannis DP**. An Antimicrobial Peptidomimetic Induces Mucorales Cell Death through Mitochondria-Mediated Apoptosis. *PLoS One* 8(10):e76981, 2013. e-Pub 10/2013. PMID: PMC3789667.
283. Palmer JM, Bok JW, Lee S, Dagenais TR, Andes DR, **Kontoyiannis DP**, Keller NP. Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in *Aspergillus fumigatus*. *PeerJ* 1:e4, 2013. e-Pub 2/2013. PMID: PMC3629006.
284. Shirazi F, **Kontoyiannis DP**. Mitochondrial Respiratory Pathways Inhibition in *Rhizopus oryzae* Potentiates Activity of Posaconazole and Itraconazole via Apoptosis. *PLoS One* 8(5):e63393, 2013. e-Pub 5/2013. PMID: PMC3656966.
285. Dimopoulou D, Hamilos G, Tzardi M, Lewis RE, Samonis G, **Kontoyiannis DP**. Anidulafungin vs Caspofungin in a Mouse Model of Candidiasis Caused by Anidulafungin-Susceptible *C. parapsilosis* Isolates with Different Degrees of Caspofungin Susceptibility. *Antimicrob Agents Chemother* 58(1):229-36, 1/2014. e-Pub 10/2013. PMID: PMC3910758.
286. Lewis RE, Georgiadou SP, Sampsonas F, Chamilos G, **Kontoyiannis DP**. Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis. *Mycoses* 57(1):49-55, 1/2014. e-Pub 6/2013. PMID: PMC3867535.
287. Gomes MZ, Mulanovich VE, Jiang Y, Lewis RE, **Kontoyiannis DP**. Incidence Density of Invasive Fungal Infections during Primary Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia in a Tertiary Cancer Center, 2009 - 2011. *Antimicrob Agents Chemother* 58(2):865-73, 2/2014. e-Pub 11/2013. PMID: PMC3910838.
288. **Kontoyiannis DP**, Azie N, Franks B, Horn DL. Prospective antifungal therapy (PATH) alliance(®) : focus on mucormycosis. *Mycoses* 57(4):240-6, 4/2014. e-Pub 10/2013. PMID: 24147728.
289. Gamaletsou MN, Rammaert B, Bueno MA, Moriyama B, Sipsas NV, **Kontoyiannis DP**, Roilides E, Zeller V, Prinapori R, Taj-Aldeen SJ, Brause B, Lortholary O, Walsh TJ. *Aspergillus osteomyelitis*: Epidemiology, clinical manifestations, management, and outcome. *J Infect* 68(5):478-93, 5/2014. e-Pub 12/2013. PMID: PMC4214682.
290. Gomes MZ, Jiang Y, Mulanovich VE, Lewis RE, **Kontoyiannis DP**. Effectiveness of Primary anti-*Aspergillus* Prophylaxis During Remission Induction Chemotherapy of Acute Myeloid Leukemia. *Antimicrob Agents Chemother* 58(5):2775-80, 5/2014. e-Pub 3/2014. PMID: PMC3993271.

291. Katragkou A, Pana ZD, Perlin DS, **Kontoyiannis DP**, Walsh TJ, Roilides E. Exserohilum infections: Review of 48 cases before the 2012 United States outbreak. *Med Mycol* 52(4):376-86, 5/2014. e-Pub 3/2014. PMID: 24682112.
292. Zhao Y, Armeanu E, DiVerniero R, Lewis TA, Dobson RC, **Kontoyiannis DP**, Roilides E, Walsh TJ, Perlin DS. Fungal DNA Detected from Blood of Patients Who Received Contaminated Methylprednisolone Injections reveals more complexity of causative agents. *J Clin Microbiol* 52(6):2212-5, 6/2014. e-Pub 4/2014. PMID: PMC4042738.
293. Shirazi F, Kontoyiannis DP. Heat shock protein 90 and calcineurin pathway inhibitors enhance the efficacy of triazoles against *Scenedosporium proliferans* via induction of apoptosis. *Microb Cell* 1(6):179-188, 6/2014. e-Pub 6/2014. PMID: PMC5354560.
294. Farmakiotis D, Tarrand JJ, **Kontoyiannis DP**. The efficacy and tolerability of monotherapy with micafungin for candidemia and deep-seated candidiasis in adults with cancer. *Antimicrob Agents Chemother* 58(6):3526-9, 6/2014. e-Pub 3/2014. PMID: PMC4068486.
295. Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, **Kontoyiannis DP**, Cooper LJ. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. *Proc Natl Acad Sci U S A* 111(29):10660-5, 7/2014. e-Pub 7/2014. PMID: PMC4115509.
296. Thompson GR, Albert N, Hodge G, Wilson MD, Sykes JE, Bays DJ, Firacative C, Meyer W, **Kontoyiannis DP**. Phenotypic Differences of *Cryptococcus* Molecular Types: implications for virulence in a *Drosophila* model of infection. *Infect Immun* 82(7):3058-3065, 7/2014. e-Pub 5/2014. PMID: PMC4097627.
297. Shirazi F, Farmakiotis D, Yan Y, Albert N, Kim-Anh D, **Kontoyiannis DP**. Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. *PLoS One* 9(9):e108635, 9/2014. PMID: PMC4182538.
298. Lewis RE, Albert ND, **Kontoyiannis DP**. Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis. *Antimicrob Agents Chemother* 58(11):6767-72, 11/2014. e-Pub 9/2014. PMID: PMC4249415.
299. Farmakiotis D, Tarrand JJ, **Kontoyiannis DP**. Drug-Resistant *Candida glabrata* Infection in Cancer Patients. *Emerg Infect Dis* 20(11):1833-40, 11/2014. PMID: PMC4214312.
300. Farmakiotis D, Shirazi F, Zhao Y, Saad PJ, Albert ND, Roilides E, Walsh TJ, Perlin DS, **Kontoyiannis DP**. Methylprednisolone Enhances the Growth of *Exserohilum rostratum* In-Vitro, Attenuates Spontaneous Apoptosis, and Increases Mortality Rates in Immunocompetent *Drosophila* Flies. *J Infect Dis* 210(9):1471-5, 11/2014. e-Pub 5/2014. PMID: 24837401.
301. Jung DS, Tverdek FP, **Kontoyiannis DP**. Switching from Posaconazole Suspension to Tablets Increased Serum Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity. *Antimicrob Agents Chemother* 58(11):6993-5, 11/2014. PMID: PMC4249440.
302. Davoudi S, Anderlini P, Fuller GN, **Kontoyiannis DP**. A Long-Term Survivor of Disseminated *Aspergillus* and *Mucorales* Infection: An Instructive Case. *Mycopathologia* 178(5-6):465-70, 12/2014. PMID: 25086667.
303. Rammaert B, Gamaletsou MN, Zeller V, Elie C, Prinapori R, Taj-Aldeen SJ, Roilides E, **Kontoyiannis DP**, Brause B, Sipsas NV, Walsh TJ, Lortholary O. Dimorphic fungal osteoarticular infections. *Eur J Clin Microbiol Infect Dis* 33(12):2131-40, 12/2014. PMID: 24939620.
304. Lewis RE, Liao G, Young K, Douglas C, **Kontoyiannis DP**. Macrophage Reporter Cell Assay for Screening Immunopharmacological Activity of Cell-Wall Active Antifungals. *Antimicrob Agents Chemother* 58(3):1738-43, 2014. PMID: PMC3957890.
305. Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, Heinz WJ, Jagannatha S, Koh LP, **Kontoyiannis DP**, Lee DG, Nucci M, Pappas PG, Slavin MA, Queiroz-Telles F, Selleslag D, Walsh TJ, Wingard JR, Maertens JA. Combination antifungal therapy for invasive aspergillosis: a randomized trial. *Ann Intern Med* 162(2):81-9, 1/2015. PMID: 25599346.



306. Farmakiotis D, Kyvernitakis A, Tarrand JJ, **Kontoyiannis DP**. Early initiation of appropriate treatment is associated with increased survival in cancer patients with *Candida glabrata* fungaemia: a potential benefit from infectious disease consultation. *Clin Microbiol Infect* 21(1):79-86, 1/2015. e-Pub 10/2014. PMID: 25636931.
307. Torres HA, Mahale P, Blechacz B, Miller E, Kaseb A, Herlong HF, Fowler N, Jiang Y, Raad II, **Kontoyiannis DP**. Effect of Hepatitis C Virus Infection in Patients with Cancer: Addressing a Neglected Population. *J Natl ComprCancNetw* 13(1):41-50, 1/2015. PMID: 25583768.
308. Simitopoulou M, Walsh TJ, Kyrpitzis D, Petraitis V, **Kontoyiannis DP**, Perlin DS, Roilides E. Methylprednisolone impairs conidial phagocytosis but does not attenuate hyphal damage by neutrophils against *Exserohilum rostratum*. *Med Mycol* 53(2):189-93, 2/2015. e-Pub 7/2014. PMID: 25056961.
309. Raad II, Zakhem AE, Helou GE, Jiang Y, **Kontoyiannis DP**, Hachem R. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. *Int J Antimicrob Agents* 45(3):283-8, 3/2015. e-Pub 10/2014. PMID: 25455847.
310. Miller AO, Gamaletsou MN, Henry MW, Al-Hafez L, Hussain K, Sipsas NV, **Kontoyiannis DP**, Roilides E, Brause BD, Walsh TJ. Successful treatment of *Candida* osteoarticular infections with limited duration of antifungal therapy and orthopedic surgical intervention. *Infect Dis (Lond)* 47(3):1-6, 3/2015. e-Pub 12/2014. PMID: 25539148.
311. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, **Kontoyiannis DP**, Pappas PG. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. *Clin Infect Dis* 60(6):892-9, 3/2015. e-Pub 1/2015. PMID: 25586686.
312. Shirazi F, **Kontoyiannis DP**, Ibrahim AS. Iron starvation induces Apoptosis in *Rhizopus oryzae* in vitro. *Virulence* 6(2):121-6, 4/2015. PMID: 25830548.
313. McCarty TP, Baddley JW, Walsh TJ, Alexander BD, **Kontoyiannis DP**, Perl TM, Walker R, Patterson TF, Schuster MG, Lyon GM, Wingard JR, Andes DR, Park BJ, Brandt ME, Pappas PG, TRANSNET Investigators. Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). *Med Mycol* 53(5):440-6, 6/2015. e-Pub 4/2015. PMID: 25908651.
314. Bellanger AP, Minetos YD, Albert N, Shirazi F, Walsh TJ, **Kontoyiannis DP**. Glucocorticosteroids do not impact directly growth rate and biomass of *Rhizopus arrhizus* (syn. *R. oryzae*) in vitro. *Virulence* 6(5):441-3, 7/2015. PMID: 25942104.
315. Wang E, Farmakiotis D, Yang D, McCue DA, Kantarjian HM, **Kontoyiannis DP**, Mathisen MS. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. *J Antimicrob Chemother* 70(8):2362-8, 8/2015. e-Pub 4/2015. PMID: 25855759.
316. Mircus G, Albert N, Ben-Yaakov D, Chikvashvili D, Shadkchan Y, **Kontoyiannis DP**, Osherov N. Identification and characterization of a novel family of selective antifungal compounds (CANBEFs) that interfere with fungal protein synthesis. *Antimicrob Agents Chemother* 59(9):5631-40, 9/2015. e-Pub 7/2015. PMID: PMC4538511.
317. Meller S, Di Domizio J, Voo KS, Friedrich HC, Chamilos G, Ganguly D, Conrad C, Gregorio J, Le Roy D, Roger T, Ladbury JE, Homey B, Watowich S, Modlin RL, **Kontoyiannis DP**, Liu YJ, Arold ST, Gilliet M. TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. *Nat Immunol* 16(10.1038/ni.3211):970-9, 9/2015. e-Pub 7/2015. PMID: 26168081.
318. Davoudi S, Kumar VA, Jiang Y, Kupferman M, **Kontoyiannis DP**. Invasive mould sinusitis in patients with haematological malignancies: a 10 year single-centre study. *J Antimicrob Chemother* 70(10):2899-905, 10/2015. e-Pub 7/2015. PMID: 26188039.
319. Shirazi F, Lewis RE, Kontoyiannis DP. Micafungin induced apoptosis in *Candida parapsilosis* independent of its susceptibility to micafungin. *Microb Cell* 2(11):445-450, 10/2015. PMID: PMC5349207.
320. Jung DS, Tverdek FP, Jiang Y, **Kontoyiannis DP**. Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with

- improvement of liver function tests. *J Antimicrob Chemother* 70(11):3100-6, 11/2015. e-Pub 8/2015. PMID: 26311837.
321. Jung DS, Farmakiotis D, Jiang Y, Tarrand JJ, **Kontoyiannis DP**. Uncommon *Candida* Species Fungemia among Cancer Patients, Houston, Texas, USA. *Emerg Infect Dis* 21(11):1942-50, 11/2015. PMID: PMC4625381.
  322. Bellanger AP, Albert ND, Lewis RE, Walsh TJ, **Kontoyiannis DP**. Effect of Preexposure to Triazoles on Susceptibility and Virulence of *Rhizopus oryzae*. *Antimicrob Agents Chemother* 59(12):7830-2, 12/2015. e-Pub 9/2015. PMID: PMC4649224.
  323. Taj-Aldeen SJ, Rammaert B, Gamaletsou M, Sipsas NV, Zeller V, Roilides E, **Kontoyiannis DP**, Miller AO, Petraitis V, Walsh TJ, Lortholary O, International Osteoarticular Mycoses Consortium. Osteoarticular Infections Caused by Non-*Aspergillus* Filamentous Fungi in Adult and Pediatric Patients: A Systematic Review. *Medicine (Baltimore)* 94(50):e2078, 12/2015. PMID: 26683917.
  324. Zanette RA, Bitencourt PE, **Kontoyiannis DP**, Figuera RA, Flores MM, Kommers GD, Silva PS, Ludwig A, Moretto MB, Alves SH, Santurio JM. Complex interaction of deferasirox and *Pythium insidiosum*: iron-dependent attenuation of growth in vitro and immunotherapy-like enhancement of immune responses in vivo. *PLoS One* 10(3):e0118932, 2015. e-Pub 3/2015. PMID: PMC4349436.
  325. Neofytos D, Railkar R, Mullane KM, Fredricks DN, Granwehr B, Marr KA, Almyroudis NG, **Kontoyiannis DP**, Maertens J, Fox R, Douglas C, Iannone R, Kauh E, Shire N. Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. *PLoS One* 10(6):e0129022, 2015. e-Pub 6/2015. PMID: PMC4480423.
  326. Shelburne SA, Ajami NJ, Chibucos MC, Beird HC, Tarrand J, Galloway-Peña J, Albert N, Chemaly RF, Ghantaji SS, Marsh L, Pemmaraju N, Andreeff M, Shpall EJ, Wargo JA, Rezvani K, Alousi A, Bruno VM, Futreal PA, Petrosino JF, **Kontoyiannis DP**. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infected Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. *PLoS One* 10(11):e0139851, 2015. e-Pub 11/2015. PMID: PMC4640583.
  327. Shirazi F, **Kontoyiannis DP**. Micafungin triggers caspase-dependent apoptosis in *Candida albicans* and *Candida parapsilosis* biofilms, including caspofungin non-susceptible isolates. *Virulence* 6(4):385-94, 2015. PMID: 26065323.
  328. Akoumianaki T, Kyrmizi I, Valsecchi I, Gresnigt MS, Samonis G, Drakos E, Boumpas D, Muszkieta L, Prevost MC, **Kontoyiannis DP**, Chavakis T, Netea MG, van de Veerdonk FL, Brakhage AA, El-Benna J, Beauvais A, Latge JP, Chamilos G. *Aspergillus* Cell Wall Melanin Blocks LC3-Associated Phagocytosis to Promote Pathogenicity. *Cell Host Microbe* 19(1):79-90, 1/2016. PMID: 26749442.
  329. Gamaletsou MN, Rammaert B, Bueno MA, Sipsas NV, Moriyama B, **Kontoyiannis DP**, Roilides E, Zeller V, Taj-Aldeen SJ, Miller AO, Petraitiene R, Lortholary O, Walsh TJ. *Candida* Arthritis: Analysis of 112 Pediatric and Adult Cases. *Open Forum Infect Dis* 3(1):ofv207, 1/2016. e-Pub 12/2015. PMID: PMC4742637.
  330. Throckmorton K, Lim FY, **Kontoyiannis DP**, Zheng W, Keller NP. Redundant synthesis of a conidial polyketide by two distinct secondary metabolite clusters in *Aspergillus fumigatus*. *Environ Microbiol* 18(10.1111/1462-2920.13007):246-59, 1/2016. e-Pub 9/2015. PMID: PMC4750049.
  331. Maertens JA, Raad II, Marr KA, Patterson TF, **Kontoyiannis DP**, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non inferiority trial. *Lancet* 387(10020):760-9, 2/2016. e-Pub 12/2015. PMID: 26684607.
  332. Ioannou P, Andrianaki A, Akoumianaki T, Kyrmizi I, Albert N, Perlin D, Samonis G, **Kontoyiannis DP**, Chamilos G. Albumin enhances caspofungin activity against *Aspergillus* species by facilitating drug delivery to germinating hyphae. *Antimicrob Agents Chemother* 60(3):1226-33, 3/2016. PMID: PMC4775923.

333. Aitken SL, Zhou J, Ghantaji SS, **Kontoyiannis DP**, Jones RB, Tam VH, Chemaly RF. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. *J Antimicrob Chemother* 71(3):727-30, 3/2016. e-Pub 11/2015. PMID: 26612873.
334. Ben Yaakov D, Rivkin A, Mircus G, Albert N, Dietl AM, Kovalerchick D, Carmeli S, Haas H, **Kontoyiannis DP**, Osherov N. Identification and characterization of haemofungin, a novel antifungal compound that inhibits the final step of haem biosynthesis. *J Antimicrob Chemother* 71(4):946-52, 4/2016. e-Pub 1/2016. PMID: 26747101.
335. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, **Kontoyiannis DP**. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. *Clin Microbiol Infect.* e-Pub 4/2016. PMID: 27085727.
336. Nigo M, Vial MR, Munita JM, Jiang Y, Tarrand J, Jimenez CA, **Kontoyiannis DP**. Fungal empyema thoracis in cancer patients. *J Infect* 72(5):615-21, 5/2016. e-Pub 3/2016. PMID: 26945845.
337. Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, **Kontoyiannis DP**, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayr WC, Rezvani K. Symptomatic BK Virus Infection Is Associated with Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. *Am J Transplant* 16(5):1492-502, 5/2016. e-Pub 3/2016. PMID: 26608093.
338. Gebremariam T, Lin L, Liu M, **Kontoyiannis DP**, French S, Edwards JE, Filler SG, Ibrahim AS. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. *J Clin Invest* 126(6):2280-94, 6/2016. e-Pub 5/2016. PMID: PMC4887168.
339. Tata AM, Mikos AG, **Kontoyiannis DP**. Factors affecting patient outcome in primary cutaneous aspergillosis. *Medicine (Baltimore)* 95(26):e3747, 6/2016. PMID: 27367980.
340. Bellanger AP, Tata AM, Shirazi F, Gebremariam T, Albert ND, Lewis RE, Ibrahim AS, **Kontoyiannis DP**. Sub-minimum inhibitory concentrations of statins attenuate the virulence of *Rhizopus oryzae*. *J Infect Dis* 214(1):114-21, 7/2016. PMID: 26984141.
341. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantaji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, **Kontoyiannis DP**, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. *Cancer* 122(14):2186-96, 7/2016. PMID: 27142181.
342. Stempel JM, Farmakiotis D, Tarrand JJ, **Kontoyiannis DP**. Time-to-reporting of blood culture positivity and central venous catheter-associated *Candida glabrata* fungemia in cancer patients. *Diagn Microbiol Infect Dis* 85(3):391-3, 7/2016. PMID: 27133559.
343. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, **Kontoyiannis DP**, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 63(4):433-42, 8/2016. PMID: PMC4967611.
344. Gamaletsou MN, Rammaert B, Bueno MA, Sipsas NV, Moriyama B, **Kontoyiannis DP**, Roilides E, Zeller V, Taj-Aldeen SJ, Henry M, Petraitis V, Denning DW, Lortholary O, Walsh TJ, International Osteoarticular Mycoses Consortium. *Aspergillus* arthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases. *Med Mycol.* e-Pub 9/2016. PMID: 27609563.
345. **Kontoyiannis DP**, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. *BMC Infect Dis* 16(1):730, 12/2016. e-Pub 12/2016. PMID: PMC5134281.
346. Shirazi F, Ferreira JA, Stevens DA, Clemons KV, **Kontoyiannis DP**. Biofilm Filtrates of *Pseudomonas aeruginosa* Strains Isolated from Cystic Fibrosis Patients Inhibit Preformed *Aspergillus fumigatus* Biofilms via Apoptosis. *PLoS One* 11(3):e0150155, 2016. e-Pub 3/2016. PMID: PMC4773012.

347. Healey KR, Zhao Y, Perez WB, Lockhart SR, Sobel JD, Farmakiotis D, **Kontoyiannis DP**, Sanglard D, Taj-Aldeen SJ, Alexander BD, Jimenez-Ortigosa C, Shor E, Perlin DS. Prevalent mutator genotype identified in fungal pathogen *Candida glabrata* promotes multi-drug resistance. *Nat Commun* 7:11128, 2016. e-Pub 3/2016. PMID: 27020939.
348. Heo ST, Aitken SL, Tverdek FP, **Kontoyiannis DP**. How Common is Subsequent Central Nervous System Toxicity in Asymptomatic Patients with Haematologic Malignancy and Supratherapeutic Voriconazole Serum Levels? *Clin Microbiol Infect*, 1/2017. PMID: 28082193.
349. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Wadsworth WD, Fellman BM, Ajami NJ, Shpall EJ, Daver N, Guindani M, Petrosino JF, **Kontoyiannis DP**, Shelburne SA. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. *Genome Med* 9(1):21, 2/2017. e-Pub 2/2017. PMID: PMC5331640.
350. Messina JA, Maziarz EK, Spec A, **Kontoyiannis DP**, Perfect JR. Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. *Open Forum Infect Dis* 4(1):ofw261, 2/2017. PMID: PMC5413986.
351. Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, **Kontoyiannis DP**, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viremia in allogeneic stem cell transplant recipients. *Transpl Infect Dis* 19(1), 2/2017. PMID: 27862740.
352. Heo ST, Tataru AM, Jiménez-Ortigosa C, Jiang Y, Lewis RE, Tarrand J, Tverdek F, Albert ND, Verweij PE, Meis JF, Mikos AG, Perlin DS, **Kontoyiannis DP**. Changes in in vitro susceptibility patterns of *Aspergillus* to triazoles and correlation with aspergillosis outcome in a tertiary care cancer center (1999-2015). *Clin Infect Dis*, 3/2017. PMID: 28379304.
353. Lionakis MS, Albert ND, Swamydas M, Lee CR, Loetscher P, **Kontoyiannis DP**. Pharmacological blockade of the chemokine receptor CCR1 protects mice from systemic candidiasis of hematogenous origin. *Antimicrob Agents Chemother* 61(3), 3/2017. PMID: PMC5328547.
354. El Boghdady Z, Oran B, Jiang Y, Rondon G, Champlin R, **Kontoyiannis DP**. Pretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome. *Bone Marrow Transplant* 52(3):476-479, 3/2017. PMID: 27941772.
355. Tataru AM, Watson E, Satish T, Scott DW, **Kontoyiannis DP**, Engel PS, Mikos AG. Synthesis and Characterization of Diol-based Unsaturated Polyesters: Poly(Diol Fumarate) and Poly(Diol Fumarate-co-Succinate). *Biomacromolecules*. e-Pub 5/2017. PMID: 28486802.
356. Ben Yaakov D, Shadkhan Y, Albert N, **Kontoyiannis DP**, Oshero N. The quinoline bromoquinol exhibits broad-spectrum antifungal activity and induces oxidative stress and apoptosis in *Aspergillus fumigatus*. *JAntimicrob Chemother*. e-Pub 5/2017. PMID: 28475687.
357. Le A, Farmakiotis D, Tarrand JJ, **Kontoyiannis DP**. Initial treatment of cancer patients with fluconazole susceptible dose-dependent *Candida glabrata* fungemia: Better outcome with an echinocandin or polyene compared to an azole? *Antimicrob Agents Chemother* 61(8), 8/2017. PMID: PMC5527607.
358. Tverdek FP, Heo ST, Aitken SL, Granwehr B, **Kontoyiannis DP**. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections: Analysis of 343 courses. *Antimicrob Agents Chemother* 61(8), 8/2017. e-Pub 7/2017. PMID: PMC5527592.
359. Chamilos G, Lionakis MS, **Kontoyiannis DP**. Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. *Clin Infect Dis*. e-Pub 9/2017. PMID: 29029010.
360. Economides MP, Ballester LY, Kumar VA, Jiang Y, Tarrand J, Prieto V, Torres HA, **Kontoyiannis DP**. Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000-2016): Uncommon, with improved survival but still deadly often. *J Infect*. e-Pub 9/2017. PMID: 28919347.
361. Risslegger B, Zoran T, Lackner M, Aigner M, Sánchez-Reus F, Rezusta A, Chowdhary A, Taj-Aldeen SJ, Arendrup MC, Oliveri S, **Kontoyiannis DP**, Alastruey-Izquierdo A, Lagrou K, Lo Cascio G, Meis JF, Buzina W, Farina C, Drogari-Apiranthitou M, Grancini A, TortoranoAM,



- Willinger B, Hamprecht A, Johnson E, Klingspor L, Arsic-Arsenijevic V, Cornely OA, Meletiadis J, Prammer W, Tullio V, Vehreschild JJ, Trovato L, Lewis RE, Segal E, Rath PM, Hamal P, Rodriguez-Iglesias M, Roilides E, Arikian-Akdagli S, Chakrabarti A, Colombo AL, Fernández MS, Martin-Gomez MT, Badali H, Petrikkos G, Klimko N, Heimann SM, Houbraken J, Uzun O, Edlinger M, Fuente S, Lass-Flörl C. A Prospective International *Aspergillus terreus* Survey: An EFISG, ISHAM and ECMM Joint Study. *Clin Microbiol Infect* 23(10):776.e1-776.e5, 10/2017. e-Pub 4/2017. PMID: 28412383.
362. **Kontoyiannis DP**, Bassetti M, Nucci M, Capparella MR, Yan JL, Aram J, Hogan PA. Anidulafungin for the treatment of candidaemia caused by *Candida parapsilosis*: Analysis of pooled data from six prospective clinical studies. *Mycoses* 60(10):663-667, 10/2017. e-Pub 6/2017. PMID: 28597967.
363. Taj-Aldeen SJ, Gamaletsou MN, Rammaert B, Sipsas NV, Zeller V, Roilides E, **Kontoyiannis DP**, Henry M, Petraitis V, Moriyama B, Denning DW, Lortholary O, Walsh TJ, International Osteoarticular Mycoses Consortium. Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century. *Med Mycol* 55(7):691-704, 10/2017. PMID: 28053147.
364. Sagiv O, Thakar SD, Kandl TJ, **Kontoyiannis DP**, Debnam JM, Esmaeli B. Clinical Course of Preseptal and Orbital Cellulitis in 50 Immunocompromised Patients with Cancer. *Ophthalmology*. e-Pub 11/2017. PMID: 29128228.
365. **Kontoyiannis DP**, Selleslag D, Mullane K, Cornely OA, Hope W, Lortholary O, Croos-Dabrera R, Lademacher C, Engelhardt M, Patterson TF. Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. *J Antimicrob Chemother*. e-Pub 11/2017. PMID: 29194488.
366. Lacourt TE, Kavelaars A, Galloway-Peña JR, Sahasrabhojane PV, Shah ND, Futreal A, **Kontoyiannis DP**, Shelburne SA, Heijnen CJ. Associations of inflammation with symptom burden in patients with acute myeloid leukemia. *Psychoneuroendocrinology* 89:203-208, 3/2018. PMID: 29414033.
367. Zoran T, Sartori B, Sappl L, Aigner M, Sánchez-Reus F, Rezusta A, Chowdhary A, Taj-Aldeen SJ, Arendrup MC, Oliveri S, **Kontoyiannis DP**, Alastruey-Izquierdo A, Lagrou K, Cascio GL, Meis JF, Buzina W, Farina C, Drogari-Apiranthitou M, Grancini A, Tortorano AM, Willinger B, Hamprecht A, Johnson E, Klingspor L, Arsic-Arsenijevic V, Cornely OA, Meletiadis J, Prammer W, Tullio V, Vehreschild JJ, Trovato L, Lewis RE, Segal E, Rath PM, Hamal P, Rodriguez-Iglesias M, Roilides E, Arikian-Akdagli S, Chakrabarti A, Colombo AL, Fernández MS, Martin-Gomez MT, Badali H, Petrikkos G, Klimko N, Heimann SM, Uzun O, Roudbary M, de la Fuente S, Houbraken J, Risslegger B, Lass-Flörl C, Lackner M. Azole-Resistance in *Aspergillus terreus* and Related Species: An Emerging Problem or a Rare Phenomenon? *Front Microbiol* 9:516, 3/2018. PMID: PMC5882871.
368. Schwartz S, **Kontoyiannis DP**, Harrison T, Ruhnke M. Advances in the diagnosis and treatment of fungal infections of the CNS. *Lancet Neurol* 17(4):362-372, 4/2018. PMID: 29477506.
369. Liu J, Mouhayar E, Tarrand JJ, **Kontoyiannis DP**. Fulminant *Cryptococcus neoformans* infection with fatal pericardial tamponade in a patient with chronic myelomonocytic leukemia who was treated with ruxolitinib: Case report and review of fungal pericarditis. *Mycoses* 61(4):245-255, 4/2018. PMID: 29280197.
370. Rausch CR, DiPippo AJ, Bose P, **Kontoyiannis DP**. Breakthrough fungal infections in leukemia patients receiving isavuconazole. *Clin Infect Dis*, 5/2018. PMID: 29771293.
371. Clancy CJ, Pappas PG, Vazquez J, Judson MA, **Kontoyiannis DP**, Thompson GR, Garey KW, Reboli A, Greenberg RN, Apewokin S, Lyon GM, Ostrosky-Zeichner L, Wu AHB, Tobin E, Nguyen MH, Caliendo AM. Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. *Clin Infect Dis*, 5/2018. PMID: 29438475.
372. Castillo P, Wright KE, **Kontoyiannis DP**, Walsh T, Patel S, Chorvinsky E, Bose S, Hazrat Y, Omer B, Albert N, Leen AM, Rooney CM, Bollard CM, Cruz CRY. A New Method for Reactivating and Expanding T Cells Specific for *Rhizopus oryzae*. *Mol Ther Methods Clin Dev* 9:305-312, 6/2018. PMID: PMC6054701.



373. Strati P, Gabutti C, Thompson PA, **Kontoyiannis DP**, Ferrajoli A. Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. *Leuk Lymphoma*:1-3, 6/2018. PMID: 29911929.
374. Kyrmizi I, Ferreira H, Carvalho A, Figueroa JAL, Zarpas P, Cunha C, Akoumianaki T, Stylianou K, Deepe GS, Samonis G, Lacerda JF, Campos A, **Kontoyiannis DP**, Mihalopoulos N, Kwon-Chung KJ, El-Benna J, Valsecchi I, Beauvais A, Brakhage AA, Neves NM, Latge JP, Chamilos G. Calcium sequestration by fungal melanin inhibits calcium-calmodulin signalling to prevent LC3-associated phagocytosis. *Nat Microbiol* 3(7):791-803, 7/2018. PMID: 29849062.
375. Lacourt TE, Kavelaars A, Ohanian M, Shah ND, Shelburne SA, Futreal A, **Kontoyiannis DP**, Heijnen CJ. Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia. *Oncotarget* 9(58):31244-31252, 7/2018. PMID: PMC6101294.
376. Andrianaki AM, Kyrmizi I, Thanopoulou K, Baldin C, Drakos E, Soliman SSM, Shetty AC, McCracken C, Akoumianaki T, Stylianou K, Ioannou P, Pontikoglou C, Papadaki HA, Tzardi M, Belle V, Ettiene E, Beauvais A, Samonis G, **Kontoyiannis DP**, Andreakos E, Bruno VM, Ibrahim AS, Chamilos G. Iron restriction inside macrophages regulates pulmonary host defense against *Rhizopus* species. *Nat Commun* 9(1):3333, 8/2018. PMID: PMC6102248.
377. Magira EE, Jiang Y, **Kontoyiannis DP**. Baseline serum *Aspergillus* galactomannan index in patients with hematologic malignancy and culture-documented invasive pulmonary aspergillosis: is there a difference among *Aspergillus* species? *Med Mycol*, 10/2018. PMID: 30339235.
378. Fernández-Cruz A, Magira E, Heo ST, Evans S, Tarrand J, **Kontoyiannis DP**. Bronchoalveolar lavage fluid cytology in culture-documented invasive pulmonary aspergillosis in patients with hematologic diseases: analysis of 67 episodes. *J Clin Microbiol* 56(10), 10/2018. PMID: PMC6156316.
379. Tataru AM, Wurster S, Lockworth CR, Albert ND, Walsh TJ, Mikos AG, Eisenhoffer GT, **Kontoyiannis DP**. Immunosuppressed Adult Zebrafish Model of Mucormycosis. *Antimicrob Agents Chemother* 62(11), 11/2018. PMID: PMC6201124.
380. Magira EE, Jiang Y, Economides M, Tarrand J, **Kontoyiannis DP**. Mixed mold pulmonary infections in haematological cancer patients in a tertiary care cancer centre. *Mycoses* 61(11):861-867, 11/2018. PMID: 30015364.
381. Alfayez M, Wang SA, Bannon SA, **Kontoyiannis DP**, Kornblau SM, Orange JS, Mace EM, DiNardo CD. Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype. *Leuk Lymphoma*:1-9. e-Pub 1/2019. PMID: 30648453.
382. DiPippo AJ, Rausch CR, **Kontoyiannis DP**. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. *Mycoses* 62(1):81-86, 1/2019. PMID: 30230043.
383. Wurster S, Lewis RE, Albert ND, **Kontoyiannis DP**. Pre-Exposure to Isavuconazole Increases the Virulence of Mucorales but not *Aspergillus fumigatus* in a *Drosophila melanogaster* Infection Model. *Antimicrob Agents Chemother* 63(2), 2/2019. PMID: PMC6355575.
384. DiPippo AJ, **Kontoyiannis DP**. Lack of toxicity with long term isavuconazole use in patients with hematologic malignancy. *Clin Infect Dis*. e-Pub 3/2019. PMID: 30861066.
385. Potenza L, Chitasombat MN, Klimko N, Bettelli F, Dragonetti G, Del Principe MI, Nucci M, Busca A, Fracchiolla N, Sciumè M, Spolzino A, Delia M, Mancini V, Nadali GP, Dargenio M, Shadrivova O, Bacchelli F, Aversa F, Sanguinetti M, Luppi M, **Kontoyiannis DP**, Pagano L. *Rhodotorula* infection in haematological patient: risk factors and outcome. *Mycoses* 62(3):223-229, 3/2019. PMID: 30525252.
386. **Kontoyiannis DP**, Shah EC, Wurster S, Aitken SL, Graviss L, Raad II, Chemaly RF. Culture-Documented Invasive Mold Infections at MD Anderson Cancer Center in Houston, Texas, Pre- and Post-Hurricane Harvey. *Open Forum Infect Dis* 6(4):ofz138, 4/2019. PMID: PMC6475585.
387. Galloway-Peña JR, Peterson CB, Malik F, Sahasrabhojane PV, Shah DP, Brumlow CE, Carlin LG, Chemaly RF, Im JS, Rondon G, Felix E, Veillon L, Lorenzi PL, Alousi AM, Jeng RR, **Kontoyiannis DP**, Shpall EJ, Shelburne SA, Okhuysen PC. Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. *Open Forum Infect Dis* 6(5):ofz173, 5/2019. PMID: PMC6499899.

388. Chow NA, Toda M, Pennington AF, Anassi E, Atmar RL, Cox-Ganser JM, Da Silva J, Garcia B, **Kontoyiannis DP**, Ostrosky-Zeichner L, Leining LM, McCarty J, Al Mohajer M, Murthy BP, Park JH, Schulte J, Shuford JA, Skrobarcek KA, Solomon S, Stryko J, Chiller TM, Jackson BR, Chew GL, Beer KD. Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey - Houston, Texas, 2017. *MMWR Morb Mortal Wkly Rep* 68(21):469-473, 5/2019. PMID: PMC6542480.
389. Wurster S, Kumaresan PR, Albert ND, Hauser PJ, Lewis RE, **Kontoyiannis DP**. Live monitoring and analysis of fungal growth, viability, and mycelial morphology using the IncuCyteNeuroTrack processing module. *MBio* 10(3), 5/2019. PMID: PMC6538782.
390. Zhang H, Tan J, **Kontoyiannis DP**, Zhou Y, Liu W, Zhu P, Shi X, Wan Z, Li R, Liu W. Screening the in vitro susceptibility of posaconazole in clinical isolates of *Candida* spp. and *Aspergillus* spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China. *Diagn Microbiol Infect Dis*. e-Pub 5/2019. PMID: 31174994.
391. Stanzani M, Vianelli N, Cavo M, **Kontoyiannis DP**, Lewis RE. Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. *J Infect* 78(6):484-490, 6/2019. PMID: 30974130.
392. Wurster S, Bandi A, Beyda ND, Albert ND, Raman NM, Raad II, **Kontoyiannis DP**. *Drosophila melanogaster* as a model to study virulence and azole treatment of the emerging pathogen *Candida auris*. *J Antimicrob Chemother* 74(7):1904-1910, 7/2019. PMID: 31225606.
393. Vargas-Cruz N, Reitzel RA, Rosenblatt J, Chaftari AM, Wilson Dib R, Hachem R, **Kontoyiannis DP**, Raad II. Nitroglycerin-Citrate-Ethanol (NiCE) Catheter Lock Solution is Highly Effective for in vitro Eradication of *Candida auris* Biofilm. *Antimicrob Agents Chemother* 63(7), 7/2019. PMID: PMC6591641.
394. Magira EE, Chemaly RF, Jiang Y, Tarrand J, **Kontoyiannis DP**. Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients With Hematologic Malignancies: A Case-Control Study. *Open Forum Infect Dis* 6(7):ofz247, 7/2019. PMID: PMC6639596.
395. Galloway-Peña JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, Daver NG, Alfayez M, Boddu PC, Khan MAW, Wargo JA, Do KA, Jenq RR, **Kontoyiannis DP**, Shelburne SA. Gut Microbiome Signatures are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. *Clin Infect Dis*, 8/2019. PMID: 31436833.
396. Tataru AM, Watson E, Albert ND, Kontoyiannis PD, **Kontoyiannis DP**, Mikos AG. A Murine Model of Cutaneous Aspergillosis for Evaluation of Biomaterials-based Local Delivery Therapies. *J Biomed Mater Res A* 107(9):1867-1874, 9/2019. PMID: PMC6626589.
397. Wang Q, **Kontoyiannis DP**, Li R, Chen W, Bu D, Liu W. A Novel Broad Allele-Specific TaqMan Real-Time PCR Method To Detect Triazole-Resistant Strains of *Aspergillus fumigatus*, Even with a Very Low Percentage of Triazole-Resistant Cells Mixed with Triazole-Susceptible Cells. *J Clin Microbiol* 57(9), 9/2019. PMID: PMC6711921.
398. Szvalb AD, **Kontoyiannis DP**. Acute acalculous cholecystitis due to *Fusarium* species and review of the literature on fungal cholecystitis. *Mycoses* 62(9):847-853, 9/2019. PMID: 31166627.
399. Abers MS, Lionakis MS, **Kontoyiannis DP**. Checkpoint Inhibition and Infectious Diseases: A Good Thing? *Trends Mol Med*, 9/2019. PMID: 31494023.
400. Cornely OA, Hoenigl M, Lass-Flörl C, Chen SC, **Kontoyiannis DP**, Morrissey CO, Thompson GR, Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM). Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. *Mycoses* 62(9):716-729, 9/2019. PMID: PMC6692208.
401. Lewis RE, **Kontoyiannis DP**, Viale P, Sarpong EM. Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension. *Antimicrob Agents Chemother*. e-Pub 9/2019. PMID: 31527039.

402. **Kontoyiannis DP**, Koons GL, Hicklen RS, Mikos AG, **Kontoyiannis DP**. Insect Bite-Associated Invasive Fungal Infections. *Open Forum Infect Dis* 6(10):ofz385, 10/2019. e-Pub 10/2019. PMID: PMC6785662.
403. Lewis RE, Wurster S, Beyda ND, Albert ND, **Kontoyiannis DP**. Comparative In Vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis. *Diagn Microbiol Infect Dis* 95(3):114861, 11/2019. e-Pub 7/2019. PMID: 31427139.
404. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, **Kontoyiannis DP**, Kullberg BJ, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler J, Lortholary O, Maertens J, Marchetti O, Marr KA, Masur H, Meis JF, Morrissey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop CS, Shoham S, Slavin MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, Pappas PG. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis*. e-Pub 12/2019. PMID: 31802125.
405. Fernández-Cruz A, Lewis RE, **Kontoyiannis DP**. How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions. *Clin Infect Dis*. e-Pub 3/2020. PMID: 32170948.
406. Robinson S, Peterson CB, Sahasrabhojane P, Ajami NJ, Shelburne SA, **Kontoyiannis DP**, Galloway-Peña JR. Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia. *mSphere* 5(2), 4/2020. e-Pub 4/2020. PMID: PMC7160678.
407. Galloway-Peña JR, **Kontoyiannis DP**. The gut mycobiome: The overlooked constituent of clinical outcomes and treatment complications in patients with cancer and other immunosuppressive conditions. *PLoSPathog* 16(4):e1008353, 4/2020. e-Pub 4/2020. PMID: PMC7117661.
408. Wurster S, Robinson P, Albert ND, Tarrand JJ, Goff M, Swamydas M, Lim JK, Lionakis MS, **Kontoyiannis DP**. PD-1 blockade improves survival and fungal clearance, induces pro-inflammatory lung cytokines and synergizes with caspofungin in a pulmonary aspergillosis model. *J Infect Dis*. e-Pub 5/2020. PMID: 32432714.
409. Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, **Kontoyiannis DP**, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. *Transpl Infect Dis*:e13395. e-Pub 6/2020. PMID: 32602954.
410. Frei M, Aitken SL, Jain N, Thompson P, Wierda W, **Kontoyiannis DP**, DiPippo AJ. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. *Leuk Lymphoma*:1-4. e-Pub 6/2020. PMID: 32530347.
411. Wurster S, Tataru AM, Albert ND, Ibrahim AS, Heitman J, Lee SC, Shetty AC, McCracken C, Graf KT, Mikos AG, Bruno VM, **Kontoyiannis DP**. Tornadic shear stress induces a transient, calcineurin-dependent hyper-virulent phenotype in Mucorales molds. *mBio* 11(3), 6/2020. e-Pub 6/2020. PMID: PMC7327176.
412. Spallone A, Hicklen RS, **Kontoyiannis DP**. Invasive fungal infections at presentation of untreated hematologic malignancies: rare and elusive. *Open Forum Infect Dis* 7(7):ofaa247, 7/2020. e-Pub 7/2020. PMID: PMC7368365.
413. Johnson MD, Lewis RE, Dodds Ashley ES, Ostrosky-Zeichner L, Zaoutis T, Thompson GR, Andes DR, Walsh TJ, Pappas PG, Cornely OA, Perfect JR, **Kontoyiannis DP**. Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. *J Infect Dis* 222(Supplement\_3):S175-S198, 8/2020. PMID: PMC7403757.
414. Szvalb AD, Malek AE, Jiang Y, Bhatti MM, Wurster S, **Kontoyiannis DP**. Serum (1,3)-Beta-d-Glucan has suboptimal performance for the diagnosis of *Pneumocystis jirovecii* pneumonia

- in cancer patients and correlates poorly with respiratory burden as measured by quantitative PCR. *J Infect* 81(3):443-451, 9/2020. e-Pub 7/2020. PMID: 32650108.
415. Wurster S, Sass G, Albert ND, Nazik H, Déziel E, Stevens DA, **Kontoyiannis DP**. Live imaging and quantitative analysis of *Aspergillus fumigatus* growth and morphology during inter-microbial interaction with *Pseudomonas aeruginosa*. *Virulence* 11(1):1329-1336, 12/2020. PMID: PMC7549912.
416. Kim ST, Sheshadri A, Shannon V, **Kontoyiannis DP**, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. *Front Immunol* 11:590494, 2020. e-Pub 1/2021. PMID: PMC7859512.
417. Chamilos G, Lionakis MS, **Kontoyiannis DP**. Are All Patients with Cancer at Heightened Risk for Severe Coronavirus Disease 2019 (COVID-19)? *Clin Infect Dis* 72(2):351-356, 1/2021. PMID: PMC7454377.
418. Wurster S, Lyos S, Albert ND, **Kontoyiannis DP**. Pharmacological serum concentrations of epinephrine and norepinephrine do not affect growth rate, morphogenesis, stress tolerance, and virulence of *Candida albicans*. *Med Mycol* 59(1):102-105, 1/2021. e-Pub 7/2020. PMID: 32678869.
419. Pérez-JacoisteAsín MA, López-Medrano F, Fernández-Ruiz M, Silva JT, San Juan R, **Kontoyiannis DP**, Aguado JM. Risk factors for the development of invasive aspergillosis after kidney transplantation: Systematic review and meta-analysis. *Am J Transplant* 21(2):703-716, 2/2021. e-Pub 9/2020. PMID: 32780498.
420. Axell-House DB, Wurster S, Jiang Y, Kyvernitakis A, Lewis RE, Tarrand JJ, Raad II, **Kontoyiannis DP**. Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer. *J Fungi (Basel)* 7(3), 3/2021. e-Pub 3/2021. PMID: PMC8002622.
421. Gudiol C, Lewis RE, Strati P, **Kontoyiannis DP**. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? *Lancet Haematol* 8(3):e216-e228, 3/2021. e-Pub 1/2021. PMID: 33460558.
422. Wurster S, Ruiz OE, Samms KM, Tataru AM, Albert ND, Kahan PH, Nguyen AT, Mikos AG, **Kontoyiannis DP**, Eisenhoffer GT. EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion. *Cell Rep* 34(12):108896, 3/2021. PMID: 33761358.
423. John TM, Jacob CN, **Kontoyiannis DP**. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. *J Fungi (Basel)* 7(4), 4/2021. e-Pub 4/2021. PMID: PMC8071133.
424. Aitken SL, Sahasrabhojane PV, **Kontoyiannis DP**, Savidge TC, Arias CA, Ajami NJ, Shelburne SA, Galloway-Peña JR. Alterations of the oral microbiome and cumulative carbapenem exposure are associated with *Stenotrophomonas maltophilia* infection in patients with acute myeloid leukemia receiving chemotherapy. *Clin Infect Dis* 72(9):1507-1513, 5/2021. e-Pub 6/2020. PMID: PMC8096257.
425. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, **Kontoyiannis DP**. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. *Clin Infect Dis* 72(10):1755-1763, 5/2021. e-Pub 4/2020. PMID: PMC8130026.
426. Lass-Flörl C, Dietl AM, **Kontoyiannis DP**, Brock M. *Aspergillus terreus* Species Complex. *Clin Microbiol Rev*:e0031120. e-Pub 6/2021. PMID: PMC8404697.
427. Viola GM, Malek AE, Rosen LB, DiNardo AR, Nishiguchi T, Okhuysen PC, Holland SM, **Kontoyiannis DP**. Disseminated cryptococcosis and anti-granulocyte-macrophage colony-stimulating factor autoantibodies: An underappreciated association. *Mycoses* 64(6):576-582, 6/2021. e-Pub 2/2021. PMID: 33476401.



428. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, **Kontoyiannis DP**, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. *Cancer* 127(14):2489-2499, 7/2021. e-Pub 4/2021. PMID: PMC8249340.
429. Korompoki E, Gavriatopoulou M, Hicklen RS, Ntanasis-Stathopoulos I, Kastritis E, Fotiou D, Stamatelopoulos K, Terpos E, Kotanidou A, Hagberg CA, Dimopoulos MA, **Kontoyiannis DP**. Epidemiology and organ specific sequelae of post-acute COVID19: A Narrative Review. *J Infect* 83(1):1-16, 7/2021. e-Pub 5/2021. PMID: PMC8118709.
430. Fekkar A, Neofytos D, Nguyen MH, Clancy CJ, **Kontoyiannis DP**, Lamoth F. COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it? *Clin Microbiol Infect* 27(9):1376-1378, 9/2021. e-Pub 6/2021. PMID: PMC8275029.
431. Dhal U, Hicklen RS, Tarrand J, **Kontoyiannis DP**. Cat Scratch Disease as a mimicker of malignancy. *Open Forum Infect Dis* 8(11):ofab500, 11/2021. e-Pub 10/2021. PMID: PMC8675392.
432. DiPippo AJ, McDaneld PM, Tverdek FP, **Kontoyiannis DP**. Effect of High-Dose Posaconazole on Serum Levels in Adult Patients with Hematologic Malignancy. *Antimicrob Agents Chemother* 65(12):e0123021, 11/2021. e-Pub 9/2021. PMID: PMC8597744.
433. Malek AE, Khalil M, Hachem R, Chaftari AM, Fares J, Jiang Y, **Kontoyiannis DP**, Fossella F, Chaftari P, Mulanovich VE, Viola GM, Raad II. Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study. *Clin Infect Dis* 73(9):e2697-e2704, 11/2021. PMID: 32564081.
434. Rossato L, Carlesse F, Nobrega de Almeida J, **Kontoyiannis DP**, Colombo AL. How different is invasive fusariosis in pediatric patients than in adults? A systematic review. *Curr Opin Infect Dis* 34(6):619-626, 12/2021. PMID: 34751181.
435. Hu C, Fong G, Wurster S, **Kontoyiannis DP**, Beyda ND. Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in *Candida glabrata*. *Microbiol Spectr* 10(1):e0183721, 2/2022. e-Pub 2/2022. PMID: PMC8809326.
436. Thompson GR, Garcia-Diaz J, Miceli MH, Nguyen MH, Ostrosky-Zeichner L, Young JH, Fisher CE, Clark NM, Greenberg RN, Spec A, Kovanda L, Croos-Dabrera R, **Kontoyiannis DP**. Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study. *Mycoses* 65(2):186-198, 2/2022. e-Pub 12/2021. PMID: 34888961.
437. Wurster S, Albert ND, **Kontoyiannis DP**. *Candida auris* bloodstream infection induces upregulation of the PD-1/PD-L1 immune checkpoint pathway in an immunocompetent mouse model. *mSphere* 7(2):e0081721, 4/2022. e-Pub 2/2022. PMID: PMC9044930.
438. Spallone A, Moran CA, Wurster S, Axell-House DB, **Kontoyiannis DP**. Taking a closer look: Clinical and histopathological characteristics of culture-positive versus culture-negative pulmonary mucormycosis. *J Fungi (Basel)* 8(4), 4/2022. e-Pub 4/2022. PMID: PMC9030790.
439. Spallone A, Alotaibi AS, Jiang Y, Daver N, **Kontoyiannis DP**. Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors. *Clin Lymphoma Myeloma Leuk* 22(5):305-310, 5/2022. e-Pub 10/2021. PMID: 34810120.
440. Wurster S, Paraskevopoulos T, Toda M, Jiang Y, Tarrand JJ, Williams S, Chiller TM, Jackson BR, **Kontoyiannis DP**. Invasive mould infections in patients from floodwater-damaged areas after hurricane Harvey - a closer look at an immunocompromised cancer patient population. *J Infect* 84(5):701-709, 5/2022. e-Pub 3/2022. PMID: 35288118.
441. Thompson GR, Boulware DR, Bahr NC, Clancy CJ, Harrison TS, Kauffman CA, Le T, Miceli MH, Mylonakis E, Nguyen MH, Ostrosky-Zeichner L, Patterson TF, Perfect JR, Spec A, **Kontoyiannis DP**, Pappas PG. Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. *Open Forum Infect Dis* 9(6):ofac112, 6/2022. e-Pub 3/2022. PMID: PMC9124589.



442. Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, **Kontoyiannis DP**, Khawaja F, Jennings K, Daver NG. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. *Cancer* 128(14):2736-2745, 7/2022. e-Pub 4/2022. PMID: PMC9232977.
443. Harish E, Sarkar A, Handelman M, Abo Kandil A, Shadkchan Y, Wurster S, Kontoyiannis DP, Osherov N. Triazole Priming as an Adaptive Response and Gateway to Resistance in *Aspergillus fumigatus*. *Antimicrob Agents Chemother* 66(8):e0045822, 8/2022. e-Pub 7/2022. PMID: PMC9380525.
444. Rausch CR, DiPippo AJ, Jiang Y, DiNardo CD, Kadia T, Maiti A, Montalban-Bravo G, Ravandi F, **Kontoyiannis DP**. Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies. *Clin Infect Dis* 75(9):1503-1510, 10/2022. e-Pub 3/2022. PMID: 35325094.
445. Stafylaki D, Maraki S, Vaporidi K, Georgopoulos D, **Kontoyiannis DP**, Kofteridis DP, Chamilos G. Impact of Molecular Syndromic Diagnosis of Severe Pneumonia in the Management of Critically Ill Patients. *Microbiol Spectr* 10(5):e0161622, 10/2022. e-Pub 9/2022. PMID: PMC9603977.
446. Colombo AL, De Almeida JN, Lewis RE, **Kontoyiannis DP**. Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis. *J Antimicrob Chemother* 77(11):2897-2900, 10/2022. e-Pub 9/2022. PMID: 36059133.
447. Gudiol C, Hicklen RS, Okhyusen PC, Malek AE, **Kontoyiannis DP**. Infections Simulating Immune Checkpoint Inhibitor Toxicities: Uncommon and Deceptive. *Open Forum Infect Dis* 9(11):ofac570, 11/2022. e-Pub 10/2022. PMID: PMC9679804.
448. Franklin A, Wurster S, Axell-House DB, Jiang Y, **Kontoyiannis DP**. Impact of Hyperglycemia and Diabetes Mellitus on Breakthrough Mucormycosis Outcomes in Patients with Hematologic Malignancies-Complex and Intriguing Associations. *J Fungi (Basel)* 9(1), 12/2022. e-Pub 12/2022. PMID: PMC9860539.
449. Gamaletsou MN, Rammaert B, Brause B, Bueno MA, Dadwal SS, Henry MW, Katragkou A, **Kontoyiannis DP**, McCarthy MW, Miller AO, Moriyama B, Pana ZD, Petraitiene R, Petraitis V, Roilides E, Sarkis JP, Simitsopoulou M, Sipsas NV, Taj-Aldeen SJ, Zeller V, Lortholary O, Walsh TJ, International Consortium for Osteoarticular Mycoses. *Osteoarticular Mycoses. Clin Microbiol Rev* 35(4):e0008619, 12/2022. e-Pub 11/2022. PMID: PMC9769674.
450. Wurster S, Albert ND, Bharadwaj U, Kasembeli MM, Tarrand JJ, Daver N, **Kontoyiannis DP**. Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis. *Front Immunol* 13:838344, 2022. e-Pub 2/2022. PMID: PMC8896628.
451. Wurster S, Watowich SS, **Kontoyiannis DP**. Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions. *Front Immunol* 13:1018202, 2022. e-Pub 10/2022. PMID: PMC9640966.
452. Franklin S, Aitken SL, Shi Y, Sahasrabhojane PV, Robinson S, Peterson CB, Daver N, Ajami NA, **Kontoyiannis DP**, Shelburne SA, Galloway-Peña J. Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients. *Front Cell Infect Microbiol* 12:848580, 2022. e-Pub 3/2022. PMID: PMC9010033.
453. Szvalb AD, Yopez Guevara E, Euscher E, Nahmod KA, **Kontoyiannis DP**. Acute Peritoneal Histoplasmosis Mimicking Ovarian Cancer and Review of the Literature on Histoplasma Peritonitis. *Open Forum Infect Dis* 10(1):ofac705, 1/2023. e-Pub 1/2023. PMID: PMC9850267.
454. Wurster S, García JP, Albert ND, Jiang Y, Bhoda K, Kulkarni VV, Wang Y, Walsh TJ, Evans S, **Kontoyiannis DP**. Development of a corticosteroid-immunosuppressed mouse model to study the pathogenesis and therapy of influenza-associated pulmonary aspergillosis. *J Infect Dis*. e-Pub 1/2023. PMID: 36611269.
455. Raad II, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Fernández Cruz A, Gorak E, Bhinder A, Mori N, Hamerschlag N,

- Shelanski S, Dragovich T, VongKiat YE, Fakhreddine S, Pierre AH, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Yepez EY, Torres HA, Ammakkanavar NR, Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, Garcia AG, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA, Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, **Kontoyiannis DP**, Malek AE, Chaftari AM. International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship. *Elife* 12, 1/2023. e-Pub 1/2023. PMID: PMC9981148.
456. Chowdhary A, Gupta N, Wurster S, Kumar R, Mohabir JT, Tatavarthy S, Mittal V, Rani P, Barman P, Sachdeva N, Singh A, Sharma B, Jiang Y, Cuomo CA, **Kontoyiannis DP**. Multimodal analysis of the COVID-19-associated mucormycosis outbreak in Delhi, India indicates the convergence of clinical and environmental risk factors. *Mycoses*. e-Pub 2/2023. PMID: 36790120.
457. Toda M, Williams S, Jackson BR, Wurster S, Serpa JA, Nigo M, Grimes CZ, Atmar RL, Chiller TM, Ostrosky-Zeichner L, **Kontoyiannis DP**. Invasive Mold Infections Following Hurricane Harvey-Houston, Texas. *Open Forum Infect Dis* 10(3):ofad093, 3/2023. e-Pub 2/2023. PMID: PMC10003735.

#### Invited Articles

458. **Kontoyiannis DP**, Rubin RH. Infection in the organ transplant recipient. An overview. *Infect Dis Clin North Am* 9(4):811-22, 12/1995. PMID: 8747767.
459. **Kontoyiannis DP**, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. *Infect Dis Clin North Am* 14(3):721-39, 9/2000. PMID: 10987117.
460. Shaikh ZH, Ueno NT, Kontoyiannis DP. Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. *Transpl Infect Dis* 3(1):29-33, 3/2001. PMID: 11429037.
461. **Kontoyiannis DP**. A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. *Infectious Diseases Society of America. Pharmacotherapy* 21(8 Pt 2):175S-187S, 8/2001. PMID: 11501990.
462. Samonis G, **Kontoyiannis DP**. Infectious complications of purine analog therapy. *Curr Opin Infect Dis* 14(4):409-13, 8/2001. PMID: 11964857.
463. Lewis RE, **Kontoyiannis DP**. Rationale for combination antifungal therapy. *Pharmacotherapy* 21(8 Pt 2):149S-164S, 8/2001. PMID: 11501988.
464. **Kontoyiannis DP**. Case records of the Massachusetts General Hospital. Case 20-2001. *New England Journal of Medicine* 344:2009-2014, 2001.
465. **Kontoyiannis DP**, Bodey GP. Invasive aspergillosis in 2002: an update. *Eur J Clin Microbiol Infect Dis* 21(3):161-72, 3/2002. PMID: 11957017.
466. De La Rosa GR, Champlin RE, **Kontoyiannis DP**. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. *Transpl Infect Dis* 4(1):3-9, 3/2002. PMID: 12123420.
467. Bodey GP, **Kontoyiannis DP**, Lewis R. Empiric antifungal therapy for persistently febrile neutropenic patients. *Curr Opin Infect Dis* 4:521-533, 2002.
468. **Kontoyiannis DP**, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. *J Hosp Infect* 53(4):243-58, 4/2003. PMID: 12660121.
469. Torres HA, Raad II, **Kontoyiannis DP**. Infections caused by *Fusarium* species. *J Chemother* 15 Suppl 2:28-35, 11/2003. PMID: 14708964.
470. Wiederhold NP, Lewis RE, **Kontoyiannis DP**. Invasive aspergillosis in patients with hematologic malignancies. *Pharmacotherapy* 23(12):1592-610, 12/2003. PMID: 14695039.
471. Antoniadou A, **Kontoyiannis DP**. Status of combination therapy for refractory mycoses. *Curr Opin Infect Dis* 16(6):539-45, 12/2003. PMID: 14624103.
472. **Kontoyiannis DP**, Lewis RE. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. *Drug Resist Updat* 6(5):257-69, 2003. PMID: 14643296.

473. Lionakis MS, **Kontoyiannis DP**. Fusarium infections in critically ill patients. *Semin Respir Crit Care Med* 25(2):159-69, 4/2004. PMID: 16088459.
474. **Kontoyiannis DP**, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. *Br J Haematol* 126(2):165-75, 7/2004. PMID: 15238137.
475. **Kontoyiannis DP**. Mycofungin. A viewpoint. *Drugs* 64(9):983-984, 2004.
476. Lionakis MS, **Kontoyiannis DP**. Fruit flies as a minihost model for studying drug activity and virulence in *Aspergillus*. *Med Mycol* 43 Suppl 1:S111-4, 5/2005. PMID: 16110801.
477. Morgan J, Wannemuehler KA, Marr KA, Hadley S, **Kontoyiannis DP**, Walsh TJ, Fridkin SK, Pappas PG, Warnock DW. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. *Med Mycol* 43 Suppl 1:S49-58, 5/2005. PMID: 16110792.
478. May GS, Xue T, **Kontoyiannis DP**, Gustin MC. Mitogen activated protein kinases of *Aspergillus fumigatus*. *Med Mycol* 43 Suppl 1:S83-6, 5/2005. PMID: 16110797.
479. Chamilos G, **Kontoyiannis DP**. Update on antifungal drug resistance mechanisms of *Aspergillus fumigatus*. *Drug Resist Updat* 8(6):344-58, 2005. PMID: 16488654.
480. Chamilos G, **Kontoyiannis DP**. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. *Curr Opin Infect Dis* 19(4):380-5, 8/2006. PMID: 16804387.
481. Chamilos G, **Kontoyiannis DP**. Defining the diagnosis of invasive aspergillosis. *Med Mycol* 44 Suppl:163-72, 9/2006. PMID: 17050435.
482. **Kontoyiannis DP**, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. *Infect Dis Clin North Am* 20(3):581-607, vi, 9/2006. PMID: 16984870.
483. Mays SR, Kunishige JH, Truong E, **Kontoyiannis DP**, Hymes SR. Approach to the morbilliform eruption in the hematopoietic transplant patient. *Semin Cutan Med Surg* 26(3):155-62, 9/2007. PMID: 18070682.
484. Ben-Ami R, Lewis RE, **Kontoyiannis DP**. Immunocompromised hosts: immunopharmacology of modern antifungals. *Clin Infect Dis* 47(2):226-35, 7/2008. PMID: 18540822.
485. **Kontoyiannis DP**, Lewis RE, Marr K. The burden of bacterial and viral infections in hematopoietic stem cell transplant. *Biol Blood Marrow Transplant* 15(1 Suppl):128-33, 1/2009. PMID: 19147091.
486. Ben-Ami R, Lewis RE, **Kontoyiannis DP**. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. *Curr Opin Infect Dis* 22(4):376-84, 8/2009. PMID: 19491674.
487. Nedel WL, **Kontoyiannis DP**, Pasqualotto AC. Aspergillosis in patients treated with monoclonal antibodies. *Rev IberoamMicol* 26(3):175-83, 9/2009. e-Pub 7/2009. PMID: 19635439.
488. Pongas GN, Lewis RE, Samonis G, **Kontoyiannis DP**. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? *Clin Microbiol Infect* 15 Suppl 5:93-7, 10/2009. PMID: 19754766.
489. Lewis RE, **Kontoyiannis DP**. Invasive aspergillosis in glucocorticoid-treated patients. *Med Mycol* 47 Suppl 1:1-11, 2009. e-Pub 7/2008. PMID: 18654923.
490. Leventakos K, Lewis RE, **Kontoyiannis DP**. Fungal infections in leukemia patients: how do we prevent and treat them? *Clin Infect Dis* 50(3):405-15, 2/2010. PMID: 20047485.
491. Ben-Ami R, Lewis RE, **Kontoyiannis DP**. Enemy of the (immunosuppressed) state: an update on the pathogenesis of *Aspergillus fumigatus* infection. *Br J Haematol* 150(4):406-17, 8/2010. e-Pub 7/2010. PMID: 20618330.
492. Lionakis MS, **Kontoyiannis DP**. The growing promise of Toll-deficient *Drosophila melanogaster* as a model for studying *Aspergillus* pathogenesis and treatment. *Virulence* 1(6):488-99, Nov-Dec, 11/2010. e-Pub 11/2010. PMID: PMC3073358.
493. Chen SC, **Kontoyiannis DP**. New molecular and surrogate biomarker-based tests in the diagnosis of bacterial and fungal infection in febrile neutropenic patients. *Curr Opin Infect Dis* 23(6):567-77, 12/2010. PMID: 20827189.

494. Person AK, **Kontoyiannis DP**, Alexander BD. Fungal infections in transplant and oncology patients. *Hematol Oncol Clin North Am* 25(1):193-213, 2/2011. PMID: 21236398.
495. Gomes MZ, Lewis RE, **Kontoyiannis DP**. Mucormycosis caused by unusual mucormycetes, non-rhizopus, -mucor, and -lichtheimia species. *Clin Microbiol Rev* 24(2):411-45, 4/2011. PMID: PMC3122490.
496. Georgiadou SP, Sipsas NV, Marom EM, **Kontoyiannis DP**. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. *Clin Infect Dis* 52(9):1144-55, 5/2011. PMID: PMC3106265.
497. Chen SC, Lewis RE, **Kontoyiannis DP**. Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of *Candida* and *Aspergillus* species. *Virulence* 2(4):280-95, Jul-Aug, 7/2011. e-Pub 7/2011. PMID: PMC3173675.
498. Mulanovich VE, **Kontoyiannis DP**. Fungal pneumonia in patients with hematologic malignancies: current approach and management. *Curr Opin Infect Dis* 24(4):323-32, 8/2011. PMID: 21666457.
499. **Kontoyiannis DP**, Lewis RE. How I treat mucormycosis. *Blood* 118(5):1216-24, 8/2011. e-Pub 5/2011. PMID: PMC3292433.
500. Marom EM, **Kontoyiannis DP**. Imaging studies for diagnosing invasive fungal pneumonia in immunocompromised patients. *Curr Opin Infect Dis* 24(4):309-14, 8/2011. PMID: 21673574.
501. Hamilos G, Samonis G, **Kontoyiannis DP**. Pulmonary mucormycosis. *Semin Respir Crit Care Med* 32(6):693-702, 12/2011. e-Pub 12/2011. PMID: 22167397.
502. Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikkos G, **Kontoyiannis DP**, Walsh TJ. Combination therapy for mucormycosis: why, what, and how? *Clin Infect Dis* 54 Suppl 1:S73-8, 2/2012. PMID: 22247449.
503. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, **Kontoyiannis DP**. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). *Clin Infect Dis* 54 Suppl 1:S55-60, 2/2012. PMID: 22247446.
504. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, **Kontoyiannis DP**. Epidemiology and clinical manifestations of mucormycosis. *Clin Infect Dis* 54 Suppl 1:S23-34, 2/2012. PMID: 22247442.
505. **Kontoyiannis DP**, Lewis RE, Lortholary O, Lortholary O, Spellberg B, Petrikkos G, Roilides E, Ibrahim A, Walsh TJ. Future directions in mucormycosis research. *Clin Infect Dis* 54 Suppl 1:S79-85, 2/2012. PMID: PMC3258101.
506. Roilides E, **Kontoyiannis DP**, Walsh TJ. Host defenses against zygomycetes. *Clin Infect Dis* 54 Suppl 1:S61-6, 2/2012. PMID: 22247447.
507. Lewis RE, Lortholary O, Spellberg B, Roilides E, **Kontoyiannis DP**, Walsh TJ. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? *Clin Infect Dis* 54 Suppl 1:S67-72, 2/2012. PMID: 22247448.
508. Walsh TJ, Bloom BE, **Kontoyiannis DP**. Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis. *Clin Infect Dis* 54 Suppl 1:S1-4, 2/2012. PMID: 22247440.
509. Ibrahim AS, Spellberg B, Walsh TJ, **Kontoyiannis DP**. Pathogenesis of mucormycosis. *Clin Infect Dis* 54 Suppl 1:S16-22, 2/2012. PMID: PMC3286196.
510. Muhammed M, Feldmesser M, Shubitz LF, Lionakis MS, Sil A, Wang Y, Glavis-Bloom J, Lewis RE, Galgiani JN, Casadevall A, **Kontoyiannis DP**, Mylonakis E. Mouse models for the study of fungal pneumonia: a collection of detailed experimental protocols for the study of *Coccidioides*, *Cryptococcus*, *Fusarium*, *Histoplasma* and combined infection due to *Aspergillus-Rhizopus*. *Virulence* 3(3):329-38, 5/2012. e-Pub 5/2012. PMID: PMC3442846.
511. Sipsas NV, **Kontoyiannis DP**. Invasive fungal infections in patients with cancer in the Intensive Care Unit. *Int J Antimicrob Agents* 39(6):464-71, 6/2012. e-Pub 2/2012. PMID: 22337064.
512. Lewis RE, Viale P, **Kontoyiannis DP**. The potential impact of antifungal drug resistance mechanisms on the host immune response to *Candida*. *Virulence* 3(4):368-76, 7/2012. e-Pub 6/2012. PMID: PMC3478239.
513. Georgiadou SP, **Kontoyiannis DP**. The impact of azole resistance on aspergillosis guidelines. *Ann N Y Acad Sci* 1272:15-22, 12/2012. PMID: 23231710.



514. Ben-Ami R, **Kontoyiannis DP**. A nonlethal murine cutaneous model of invasive aspergillosis. *Methods Mol Biol* 845:569-82, 2012. PMID: 22328405.
515. Lionakis MS, **Kontoyiannis DP**. *Drosophila melanogaster* as a model organism for invasive aspergillosis. *Methods Mol Biol* 845:455-68, 2012. PMID: 22328395.
516. Gamaletsou M, Sipsas NV, **Kontoyiannis DP**. Micafungin in hematology. *Mycoses* 55(Suppl 1):13-23, 2012, 2012.
517. Hamilos G, Samonis G, **Kontoyiannis DP**. Recent Advances in the Use of *Drosophila melanogaster* as a Model to Study Immunopathogenesis of Medically Important Filamentous Fungi. *Int J Microbiol* 2012:583792, 2012. e-Pub 2/2012. PMID: PMC3299265.
518. Granwehr BP, **Kontoyiannis DP**. The impact of infectious diseases consultation on oncology practice. *Curr Opin Oncol* 25(4):353-9, 7/2013. PMID: 23736876.
519. Lewis RE, **Kontoyiannis DP**. Epidemiology and treatment of mucormycosis. *Future Microbiol* 8:1163-75, 9/2013. PMID: 24020743.
520. **Kontoyiannis DP**. Rational approach to pulmonary infiltrates in leukemia and transplantation. *Best Pract Res Clin Haematol* 26(3):301-6, 9/2013. PMID: 24309535.
521. Ibrahim AS, **Kontoyiannis DP**. Update on mucormycosis pathogenesis. *Curr Opin Infect Dis* 26(6):508-15, 12/2013. e-Pub 10/2013. PMID: 24126718.
522. **Kontoyiannis DP**, Mathur M, Chen YB, Shellito PC, Tse JY. Case records of the Massachusetts General Hospital. Case 13-2014. A 41-year-old man with fever and abdominal pain after stem-cell transplantation. *N Engl J Med* 370(17):1637-46, 4/2014. PMID: 24758620.
523. Ariza-Heredia EJ, **Kontoyiannis DP**. Our recommendations for avoiding exposure to fungi outside the hospital for patients with haematological cancers. *Mycoses* 57(6):336-41, 6/2014. e-Pub 1/2014. PMID: 24446760.
524. McCarthy M, Rosengart A, Schuetz AN, **Kontoyiannis DP**, Walsh TJ. Mold Infections of the Central Nervous System. *N Engl J Med* 371(2):150-160, 7/2014. PMID: 25006721.
525. **Kontoyiannis DP**, Patterson TF. Diagnosis and treatment of invasive fungal infections in the cancer patient: Recent progress and ongoing questions. *Clin Infect Dis* 59 Suppl 5:S356-9, 11/2014. PMID: 25352631.
526. Walsh TJ, Skiada A, Cornely OA, Roilides E, Ibrahim A, Zaoutis T, Groll A, Lortholary O, **Kontoyiannis DP**, Petrikos G. Development of new strategies for early diagnosis of mucormycosis from bench to bedside. *Mycoses* 57 Suppl 3:2-7, 12/2014. PMID: PMC4464811.
527. **Kontoyiannis DP**, Lewis RE. Treatment principles for the management of mold infections. *Cold Spring Harb Perspect Med* 5(4), 4/2015. e-Pub 11/2014. PMID: 25377139.
528. Farmakiotis D, **Kontoyiannis DP**. Emerging issues with diagnosis and management of fungal infections in solid organ transplant recipients. *Am J Transplant* 15(5):1141-7, 5/2015. e-Pub 2/2015. PMID: 25655091.
529. Ananda-Rajah MR, **Kontoyiannis D**. Isavuconazole: a new extended spectrum triazole for invasive mold diseases. *Future Microbiol* 10:693-708, 5/2015. e-Pub 5/2015. PMID: 26000646.
530. Davoudi S, Graviss LS, **Kontoyiannis DP**. Health care-associated outbreaks due to Mucorales and other uncommon fungi. *Eur J Clin Invest* 45(7):767-73, 7/2015. e-Pub 5/2015. PMID: 25989947.
531. Chitasombat MN, **Kontoyiannis DP**. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. *Expert Opin Pharmacother* 16(10):1543-58, 7/2015. e-Pub 6/2015. PMID: 26100603.
532. Halpern AB, Lyman GH, Walsh TJ, **Kontoyiannis DP**, Walter RB. Evidence-based focused review of primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. *Blood* 126(26):2790-7, 12/2015. e-Pub 10/2015. PMID: PMC4692139.
533. Farmakiotis D, **Kontoyiannis DP**. Mucormycoses. *Infect Dis Clin North Am* 30(1):143-63, 3/2016. PMID: 26897065.
534. Tverdek FP, Kofteridis D, **Kontoyiannis DP**. Antifungal agents and liver toxicity: a complex interaction. *Expert Rev Anti Infect Ther* 14(8):765-76, 8/2016. e-Pub 6/2016. PMID: 27275514.



535. Chitasombat MN, **Kontoyiannis DP**. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents. *Curr Opin Infect Dis* 29(4):340-5, 8/2016. PMID: 27191199.
536. Osherov N, **Kontoyiannis DP**. The anti-Aspergillus drug pipeline: Is the glass half full or empty? *Med Mycol* 55(1):118-124, 1/2017. e-Pub 8/2016. PMID: 27562862.
537. Watson E, Tatar A, **Kontoyiannis DP**, Mikos A. Inherently Antimicrobial Biodegradable Polymers in Tissue Engineering. *ACS Biomaterials Science & Engineering* 3(7):1207-1220, 7/2017.
538. McCarthy MW, **Kontoyiannis DP**, Cornely OA, Perfect JR, Walsh TJ. Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. *J Infect Dis* 216(suppl\_3):S474-S483, 8/2017. PMID: 28911042.
539. Farmakiotis D, **Kontoyiannis DP**. Epidemiology of antifungal resistance in human pathogenic yeasts: Current viewpoint and practical recommendations for management. *Int J Antimicrob Agents* 50(3):318-324, 9/2017. PMID: 28669831.
540. Tatar A, **Kontoyiannis DP**, Mikos AG. Drug delivery and tissue engineering to promote wound healing in the immunocompromised host: Current challenges and future directions. *Adv Drug Deliv Rev*. e-Pub 12/2017. PMID: 29221962.
541. Carmona-Gutierrez D, Bauer MA, Zimmermann A, Aguilera A, Austriaco N, Ayscough K, Balzan R, Bar-Nun S, Barrientos A, Belenky P, Blondel M, Braun RJ, Breitenbach M, Burhans WC, Büttner S, Cavalieri D, Chang M, Cooper KF, Côte-Real M, Costa V, Cullin C, Dawes I, Dengjel J, Dickman MB, Eisenberg T, Fahrenkrog B, Fasel N, Fröhlich KU, Gargouri A, Giannattasio S, Goffrini P, Gourlay CW, Grant CM, Greenwood MT, Guaragnella N, Heger T, Heinisch J, Herker E, Herrmann JM, Hofer S, Jiménez-Ruiz A, Jungwirth H, Kainz K, **Kontoyiannis DP**, Ludovico P, Manon S, Martegani E, Mazzoni C, Megeney LA, Meisinger C, Nielsen J, Nyström T, Osiewacz HD, Outeiro TF, Park HO, Pendl T, Petranovic D, Picot S, Polcic P, Powers T, Ramsdale M, Rinnerthaler M, Rockenfeller P, Ruckstuhl C, Schaffrath R, Segovia M, Severin FF, Sharon A, Sigrist SJ, Sommer-Ruck C, Sousa MJ, Thevelein JM, Thevissen K, Titorenko V, Toledano MB, Tuite M, Vögtle FN, Westermann B, Winderickx J, Wissing S, Wölfl S, Zhang ZJ, Zhao RY, Zhou B, Galluzzi L, Kroemer G, Madeo F. Guidelines and recommendations on yeast cell death nomenclature. *Microb Cell* 5(1):4-31, 1/2018. PMID: PMC5772036.
542. Kumaresan PR, da Silva TA, **Kontoyiannis DP**. Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells. *Front Immunol* 8:1939, 1/2018. PMID: PMC5766637.
543. Lionakis MS, Lewis RE, **Kontoyiannis DP**. Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions. *Clin Infect Dis*, 5/2018. PMID: 29860307.
544. Mulanovich V, **Kontoyiannis DP**. Acute myeloid leukemia and the infectious diseases consultant. *Leuk Lymphoma*:1-8, 6/2018. PMID: 28914100.
545. Sipsas NV, Gamaletsou MN, Anastasopoulou A, **Kontoyiannis DP**. Therapy of Mucormycosis. *J Fungi (Basel)* 4(3), 7/2018. PMID: 30065232.
546. Dadwal SS, **Kontoyiannis DP**. Recent advances in the molecular diagnosis of mucormycosis. *Expert Rev Mol Diagn* 18(10):845-854, 10/2018. PMID: 30203997.
547. Yong MK, Slavin MA, **Kontoyiannis DP**. Invasive Fungal Disease and Cytomegalovirus infection: is there an association? *Curr Opin Infect Dis* 31(6):481-489, 12/2018. PMID: 30299361.
548. Chikley A, Ben-Ami R, **Kontoyiannis DP**. Mucormycosis of the central nervous system. *J Fungi (Basel)* 5(3), 7/2019. PMID: PMC6787740.
549. Walsh TJ, Hospenthal DR, Petraitis V, **Kontoyiannis DP**. Necrotizing Mucormycosis of Wounds Following Combat Injuries, Natural Disasters, Burns, and Other Trauma. *J Fungi (Basel)* 5(3), 7/2019. PMID: 31277364.
550. Lamoth F, **Kontoyiannis DP**. Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients. *Antimicrob Agents Chemother* 63(11), 11/2019. PMID: PMC6811444.
551. Pappas PG, Boulware DR, **Kontoyiannis DP**, Miceli MH, Ostrosky-Zeichner L, Spec A, Thompson GR, Chen S, Perfect JR, MSGERC investigators. Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second

- biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda. *Med Mycol.* e-Pub 5/2020. PMID: 32407483.
552. Koehler P, Denis B, Denning DW, Gangneux JP, Hoenigl M, **Kontoyiannis DP**, Krause R, Lagrou K, Lass-Flörl C, Maertens J, Marekovic I, Meis JF, Molina JM, Pleško S, Prattes J, Rath PM, Rautemaa-Richardson R, Richardson M, Segal E, Seidel D, Spriet I, Steinmann J, Verweij PE, Cornely OA, European Confederation of Medical Mycology (ECMM). European confederation of medical mycology expert consult-An ECMM excellence center initiative. *Mycoses* 63(6):566-572, 6/2020. e-Pub 4/2020. PMID: 32181546.
553. Puerta-Alcalde P, Champlin R, **Kontoyiannis DP**. How I transplant a patient with a history of invasive fungal disease. *Blood.* e-Pub 8/2020. PMID: 32845974.
554. Lamoth F, Lewis RE, **Kontoyiannis DP**. Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. *J Fungi (Basel)* 7(1), 12/2020. e-Pub 12/2020. PMID: PMC7823995.
555. Dadwal SS, Hohl TM, Fisher CE, Boeckh M, Papanicolaou G, Carpenter PA, Fisher BT, Slavin MA, **Kontoyiannis DP**. American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. *Transplant Cell Ther* 27(3):201-211, 3/2021. PMID: 33781516.
556. Lockhart SR, Bialek R, Kibbler CC, Cuenca-Estrella M, Jensen HE, **Kontoyiannis DP**. Molecular Techniques for Genus and Species Determination of Fungi From Fresh and Paraffin-Embedded Formalin-Fixed Tissue in the Revised EORTC/MSGERC Definitions of Invasive Fungal Infection. *Clin Infect Dis* 72(Suppl 2):S109-S113, 3/2021. PMID: PMC7952508.
557. Lamoth F, Lewis RE, Walsh TJ, **Kontoyiannis DP**. Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA). *J Infect Dis.* e-Pub 3/2021. PMID: PMC8083649.
558. Ben-Ami R, **Kontoyiannis DP**. Resistance to Antifungal Drugs. *Infect Dis Clin North Am* 35(2):279-311, 6/2021. PMID: 34016279.
559. Wurster S, Ruiz OE, Tatara AM, **Kontoyiannis DP**, Eisenhoffer GT. Protocol for fungal infection following the induction of epithelial cell loss in larval zebrafish. *STAR Protoc* 2(4):100963, 12/2021. e-Pub 11/2021. PMID: PMC8609045.
560. Lamoth F, Lewis RE, **Kontoyiannis DP**. Investigational antifungal agents for invasive mycoses: a clinical perspective. *Clin Infect Dis* 75(3):534-544, 8/2022. e-Pub 1/2022. PMID: 34986246.
561. Wurster S, Albert ND, **Kontoyiannis DP**. *Drosophila melanogaster* as a Rapid and Reliable In Vivo Infection Model to Study the Emerging Yeast Pathogen *Candida auris*. *Methods Mol Biol* 2517:299-316, 2022. PMID: 35674964.
562. Vuong NV, Hammond D, **Kontoyiannis DP**. Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges. *J of Fungii.* In Press.
563. Dailey Garnes J, **Kontoyiannis DP**. Mucormycosis: an update in diagnosis and management. *Current Opinion in Infectious Diseases.* In Press.
564. Lamoth F, **Kontoyiannis DP**. PCR diagnostics for infections caused by non-Aspergillus molds: Ready for prime time? *Current Opinion in Molecular Diagnostics.* In Press.
565. Matsuo T, Wurster S, **Kontoyiannis DP**. Point of care diagnostics in medical mycology. *Current Opinion in Molecular Diagnostics.* In Press.

#### Editorials

1. Lewis RE, **Kontoyiannis DP**. The epidemiology of invasive candidiasis in BMT patients in the 2000s: Is fluconazole the only factor for the emergence of some-non-albicans *Candida* species? *Infections in Medicine* 21:40, 2004.
2. John BV, Chamilos G, **Kontoyiannis DP**. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. *Clin Microbiol Infect* 11(7):515-7, 7/2005. PMID: 15966968.
3. **Kontoyiannis DP**. Cutaneous zygomycosis. *Infections in Medicine* 22(42), 2005.
4. Walsh TJ, **Kontoyiannis DP**. Editorial commentary: what is the role of combination therapy in management of zygomycosis? *Clin Infect Dis* 47(3):372-4, 8/2008. PMID: 18558877.
5. Adachi J, **Kontoyiannis DP**. Gastrointestinal Mucormycosis: An Elusive, Unusual, and Severe. *Gastroenterology & Hepatology* 5:661-62, September 2009, 2009.

6. **Kontoyiannis DP.** Manipulation of host angiogenesis: A critical link for understanding the pathogenesis of invasive mold infections? *Virulence* 1(3):192-6, May-Jun, 5/2010. PMID: PMC3073245.
7. Tsatsanis C, Margioris AN, **Kontoyiannis DP.** Association between H1N1 infection severity and obesity-adiponectin as a potential etiologic factor. *J Infect Dis* 202(3):459-60, 8/2010. PMID: 20557238.
8. **Kontoyiannis DP.** Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success. *Bone Marrow Transplant* 46(2):165-73, 2/2011. e-Pub 11/2010. PMID: 21042306.
9. **Kontoyiannis DP.** A clinical approach to assess treatment for presumed and documented invasive mold infections in patients with hematologic malignancies: focus on Spanish Society of Chemotherapy Guidelines. *Rev Esp Quimioter* 24(4):173-4, 12/2011. PMID: 22173185.
10. Chamilos G, Samonis G, **Kontoyiannis DP.** *Drosophila melanogaster* as a Model Host for the Study of Microbial Pathogenicity and the Discovery of Novel Antimicrobial Compounds. *Curr Pharm Des* 17(13):1246-53, 2011. e-Pub 4/2011. PMID: 21470115.
11. Ben-Ami R, **Kontoyiannis DP.** Resistance to echinocandins comes at a cost: the impact of FKS1 hotspot mutations on *Candida albicans* fitness and virulence. *Virulence* 3(1):95-7, Jan-Feb, 1/2012. e-Pub 1/2012. PMID: PMC3337155.
12. **Kontoyiannis DP.** Preventing fungal disease in chronically immunosuppressed outpatients: time for action? *Ann Intern Med* 158(7):555-6, 4/2013. PMID: 23546567.
13. Pappas PG, **Kontoyiannis DP,** Perfect JR, Chiller TM. Real-Time Treatment Guidelines: Considerations during the *Exserohilum rostratum* Outbreak in the United States. *Antimicrob Agents Chemother* 57(4):1573-6, 4/2013. e-Pub 2/2013. PMID: PMC3623335.
14. Thompson GR, **Kontoyiannis DP,** Patterson TF. Real-world experience in the midst of an *Exserohilum meningitis* outbreak. *JAMA* 309(23):2493-5, 6/2013. PMID: 23780464.
15. **Kontoyiannis DP.** Virulence Profile: Dimitrios P Kontoyiannis. *Virulence* 4(5):429-31, 7/2013. PMID: PMC3714135.
16. **Kontoyiannis DP,** Perlin DS, Roilides E, Walsh TJ. What can we learn and what do we need to know amidst the iatrogenic outbreak of *exserohilum rostratum meningitis*? *Clin Infect Dis* 57(6):853-9, 9/2013. e-Pub 5/2013. PMID: PMC3888152.
17. **Kontoyiannis DP.** Are respiratory complications more likely in patients with pulmonary aspergillosis treated with echinocandins in the setting of neutrophil influx? *Virulence* 5(3):375-7, 4/2014. e-Pub 2/2014. PMID: PMC3979863.
18. Jung DS, **Kontoyiannis DP.** Co-infection with Influenza: Do Not Forget *Aspergillus* in the Immunosuppressed Neutropenic Host. *Tuberc Respir Dis (Seoul)* 76(5):249, 5/2014. e-Pub 5/2014. PMID: PMC4050075.
19. Askew DS, **Kontoyiannis DP,** Clemons KV. Advances Against Aspergillosis: Biology, Host response, Diagnosis and Treatment. *Mycopathologia* 178(5-6):321-4, 12/2014. e-Pub 10/2014. PMID: 25287755.
20. Granwehr B, **Kontoyiannis DP.** The evolving landscape of gastrointestinal infections in neutropenic patients. *Oncology (Williston Park)* 29(8):590, 592-3, 8/2015. PMID: 26349340.
21. **Kontoyiannis DP.** Infections following allogeneic stem cell transplantation: New concepts, improved insights, and renewed hope for better outcomes. *Virulence*:0. e-Pub 10/2016. PMID: 27791470.
22. **Kontoyiannis DP.** Antifungal Resistance: An Emerging Reality and A Global Challenge. *J Infect Dis* 216(suppl\_3):S431-S435, 8/2017. PMID: 28911044.
23. Lamoth F, **Kontoyiannis DP.** The *Candida auris* Alert: Facts and Perspectives. *J Infect Dis* 217(4):516-520, 1/2018. PMID: 29390110.
24. Cornely OA, **Kontoyiannis DP.** How to prophylax against invasive fungal infections in adult ALL? An unmet need. *Mycoses*, 4/2018. PMID: 29693737.
25. Casadevall A, **Kontoyiannis DP,** Robert V. On the emergence of *Candida auris*: climate change, azoles, swamps and birds. *MBio* 10(4), 7/2019. PMID: PMC6650554.
26. Garcia-Vidal C, Lewis RE, **Kontoyiannis DP.** Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: when management reasoning eclipses evidence-based medicine. *J Antimicrob Chemother.* e-Pub 7/2020. PMID: 32719877.

27. Malek AE, Granwehr BP, **Kontoyiannis DP**. Doxycycline as a potential partner of COVID-19 therapies. *IDCases* 21:e00864, 2020. e-Pub 6/2020. PMID: PMC7298522.
28. Colombo AL, Agnelli C, **Kontoyiannis DP**. Knowledge gaps in candidaemia/invasive candidiasis in haematological cancer patients. *J Antimicrob Chemother* 76(3):543-546, 2/2021. PMID: 33150364.
29. Casadevall A, **Kontoyiannis DP**, Robert V. Environmental Candida auris and the Global Warming Emergence Hypothesis. *mBio* 12(2), 3/2021. e-Pub 3/2021. PMID: PMC8092241.
30. Korompoki E, Gavriatopoulou M, **Kontoyiannis DP**. COVID-19 Vaccines in Patients With Cancer-A Welcome Addition, but There Is Need for Optimization. *JAMA Oncol* 7(8):1113-1114, 8/2021. e-Pub 5/2021. PMID: 33983372.
31. Skaria J, John TM, Varkey S, **Kontoyiannis DP**. Are Unique Regional Factors the Missing Link in India's COVID-19-Associated Mucormycosis Crisis? *mBio* 13(2):e0047322, 4/2022. e-Pub 3/2022. PMID: PMC9040830.

#### Other Articles

1. Kontoyiannis DP. SCH 56592: Hosted in Aspergillus web page, 2000.
2. **Kontoyiannis DP**. Invasive aspergillosis: a management overview. 7:42-44, 2003.
3. Liu W, May GS, **Kontoyiannis DP**, Li RY. Cloning of the *Aspergillus fumigatus* squalene epoxidase gene. *Beijing Da Xue Xue Bao* 36(5):476-82, 10/2004. PMID: 15489926.
4. **Kontoyiannis DP**. (honorary contributor, state to the art monograph): Evolution of Invasive Fungal Infections: Epidemiology and Treatment. 8th Foundations of Clinical Care Research Symposium Annual Newsletter Redefining the Target: Revolutionary Approached to Targeted Therapeutics, 2005.
5. **Kontoyiannis DP**, Lewis RE. A fly model to study fungal disease. *Microbe*, ASM Press 5(7):291-4, 2009.
6. Campo M, **Kontoyiannis DP**. A man with AML, fever and hip pain. *The J of Inv Fungal Infect*(3):15-17, 2009.
7. Mulanovich V, **Kontoyiannis DP**. (honorary contributor, state to the art monograph): The future of antibacterial prophylaxis for patients with hematologic malignancies. 12th Foundations of Clinical Cancer Research Symposium Annual Newsletter The Future of Antibacterial Prophylaxis in patients with Hematologic Malignancies, 2010.
8. **Kontoyiannis DP**. (honorary contributor, state to the art monograph): A clinical approach to assess immunosuppression in the leukemia patient. 14th Foundations of Clinical Cancer Research Symposium Annual Newsletter A clinical approach to assess immunosuppression in leukemia patients., 2012.
9. **Kontoyiannis DP**. Is *Candida auris* here to stay? An interview with Dimitrios Kontoyiannis. *Future Microbiol* 14:1083-1085, 9/2019. PMID: 31512518.
10. Spallone A, **Kontoyiannis DP**. Case of the Month//Fusariosis. *DrFungus.org*. e-Pub 2019.

#### Abstracts

N/A

#### Book Chapters

1. Anaissie, EJ, Nelson P, Beremand M, Kontoyiannis DP, Rinaldi M. *Fusarium* caused hyalohyphomycosis: An overview. In: *Current Topics in Medical Mycology*. 4. Springer-Verlag, 231-249, 1992.
2. **Kontoyiannis DP**, Anaissie EJ, Bodey GP. Infection in chronic lymphocytic leukemia: A reappraisal. In: *Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments*. Marcel Dekker, 399-417, 1993.
3. Torres H, **Kontoyiannis DP**. Hyalohyphomycoses. In: *Oxford Textbook of Clinical Mycology*. Oxford University Press, 252-270, 2003.
4. Bodey, GP, Chemaly R, **Kontoyiannis DP**. Fungal and Viral infections in cancer patients. In: *The MD Anderson Manual of Medical Oncology*. Mc Graw-Hill, 2004.
5. Bodey GP, **Kontoyiannis DP**, Keating MJ. Infections in patients with chronic lymphocytic leukemia. In: *Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management*. The Humana Press Inc., 2004.
6. **Kontoyiannis DP**. Mycetoma. In: *Cecil Textbook of Medicine*, 22nd Edition. W. B. Sanders Co., 2004.



7. **Kontoyiannis DP.** Nocardia. In: Infectious Diseases. Ed(s) S. Gorbach. Lippincott Williams and Wilkins, 2004.
8. Chamilos G, **Kontoyiannis DP.** Aspergillus and opportunistic fungal infections of the lung. In: Pulmonary Diseases and Disorders, 5th Edition. Ed(s) Grippi M, Elias J, Fishman J, et al. McGraw-Hill: New York, 2008.
9. Chamilos G, **Kontoyiannis DP.** Emerging role of mini-host models to study aspergillosis. In: The Aspergilli: Genomics, Medical Aspects, Biotechnology and Research Methods.. Ed(s) GH Goldman, SA Osmani. CRC Press, 2008.
10. **Kontoyiannis DP.** Insert models of infection. In: The Aspergilli: Genomics, Medicine, Biotechnology and Research Methods. Ed(s) G. Goldman and S. Osmani. CRC Press, 2008.
11. **Kontoyiannis DP.** Mycormycosis. In: Cecil Textbook of Medicine, 23rd Edition. W. B. Saunders Co., 2008.
12. **Kontoyiannis DP.** Trichosporon species and Blastoschizomycescapitatus. In: Antimicrobial Therapy and Vaccines. I: Microbes, 3rd Edition. Ed(s) Yu VI, Weber R, Raoult D. Williams and Wilkins Press: Lippincott, 2008.
13. **Kontoyiannis DP,** Lewis RE, Walsh TJ. Fungal infections in immunocompromised hosts with cancer. In: Medical Care of Cancer Patients.. Ed(s) S-C Yeung, CP Escalante, RF Gagel. BC Decker Inc, 2009.
14. **Kontoyiannis DP.** Primary and salvage treatment of aspergillosis. In: Aspergillus fumigatus and Aspergillosis. Ed(s) W. Steinback& P. Latge. ASM Press, 2009.
15. **Kontoyiannis DP,** Lewis RE. A clinical approach to Candida resistance. In: Candida and Candidiasis. ASM Press, 2010.
16. Ben-Ami R, **Kontoyiannis DP.** Cutaneous model of aspergillosis. In: Host-Fungal Interactions. Ed(s) Alex Brand and Donna MacCallum. Humana Press, 2010.
17. Lewis RE, **Kontoyiannis DP.** Echinocandins. In: Use of Antibiotics, 6th Edition. Ed(s) Kucers B. ASM Press, 2010.
18. Lionakis M, **Kontoyiannis DP.** Fly model to study fungal disease. In: Host-Fungal Interactions. Ed(s) Alex Brand and Donna MacCallum. Humana Press, 2010.
19. **Kontoyiannis DP.** Pathogenesis of invasive pulmonary aspergillosis. In: Aspergillosis: from diagnosis to prevention. Ed(s) Pasqualotto AC. Springer: The Netherlands, 2010.
20. Granwher BP, Chemaly RF, **Kontoyiannis DP.** Fungal and viral infections in cancer patients. In: The MD Anderson Manual of Medical Oncology.. Ed(s) HM Kantarjian, RA Wolff, CA Koller. Mc Graw Hill Medical, 2011.
21. Torres HA, **Kontoyiannis DP.** Hyalohyphomycoses (Hyaline molds). In: Essentials of Clinical Mycology, 2nd Edition. Ed(s) CA Kauffman, PG Pappas, JD Sobel, WE Dismukes. Springer, 2011.
22. **Kontoyiannis DP.** Mycetoma. In: Cecil Textbook of Medicine. W. B. Saunders Co., 2012.
23. **Kontoyiannis DP.** Mycormycosis. In: Cecil Textbook of Medicine, 24rd Edition. W. B. Sanders Co., 2012.
24. Shelburne S, Lewis RE, **Kontoyiannis DP.** Clinical approach to infections in the Compromised Host. In: Hematology: Basic Principles and Practice, 6th Edition. Ed(s) Hoffman, Benz, Silberstein, Heslop, Weitz & Anastasi. Saunders, Inc., 2013.
25. Chamilos, **Kontoyiannis DP.** In: Fishman's Pulmonary Diseases and Disorders, 5th. Ed(s) Grippi M, Elias J, Fishman J, Kotloff R, Pack A, Senior R, eds. McGraw-Hill Professional, 2015.
26. **Kontoyiannis DP.** Mycormycosis. In: Cecil Textbook of Medicine, 25th Edition. W. B. Saunders Co., 2015.
27. Lewis RE, **Kontoyiannis DP.** Treatment Principles in non-Aspergillus molds. In: Human Fungal Pathogens. Ed(s) A Casadevall, AP Mitchell, J Berman, KJ Kwon-Chung, JR Perfect and J Heitman. Cold Spring Harbor Press, 2015.
28. Georgiadou S., **Kontoyiannis DP.** In: Fungal Infections in Primary and Acquired Immunodeficiencies In: Carvalho's Book Immunogenetics of Fungal Diseases, 1st. Springer International Publishing, 2016.
29. Lewis RE, **Kontoyiannis DP.** Buftenafine. In: Use of Antibiotics, 7th Edition. Ed(s) Kucers B. ASM Press, 2016.

30. Lewis RE, **Kontoyiannis DP**. Echinocandins. In: Use of Antibiotics, 8th. Ed(s) Editor: Kucers B. ASM Press, 2016.
31. Chao A, **Kontoyiannis DP**. In: Invasive Fungal Sinusitis In Immunosuppressed Hosts. In Infections of the Ears, Nose, Throat and Sinuses. Ed(s) Durand M, Deschler D. Springer, 177-188, 2017.
32. Shelburne S, Lewis RE, **Kontoyiannis DP**. Clinical approach to infections in the Compromised Host. In: Hematology: Basic Principles and Practice, 8th Edition. Ed(s) Hoffman, Benz, Silberstein, Heslop, Weitz, Anastasi, 2017.
33. Shelburne S, Lewis RE, **Kontoyiannis DP**. Clinical approach to infections in the Compromised Host. In: Hematology: Basic Principles and Practice, 7th Edition. Ed(s) Hoffman, Benz, Silberstein, Heslop, Weitz, Anastasi, 2018.
34. Thuro B, Thakar S, Sagiv O, **Kontoyiannis DP**, Esmaeli B. Orbital Infections in the Cancer Patient. In: Orbital Cellulitis and Periorbital Infections: Evaluation and Management. Ed(s) Yen MT, Johnson TE. Springer Press, 2018.
35. Granwehr BP, Sipsas NV, **Kontoyiannis DP**. Fungal infections in ICU cancer patients. In: Oncologic Critical Care. Ed(s) JL Nates, KJ Price. Springer Nature, 2019.
36. Granwehr B, **Kontoyiannis DP**. Fungal infections in cancer. In: Encyclopedia of Mycology. Ed(s) O Zaragoza, A Casadevall, 2021.
37. Chamilos G, **Kontoyiannis DP**. Aspergillus and opportunistic fungal infections of the lung. In: Pulmonary Diseases and Disorders, 6th Edition. Ed(s) Ed(s) Grippi M, Elias J, Fishman J, et al. McGraw-Hill: New York, 2022.
38. Granwehr BP, **Kontoyiannis DP**. Fungal infections in cancer patients. In: The MD Anderson Manual of Medical Oncology, 4th Edition. Ed(s) HM Kantarjian, RA Wolff, AG Rieber, 2022.
39. **Kontoyiannis DP**, Lewis RE. Agents of Mucormucosis. In: Principle and Practices of Infectious Diseases, 7th Edition. Ed(s) Mandell G., Bennet J., and Dolin R. Elsevier Press, 2010, 2015, 2020, 2023.
40. Torres HA, **Kontoyiannis DP**, Rolston K. Infections in Patients with Cancer. In: Cancer Medicine, 10th Edition. Ed(s) RC Bast. In Press.
41. Pappas P, **Kontoyiannis DP**. Mycetoma and dematiaceous fungal Infections. In: Cecil Textbook of Medicine, 27nd Edition. W. B. Sanders Co. In Press.
42. Ostrosky-Zeichner L, **Kontoyiannis DP**. Mycormycosis. In: Cecil Textbook of Medicine, 27th Edition. W. B. Saunders Co. In Press.

#### Books (edited and written)

1. Ed(s) H Kantarjian, R Wolff. The MD Anderson Manual of Oncology, Section Editor. In: Supportive Care. McGraw-Hill Medical, 2015.

#### Letters to the Editor

1. **Kontoyiannis DP**, Olivero JJ. Intestinal obstruction in a dialysis patient with a broken leg. Hosp Pract (Off Ed) 29(1):133-4, 1/1994. PMID: 8288685.
2. **Kontoyiannis DP**, May GS. Delta-aminolaevulinic acid modulates the resistance to fluconazole in a hem1 mutant of *Saccharomyces cerevisiae*. J Antimicrob Chemother 46(6):1044-6, 12/2000. PMID: 11102434.
3. **Kontoyiannis DP**, Basgoz N. Klebsiella ozoniae empyema complicating longstanding oleothorax. Scand J Infect Dis 10(32):579, 2000. PMID: 11055678.
4. **Kontoyiannis DP**, May GS. Identification of azole-responsive genes by microarray technology: why are we missing the efflux transporter genes? Antimicrob Agents Chemother 45(12):3674-6, 12/2001. PMID: PMC90898.
5. **Kontoyiannis DP**. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 34(9):1281-3; author reply 1283, 5/2002. PMID: 11941561.
6. **Kontoyiannis DP**, Lewis RE, May GS, Oshero N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 45(9-10):406-7, 11/2002. PMID: 12421291.
7. **Kontoyiannis DP**, Pasqualini R, Arap W. Could aminopeptidase N inhibitors be effective against severe acute respiratory syndrome? Lancet 361(9368):1558, 2003.

8. **Kontoyiannis DP**, Murray PJ. Fluconazole toxicity is independent of oxidative stress and apoptotic effector mechanisms in *Saccharomyces cerevisiae*. *Mycoses* 46(5-6):183-6, 2003. PMID: 12801359.
9. **Kontoyiannis DP**, Chagua MR, Ramirez I, Prieto V. Locally invasive auricular aspergillosis after ear-piercing in a neutropenic patient with leukemia. *Am J Hematol.* 73(4):296-297, 2003.
10. **Kontoyiannis DP**. What is the significance of an isolated positive cryptococcal antigen in the cerebrospinal fluid of cancer patients? *Mycoses* 46:161-63, 2003.
11. Lewis RE, **Kontoyiannis DP**. Challenges in designing animal studies to detect antagonism of polyene activity. *Antimicrob Agents Chemother* 48(8):3211; author reply 3211-2, 8/2004. PMID: PMC478508.
12. Montes M, White AC, **Kontoyiannis DP**. Symptoms of intestinal schistosomiasis presenting during treatment of large B cell lymphoma. *Am J Trop Med Hyg* 71(5):552-3, 11/2004. PMID: 15569782.
13. **Kontoyiannis DP**, Lewis RE. Caspofungin versus liposomal amphotericin B for empirical therapy. *N Engl J Med* 352(4):410-4; author reply 410-4, 1/2005. PMID: 15673808.
14. Lionakis MS, **Kontoyiannis DP**. Sinus zygomycosis in a patient receiving voriconazole prophylaxis. *Br J Haematol* 129(1):2, 4/2005. PMID: 15801950.
15. Chamilos G, **Kontoyiannis DP**. Voriconazole-resistant disseminated *Paecilomyces variotii* infection in a neutropenic patient with leukaemia on voriconazole prophylaxis. *J Infect* 51(4):e225-8, 11/2005. PMID: 16291275.
16. **Kontoyiannis DP**, Lewis RE. Problems in evaluation of baseline and breakthrough fungal infections in modern febrile neutropenia trials. *New Eng J Med* 352:410-14, 2005.
17. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, Drusano G, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Graziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, **Kontoyiannis DP**, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tudela JL, Rotstein C, Ruhnke M, Schuster M, Shoham S, Sia IG, Siebel N, Silveira F, Singh N, Sobel J, Solomkin JS, Sorrell TC, Steinbach WJ, Temesgen Z, Tortorano A, Vartivarian S, VerWeij P, Viscoli C, Viviani MA, Walker RC, Wheat JL, Wiley J, Williamson P, Wingard JR, Yu VL, Zaoutis T. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. *Clin Infect Dis* 43(8):1031-9, 10/2006. e-Pub 9/2006. PMID: 16983616.
18. Chamilos G, **Kontoyiannis DP**. Refractory Cellulitis in a Woman With Chronic Lymphedema. *Infect Dis Clin Pract*(14):244-5, 2006.
19. **Kontoyiannis DP**, Lewis RE. Posaconazole prophylaxis in hematologic cancer. *N Engl J Med* 356(21):2214-5, 5/2007. PMID: 17526090.
20. **Kontoyiannis DP**. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. *Clin Infect Dis* 44(8):1089-90, 2007. PMID: 17366455.
21. **Kontoyiannis DP**. Echinocandin-based initial therapy in fungemic patients with cancer: a focus on recent guidelines of the Infectious Diseases Society of America. *Clin Infect Dis* 49(4):638-9; author reply 639-40, 8/2009. PMID: 19619044.
22. Cahuayme-Zuniga L, **Kontoyiannis DP**. Is it safe to proceed with stem cell transplant in cancer patients treated for cryptococcal infection? A focus on recent IDSA cryptococcal guidelines. *Clin Infect Dis* 50(12):1687-9, 6/2010. PMID: 20482268.
23. **Kontoyiannis DP**. Are serum cytokines sensitive and specific enough to prognosticate in aspergillosis? *J Infect Dis* 203(10):1503; author reply 1504, 5/2011. PMID: PMC3080899.



24. **Kontoyiannis DP.** Deferasirox lacks in vitro activity against *Fusarium* and *Scedosporium* species and black molds. *Virulence* 2(3):257-8, 5/2011. PMID: 21543881.
25. **Kontoyiannis DP.** The power of a legend. *Ann Intern Med* 155(6):400, 9/2011. PMID: 21930861.
26. **Kontoyiannis DP, Lewis RE.** Reply to "Risk for Invasive Fungal Infections during Acute Myeloid Leukemia Induction Therapy: a True Association with Echinocandins?" *Antimicrob Agents Chemother* 58(8):4990-4991, 8/2014. PMID: PMC4136037.
27. Zhao Y, **Kontoyiannis DP, Roilides E, Walsh TJ, Perlin DS.** Reply to "Detection of Multiple Fungal Species in Blood Samples by Real-Time PCR: an Interpretative Challenge". *J Clin Microbiol* 52(9):3517, 9/2014. PMID: 25143425.
28. Zhao Y, **Kontoyiannis DP, Roilides E, Walsh TJ, Perlin DS.** Reply to "Not Over Yet: Fungal Infections following Methyl Prednisolone Injections Smoulder On". *J Clin Microbiol* 52(9):3508, 9/2014. PMID: 25143421.
29. Pemmaraju N, Shetty AV, Prieto VG, Jain N, **Kontoyiannis DP, Borthakur G.** Disseminated *Saprochaete capitata* (formerly known as *Geotrichum capitatum*, and *Blastoschizomyces capitatus*) in a patient with acute myeloid leukemia. *Eur J Haematol* 93(6):543-4, 12/2014. e-Pub 3/2014. PMID: 24592915.
30. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, **Kontoyiannis DP, Pappas PG.** Reply to Bauer and Goff. *Clin Infect Dis* 61(3):487-8, 8/2015. e-Pub 5/2015. PMID: 25944341.
31. Oliver N, Luong T, Tchakarov A, Abdelrahim M, Mulanovich VE, **Kontoyiannis DP, Jones R, Kebriaei P, Samuels J, Glass W, Abudayyeh A.** Disseminated cryptococcal infection in allogeneic stem cell transplant patients: a rare cause of acute kidney injury. *Bone Marrow Transplant.* e-Pub 5/2016. PMID: 27159179.
32. Sunil M, Tarand JJ, **Kontoyiannis DP.** A Patient with Acute Promyelocytic Leukemia and Persistent Skin Lesions Following Thorn Injury. *J Bacteriol Mycol* 3(2), 6/2016.
33. Pemmaraju N, Jain P, Medeiros LJ, Jorgenson JL, Jain N, Willis J, Kontoyiannis DP, Estrov Z, Wierda W. PET-positive lymphadenopathy in CLL - Not always Richter transformation. *Am J Hematol.* e-Pub 9/2016. PMID: 27677095.
34. Aitken SL, **Kontoyiannis DP, DePombo AM, Bhatti MM, Tverdek FP, Gettys SC, Nicolau DP, Nunez CA.** Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant *Pseudomonas aeruginosa* Bloodstream Infection in a Pediatric Leukemia Patient. *Pediatr Infect Dis J* 35(9):1040-1042, 9/2016. PMID: 27254038.
35. **Kontoyiannis DP.** A Potential Explanation of a Positive Serum  $\beta$ -Glucan Assay in Mucormycosis. *Open Forum Infect Dis* 3(4):ofw209, 10/2016. e-Pub 12/2016. PMID: PMC5144653.
36. Kyvernitakis A, Azzi J, **Kontoyiannis DP.** Mixed *Mycobacterium Avium-Intracellulare* and *Serratia Marcescens* Cellulitis of the Breast in an HIV-Negative Patient with Breast Cancer: A Case Report. *Cureus* 8(6):e634, 2016. e-Pub 6/2016. PMID: PMC4938626.
37. Jain P, Nagarajan P, Prayag P, Benton CB, Kadia T, Groisberg R, **Kontoyiannis DP, Mulanovich VE, Pemmaraju N.** Mixed angioinvasive *Exserohilum* and *Scedosporium* infection in a patient with AML. *Am J Hematol* 92(1):119-120, 1/2017. e-Pub 7/2016. PMID: 27341684.
38. **Kontoyiannis DP.** What to Do for the Asymptomatic Pulmonary Coccidioidal Nodule or Cavity in Immunosuppressed Patients? A Focus in the Recent Coccidioidomycosis Guidelines. *Clin Infect Dis* 64(2):232-233, 1/2017. e-Pub 11/2016. PMID: 27986674.
39. Foolad F, **Kontoyiannis DP.** Persistent CNS toxicity in a patient receiving posaconazole tablets after discontinuation of voriconazole due to supratherapeutic serum levels. *J Antimicrob Chemother*, 10/2017. PMID: 29121264.
40. Daver N, **Kontoyiannis DP.** Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis. *Lancet Oncol* 18(12):1571-1573, 12/2017. PMID: 29208429.
41. Chamilos G, Lionakis MS, **Kontoyiannis DP.** Reply to Bazaz and Denning. *Clin Infect Dis*, 1/2018. PMID: 29370370.
42. Zoran T, Sartori B, Sappl L, Aigner M, Sánchez-Reus F, Rezusta A, Chowdhary A, Taj-Aldeen SJ, Arendrup MC, Oliveri S, **Kontoyiannis DP, Alastruey-Izquierdo A, Lagrou K, Lo Cascio G, Meis JF, Buzina W, Farina C, Drogari-Apiranthitou M, Grancini A, Tortorano AM,**



- Willinger B, Hamprecht A, Johnson E, Klingspor L, Arsic-Arsenijevic V, Cornely OA, Meletiadiis J, Prammer W, Tullio V, Vehreschild JJ, Trovato L, Lewis RE, Segal E, Rath PM, Hamal P, Rodriguez-Iglesias M, Roilides E, Arikani-Akdagli S, Chakrabarti A, Colombo AL, Fernández MS, Martin-Gomez MT, Badali H, Petrikkos G, Klimko N, Heimann SM, Uzun O, Roudbary M, de la Fuente S, Houbraken J, Risslegger B, Sabino R, Lass-Flörl C, Lackner M. Corrigendum: Azole-Resistance in *Aspergillus terreus* and Related Species: An Emerging Problem or a Rare Phenomenon? *Front Microbiol* 9:3245, 1/2019. PMID: PMC6340063.
43. Rausch CR, **Kontoyiannis DP**. Prolonged voriconazole treatment in a patient with chronic lymphocytic leukemia resulting in a litany of chronic overlapping toxicities. *J Oncol Pharm Pract* 25(3):1078155218762624, 4/2019. PMID: 29554829.
  44. De la Hoz A, Foolad F, Gallegos C, Kornblau S, **Kontoyiannis DP**. Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin's disease. *Bone Marrow Transplant* 54(5):749-751, 5/2019. PMID: 30323308.
  45. Mason MJ, McDaneld PM, Musick WL, **Kontoyiannis DP**. Serum Levels of Crushed Posaconazole Delayed Release Tablets. *Antimicrob Agents Chemother* 63(5), 5/2019. PMID: PMC6496040.
  46. Dipippo AJ, **Kontoyiannis DP**. Azole-Associated Pseudohyperaldosteronism: A Class Effect or Azole-Specific? *Clin Infect Dis*. e-Pub 11/2019. PMID: 31674639.
  47. Magira EE, Chemaly RF, Jiang Y, Tarrand J, **Kontoyiannis DP**. Corrigendum: Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients With Hematologic Malignancies: A Case-Control Study. *Open Forum Infect Dis* 6(11):ofz458, 11/2019. e-Pub 11/2019. PMID: PMC6876540.
  48. Lewis RE, **Kontoyiannis DP**. Chimeric antigen receptor T cell immunotherapy and need for prophylaxis for invasive mold infections. *Clin Infect Dis*. e-Pub 1/2020. PMID: 31927567.
  49. Lewis RE, **Kontoyiannis DP**. Infectious disease consultation for candidaemia. *Lancet Infect Dis* 20(2):164, 2/2020. PMID: 32006498.
  50. Malek AE, Taremi M, Spallone A, Alvarez-Cardona JJ, **Kontoyiannis DP**. Necrotizing soft tissue invasive aspergillosis in a cancer patient treated with immunosuppressants due to checkpoint inhibitor-induced hepatitis. *J Infect* 80(2):232-254, 2/2020. e-Pub 11/2019. PMID: 31705917.
  51. Yang X, Shi X, Chen W, Zhou Y, Lionakis MS, **Kontoyiannis DP**, Liu W. First report of kerion (tinea capitis) caused by combined Trichophyton mentagrophytes and Microsporum canis. *Med Mycol Case Rep* 29:5-7, 9/2020. e-Pub 5/2020. PMID: PMC7251309.
  52. Malek AE, **Kontoyiannis DP**. Superficial Thrombophlebitis From Intravenous Pentamidine in Hematopoietic Cell Transplantation Recipient. *Mayo Clin Proc* 96(1):257-258, 1/2021. PMID: 33413823.
  53. John TM, **Kontoyiannis DP**. Do not forget daptomycin as a cause of eosinophilic pneumonia. *Chest* 159(4):1687-1688, 4/2021. e-Pub 4/2021. PMID: 34022008.
  54. Johnson MD, Lewis RE, Dodds Ashley ES, Perfect JR, **Kontoyiannis DP**. Reply to Day et al. *J Infect Dis*. e-Pub 4/2021. PMID: 33822103.
  55. Sassine J, **Kontoyiannis DP**. A 77-Year-Old Man with Multiple Myeloma and a Lytic Bone Lesion. *Am J Med* doi: 10.1016/j.amjmed.2021.01.032(7):860-862, [https://www.amjmed.com/article/S0002-9343\(21\)00115-7/fulltext](https://www.amjmed.com/article/S0002-9343(21)00115-7/fulltext), 7/2021. e-Pub 2/2021. PMID: 33621531.
  56. **Kontoyiannis DP**. Statin use and aspergillosis risk -More that meets the eye? *Clin Infect Dis* 76(2):368, 1/2023. e-Pub 9/2022. PMID: 36049031.

#### Manuals, Teaching Aids, Other Teaching Publications

1. **Kontoyiannis DP**. Infectious Diseases Outlook: A StratFOCUS<sup>®</sup> Report. 1, 4, 1999.
2. **Kontoyiannis DP**. Scedosporiosis in a neutropenic AML patient. *Fungus.org*, 2006.
3. **Kontoyiannis DP**. Insights into early empiric or prophylactic antifungal therapy in the transplant setting. *Blood and Marrow Transplantation Review*, 2007.
4. Tarrand JJ, Wagar EA, Love GL, **Kontoyiannis DP**. Environmental molds and systemic fungal infections. *Clinical Laboratory International-online.com*, 4/2011.

5. **Kontoyiannis DP.** Chair, Interactive Web-Based MSG Education and Research Consortium Activity. The New Antifungals Toolkit, 2017.
6. **Kontoyiannis DP.** Fusariosis in a neutropenic AML patient. DrFungus.org, 2019.
7. ASM Editors in conversation/AAC Podcast: Candida auris at the intersection of COVID-19 pandemic, 2021.
8. **Kontoyiannis DP,** Thompson GR, Nguyen M-H T. Interactive Web-Based MSG Education and Research Consortium Activity. COVID19-associated invasive fungal infections, 2021.

#### **Other Publications**

1. Media Interviews. Interview as fungal expert by CNN, Associate Press, Wall Street Journal and featured in Kathierini

#### **EDITORIAL AND REVIEW ACTIVITIES**

##### **Editor/Service on Editorial Board(s)**

- Deputy Editor, Medical Mycology, 2006-2012
- Advisory Board, Virulence, 2009-present
- Deputy Editor, Mycoses, 2011-present
- Advisory Board, Hematology Vision, 2013-present
- Deputy Editor, Journal of Infection, 2013-present
- Special Editor, AAA6 Meeting Proceedings, Mycopathologia, 2014
- Editorial Board, Microbial Cell, 2015-present
- Guest Editor, Contemporary Topics regarding Infections Post Allogeneic Stem Cell Transplantation, Virulence, 2016
- Guest Editor, Contemporary Topics in Antifungal Drug Resistance, Journal of Infectious Diseases, 2017
- Special Editor, ICHS 2020 Meeting Proceedings, Fungal infections in Immunocompromised Hosts, Journal of Fungi, (supplement), 2019
- Guest Editor, Core Elements for Antifungal Stewardship, Journal of Infectious Diseases (supplement), 2020
- Guest editor, Frontiers Immunol, Immune intervention strategies to control fungal infections in immunocompromised individuals, 2022
- Associate Editor, Frontiers in Fungal Biology/Section of Medical Mycology, 2022
- Guest Editor, Journal of Fungii Fungal Pneumonia, 2022

##### **Member of Editorial Review Board**

- Editorial Board, Transplant Infectious Diseases, 1999-present
- Editorial Board, Antimicrobial Agents and Chemotherapy, 2006-2020
- Editorial Board, Journal of Invasive Fungal Infections, 2007-2011
- Editorial Board, Current Fungal Infection Reports, 2007-present
- Editorial Board, Journal of Infectious Diseases, 2008-present
- Editorial Board, Journal of Infection, 2009-2012
- Editorial Board, Neglected Tropical Infectious Diseases, 2012-present
- Editorial Board, Faculty 1000, 2013-2016
- Editorial Board, Virulence, 2013-2018
- Editorial Board, Molecular Microbiology, 2013-present
- Editorial Board, GMS Infectious Diseases, 2016
- Editorial Board, Frontiers in Medicine, 2016-present

Editorial Board, *Frontiers in Microbiology*, 2019-present

Editorial Board, *Journal of Fungii* (Section of fungal pathogenesis and disease control), 2020-present

Editorial Board, *World Academy of Sciences*, 2021-present

Editorial Board Member, *Spectrum*, 2022

#### **Journal Reviewer**

Reviewer, *Clinical Infectious Diseases*, 1998-present

Reviewer, *Antimicrobial Agents and Chemotherapy*, 1999-present

Reviewer, *Transplant Infectious Diseases*, 1999-present

Reviewer, *Journal of Antimicrobial Chemotherapy*, 2000-present

Reviewer, *American Journal of Hematology*, 2001

Reviewer, *Fungal Genetics and Biology*, 2001

Reviewer, *Cancer*, 2001-present

Reviewer, *Clinical Microbiology and Infection*, 2001-present

Reviewer, *International Journal of Gastroenterology*, 2002

Reviewer, *Kidney International*, 2002

Reviewer, *Leukemia and Lymphoma*, 2002

Reviewer, *Journal of Infectious Diseases*, 2002-present

Reviewer, *American Journal of Clinical Pathology*, 2003

Reviewer, *American Journal of Medical Science*, 2003

Reviewer, *American Journal of Transplantation*, 2003

Reviewer, *British Journal of Hematology*, 2003

Reviewer, *Infections in Medicine*, 2003

Reviewer, *Neurosurgery*, 2003

Reviewer, *Respiration*, 2003

Reviewer, *The Lancet*, 2003

Reviewer, *Medical Mycology*, 2003-present

Reviewer, *Annals of Oncology*, 2004

Reviewer, *Cytokine*, 2004

Reviewer, *European Journal of Clinical Microbiology and Infectious Diseases*, 2004

Reviewer, *Infection and Immunity*, 2004

Reviewer, *Journal of Laboratory and Clinical Medicine*, 2004

Reviewer, *Scandinavian Journal of Infectious Diseases*, 2004

Reviewer, *Bone Marrow Transplantation*, 2005

Reviewer, *Emerging Infect Diseases*, 2005

Reviewer, *Eur J Clin Microb & Infect Diseases*, 2005

Reviewer, *FEMS Immunology and Med Microbiology*, 2005

Reviewer, *Mycopathologia*, 2005

Reviewer, *Journal of Clinical Microbiology*, 2005-present

Reviewer, *Biology of Blood and Marrow Transplantation*, 2006

Reviewer, Critical Care Medicine, 2006  
Reviewer, Journal of Experimental Medicine, 2006  
Reviewer, BMC Microbiology, 2007  
Reviewer, Lancet Oncology, 2007  
Reviewer, New England J Medicine, 2007  
Reviewer, Blood, 2011-present  
Reviewer, Journal of Immunology, 2012  
Reviewer, Metabolism, 2012  
Reviewer, Nature-Clinical Practice Oncology, 2012  
Reviewer, Molecular Microbiology, 2013  
Reviewer, Journal of Clinical Oncology, 2014-present  
Reviewer, Proceedings of the National Academy of Sciences, 2015  
Reviewer, Biology of Blood and Marrow Transplantation, 2015  
Reviewer, Disease Models and Mechanisms, 2015  
Reviewer, Future Microbiology, 2015  
Reviewer, Journal of Respiratory and Critical Care Medicine, 2015  
Reviewer, Lancet Infectious Diseases, 2015  
Reviewer, Open Forum for Infectious Diseases, 2015  
Reviewer, Pathogens and Disease, 2015  
Reviewer, Cellular Microbiology, 2016  
Reviewer, British Medical Journal (Case Reports), 2017  
Reviewer, Frontiers in Cellular Microbiology, 2017  
Reviewer, Frontiers in Microbiology, 2017  
Reviewer, Leukemia and Lymphoma, 2018  
Reviewer, mBio, 2018  
Reviewer, Medical Mycology, 2018  
Reviewer, mBio, 2019  
Reviewer, PLOS Pathogens, 2019  
Reviewer, The Lancet Digital Health, 2019  
Reviewer, Future Microbiology, 2020  
Reviewer, OBM Transplantation, 2020  
Reviewer, mBio, 2021  
Reviewer, Frontiers in Cellular and Infection Microbiology, 2022  
Reviewer, Frontiers Microbiology, 2022  
Reviewer, Journal of Clinical Investigation, 2022  
Reviewer, Microorganisms, 2022  
Reviewer, Nature Communications, 2022  
Reviewer, Annals of Internal Medicine, 2000, 2023  
Reviewer, Clinical Lymphoma, Myeloma and Leukemia, 2023



**Other Editorial and Review Activities**

Section Editor, Mucormycosis, Doctor Fungus website, 2011

Ad Hoc Section Editor, Cellular and Infection Microbiology, 2021

**TEACHING**

**Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center**

**Formal Teaching**

**Courses Taught**

Fluconazole resistance in fungi: *Saccharomyces cerevisiae* as a model organism  
11/1998

Two Mycology-focused formal lectures /year for the infectious disease fellows at  
MD Anderson Cancer Center  
1998-present

Endophthalmitis/Uveitis/Retinitis  
4/1999

General principles of immunoprophylaxis and travel advice in the immunocompromised host  
4/1999

Prevention of nosocomial infections in BMT recipients  
6/1999

Systemic Aspergillosis: A translational approach. Topic: Invasive aspergillosis in the  
immunocompromised patient with cancer, Division of Medicine Grand Rounds  
6/1999

The CDC guidelines for the prevention of fungal infections in bone marrow transplant  
recipients  
6/1999

Infections of cerebrospinal fluid shunts  
3/2000

Newer drugs for antifungal prophylaxis in BMT  
4/2000

Antifungal drug resistance in pathogenic fungi, The University of Texas MD Anderson  
Cancer Center Pediatric Grand Rounds  
6/2000

Perspectives in the management of invasive fungal infections in immunocompromised  
patients with cancer, Institutional Grand Rounds  
2/2001

Cryptococcosis  
3/2001

Update in fungal infections, The University of Texas M. D. Anderson Cancer Center  
3/2001

Echinocandins: A research update  
6/2001

Echinocandins  
8/2001

Antifungal drug resistance and interactions: From bench to the bedside  
1/2002

Invasive aspergillosis in the 2000's: Impact and future challenges, The University of  
Texas and MD Anderson Cancer Center Institutional Grand Rounds  
1/2002

Combination antifungal therapy in aspergillosis

9/2002

New Agents and Evolving Strategies for Life-Threatening Fungal Infections in the Immunocompromised H, The University of Texas and MD Anderson Cancer Center

10/2002

Update on aspergillosis, The University of Texas and MD Anderson Cancer Center

2/2004

BMT Fungal pathways at MDACC, The University of Texas and MD Anderson Cancer Center

6/2004

New frontiers in the management of invasive fungal infections patients with leukemia, The University of Texas and MD Anderson Cancer Center

4/2005

New frontiers in the management of invasive fungal infections in patients with stem cell transplant, The University of Texas and MD Anderson Cancer Center

5/2005

Lecturer, Oncology fellows lecture series: "Update on Fungal Infections"

8/2005

Lecturer, The emerging role of mini-host models in the study of opportunistic fungi

1/2006

Lecturer, Morbidity and Mortality Conference, Department of Pediatric Hematology, "Fulminant Zygomycosis"

5/2006

Lecturer, Department of Bone Marrow Transplantation, "Early diagnosis of aspergillosis: advances and controversies"

6/2006

Lecturer, Institutional Grand Rounds: "Pneumonia in leukemia patients: Epidemiology, pathogenesis, challenges in management"

6/2006

Lecturer, Department of Leukemia, "Antifungal Formulary"

9/2006

Lecturer, Department of Pediatrics Grand Rounds: "Antifungal treatment in pediatric patients"

10/2006

Lecturer, Department of Thoracic Medical Oncology, "Infectious diseases problems in the management of lung cancer patients"

1/2007

Lecturer, Cytokines and Supportive Care Working Group, "State of the art management of fungal infections"

5/2007

Lecturer, Department of Leukemia, "Pre-emptive or targeted antifungal therapy in the era of azole prophylaxis in the high risk hematology patient"

11/2007

Lecturer, Department of Bone Marrow Transplantation, "Iron Chelation in the treatment of zygomycosis"

4/2008

Lecturer, Division of Internal Medicine Grand Rounds, "New insights into the immunopathogenesis of opportunistic fungal pneumonias"

4/2009

Lecturer, Graduate program in Health Sciences/Principles in Therapeutics Course:  
Microbes and Diseases

8/2009-present

Lecturer, Department of Leukemia, "Recent insights regarding the immunobiology of  
aspergillosis"

5/2010

Lecturer, Division of Internal Medicine Grand Rounds, "Breakthrough mold infections in  
the compromised patient with hematologic malignancy"

5/2010

Lecturer, Department of Bone Marrow Transplantation, "Future directions in medical  
mycology in hemo-oncology patients"

9/2010

Lecturer, Department of Leukemia Research Grand Rounds, "Iron metabolism and  
invasive fungal infections"

11/2010

Chair, Institutional Grand Rounds, "Hot research topics in cancer infectious diseases for  
the upcoming decade"

12/2011

Lecturer, Department of Laboratory Medicine Grand Rounds, "Mucormycosis"

1/2012

Lecturer, Nursing in General Internal Medicine Education Series, "Chemotherapy-  
associated immune suppression"

3/2012

Lecturer, Department of Leukemia Research Grand Rounds, "Infection control issues and  
safe living to prevent fungal infections in the outpatient leukemia patient"

10/2012

Chair, Institutional Grand Rounds, "Infectious causes of cancer"

5/2013

Lecturer, Department of Leukemia, "The value of skin biopsy in leukemia patients with  
presumed infections"

8/2013

Lecturer, Department of Stem Cell Transplantation, "Neutropenic typhlitis post SCT"

8/2013

Lecturer, Advances in Oncology Institutional Grand Rounds, "Advances in Prevention of  
Invasive Fungal Infections in Hematologic Malignancy"

4/2014

Lecturer, Department of Leukemia, "Antifungal Prophylaxis in Leukemia"

4/2014

Master Clinician, Cafe Discussion, Hospitalist Group/Department of General Internal  
Medicine

2/2015

Lecturer, Department of Leukemia, "Mucormycosis Research at MDACC: The Last 15  
Years"

8/2015

Lecturer, Division of Internal Medicine Grand Rounds, "Mucormycosis"

9/2015

Lecturer, Leukemia Fellows Course, Department of Leukemia, MDACC "Overview of Antifungal Therapy"  
12/2015

Lecturer, Department of Leukemia, "My two most challenging recent cases for fungal infections at MDACC and what I learned from them"  
6/2016

Lecturer, Division of Internal Medicine Grand Rounds, "Current Thinking in risk stratification and principles of management of fungal infections"  
6/2016

Lecturer, Department of Leukemia, "Invasive Mucormycosis and Fusariosis: Update on Current Management"  
12/2016

Lecturer, Department of Leukemia, "Combination Antifungal Therapy"  
1/2017

Lecturer, Division of Internal Medicine Grand Rounds, "Fungi: Their Role in Modern History and Human Disease"  
7/2017

Lecturer, Department of Leukemia, "Fungi: Their Role in Modern History and Human Disease"  
8/2017

Lecturer, Department of Infectious Diseases, "How to prepare and publish a research article"  
1/2018

Lecturer, Emil J Freireich Leukemia Hematology Grand Rounds, "Invasive infections due to non-Aspergillus molds in hematology patients"  
3/2018

Lecturer, Department of Leukemia, "New treatments for leukemia and fungal risk"  
5/2018

Lecturer, Institutional Grand Rounds "Antifungal therapy in cancer patients: past, present and future"  
11/2018

Lecturer, Internal Medicine Residency Program Lecture Series, "Update in Modern Antifungal Therapy"  
2/2019

Lecturer, Department of Leukemia, "Toxicity issues of chronic antifungal use"  
5/2019

Discussant, Division of Internal Medicine Grand Rounds, CPC  
9/2019

Lecturer, Enjoy Science Seminar Series: "How changing in oncology treatment will impact fungal risk", Virtual Lecture  
5/2020

Lecturer, Department of Leukemia, "Principles of antifungal therapy"  
5/2021

Lecturer, Division of Internal Medicine Grand Rounds. "How transformation in the management of hematologic cancer will impact the invasive fungal disease ecosystem"  
6/2021

Panelist, Mentoring Day: Beyond Promotion and Tenure: Making the most of your faculty mentoring relationship



2/2022

Invited Discussant, Organizing clinical research in Hospitalist Service, Department of Hospital Medicine

3/2022

Panelist, Mentoring Day, Never too old, never too Young: Mentoring Across a Lifetime

2/2023

Lecturer, Department of Infectious Diseases, ID PAs, Endemic Mycoses

3/2023

**Training Programs**

Core Faculty, Division of Internal Medicine, Residency Program

7/2015-present

**Other Formal Teaching**

N/A

**Supervisory Teaching**

**Committees**

**Advisory Committees**

K01 Career Development Award, Xerxes Pundole, PhD

**Supervisory Committees**

Thesis Advisory Committee, GSBS, D. Conley, PhD, 10/2007-12/2010

Thesis Advisory Committee, GSBS, T. Schoberle, PhD, 1/2011-8/2013

Thesis Advisory, University of Athens School of Medicine, Athens School of Medicine, I. Apostolidou, MD, 6/2014-2019

Thesis Advisory Committee, Baylor College of Medicine, A. Parelukar, MD, 12/2014-2/2017

Thesis Advisory Committee, Rice University, Alex Tatara, MD, PhD, 8/2015-2/2017

Thesis Advisory Committee, Texas A&M University, Alex Myers, DVM, PhD, 4/2018-4/2020

Masters Advisory committee, Master of Scientific Illustration, Zuyd University and Maastricht University, Yixin Jiao, 10/2022-present

**Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

N/A

**Graduate Students**

Tatara, A., M.D., Ph.D., Rice-Baylor Medical Student, 2015-2017

**Postdoctoral Research Fellows**

Antoniadou, A., M.D., visiting faculty

Bellanger A.P., Pharm D, Visiting faculty

Ben-Ami, R., M.D. (now Chair of ID Department Tel Aviv Souracky Medical Center)

Chamilos, G., M.D. (now associate professor, University of Crete, Greece)

Davoudi, S., M.D., visiting faculty

Economides M, MD

Georgiadou, S., M.D., visiting faculty  
Gomez, M., M.D., visiting faculty  
Heo, S., MD, visiting faculty  
Jung, S., M.D., visiting faculty  
Kofteridis, D., M.D., visiting faculty  
Kyvernitakis A., MD  
Lamaris, G., M.D.  
Leventakos, K., M.D.  
Lionakis, M., M.D. (now Head, Fungal Pathogenesis Unit, NIAID/NIH)  
Liu, W., M.D., Ph.D. (now Professor, Peking University First Hospital, Peking, Beijing, People's Republic of China)  
Magira, E., M.D.  
Martinez, L., Ph.D.  
Nanos, G., M.D.  
Pongas, G., M.D.  
Puerta, P., M.D.  
Raman, N., Ph.D.  
Reddy, B., M.D.  
Rivero, G., M.D.  
Roussos, P. (now assistant professor, Albert Einstein Medical School, NY)  
Sampsonas, F., M.D.  
Shirazi, F., Ph.D.  
Sipsas, N., M.D., visiting faculty  
Wurster, S., M.D. (current position: Assistant Professor, MDACC)  
Zannette, R., DVM

**Clinical Residents and Fellows**

Axel-House, D., M.D.  
Best, L., M.D.  
Cahuayme, L., M.D.  
Campo, M., M.D.  
Chitasombat, M., M.D. (now assistant professor, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand)  
Dhal, U., M.D.  
Egge S., M.D.  
El Boghdady Z, M.D. (now assistant professor, Ohio State University)  
Farmakiotis, D., M.D. (Now assistant professor, Brown University)  
Franklin A, MD  
Granger, J., M.D.  
Haddad F, MD  
Kassis, K., M.D.

Kondapi, D., M.D.

Kumashi, P., M.D.

Mashuo, T. M.D.

Morado O, MD

Munita, J., M.D. (now associate professor, University of Santiago, Chile)

Nigo, M., M.D.

Quezada, G., M.D.

Saad, P., M.D.

Sassine, J., M.D.

Spallone, A., M.D.

Torres, H., M.D., clinical fellow (now associate professor, Department of Infectious Diseases, MDACC)

Watson, C., M.D.

**Other Supervisory Teaching**

Banti, A., Summer Student

Chou, L., Pharm.D., Pharmacy Resident

Gottreau, J., Pharm.D., Pharmacy Resident

Lyos S, Summer Student

Minetos, Y, Summer Student

Peitsch, W., M.D., Visiting Student

Pontikos, M., Summer Student

Wessel, V., M.D., Visiting Student

**Teaching Outside Current Institution**

**Formal Teaching**

**Courses Taught**

Lecturer, Veterans Administration Medical Center/Clinical Pathological Conference (monthly), Baylor College of Medicine  
1/1994

Preceptor, Massachusetts General Hospital for 2nd year students/"Patient-Doctor II" course, Harvard Medical School  
3/1995

Lecturer, Infectious Diseases Pharmacotherapy Symp, An Overview of Infectious in the Immunocompromised Patient, The University of Houston College of Pharmacy  
5/2002

An Overview of Infectious in the Immunocompromised Patient, The University of Houston College of Pharmacy  
5/2002

**Training Programs**

Chief Resident (rounds-weekly), Veterans Administration Medical Center, Baylor College of Medicine  
1/1994

Faculty, Infectious Diseases Joint Fellowship, The University of Houston College of Pharmacy  
1998-present

**Other Formal Teaching**

Member, Post-graduate program in "Cellular and Genetic Causality: Diagnostics and Therapeutics of Human Diseases, University of Crete, Heraklion, Greece  
10/2006-10/2010

**Supervisory Teaching**

**Committees**

**Advisory Committees**

Co-Mentor, T32, Egge, S. MD

Zuyd University and Maastricht University, YixinJiaop, Master of Scientific Illustration

**Supervisory Committees**

N/A

**Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

Preceptor, "Patient-Doctor II" course for 2nd year students of Harvard Medical School, Massachusetts General Hospital, various, 3/1995

**Graduate Students**

Teacher, weekly, Interns Journal Club, Veterans Administration Medical Center, Baylor College of Medicine, various, 1/1994

Instructor, Graduate Program on Clinical Investigation, University of Crete, Greece, various, 2006

**Postdoctoral Research Fellows**

N/A

**Clinical Residents and Fellows**

Chief Resident, rounds-weekly, Baylor College of Medicine, Veterans Administration Medical Center, 1/1994

**Other Supervisory Teaching**

University of Houston, W. N. Wielderhold (now director, Fungus Research Laboratory, UT San Antonio, Associate Professor), Pharm.D.

**CONFERENCES AND SYMPOSIA**

**Organization of Conferences/Symposia (Include chairing session)**

36th Annual Meeting of the Infectious Diseases Society of America, Denver, CO, Chair, 11/1998

Session: Infections in Leukemia, Second International Conference of GOAL (Global Organization Against Leukemia), Miami, FL, Chairman, 9/2002

15th Congress of the International Society for Human and Animal Mycology (ISHAM), San Antonio, TX, Co-Chairman, 5/2003

"43rd ICAAC. Session: "From the Mycology Laboratory," , Chicago, IL, Invited Co-Moderator, 9/2003

Scientific Advisory Board, 14th Mediterranean Congress of Chemotherapy, Cyprus, 11/2004, 2004

16th Congress of the International Society for Human and Animal Mycology, Paris, France, Chair, 6/2005



Chair, plenary session: "Laboratory contribution to the diagnosis and management of aspergillosis," 2nd International conference "Advances Against Aspergillosis," Athens, Greece, Chairman, 2/2006

Chair, Symposium: Combination Antifungal therapy in vitro/in vivo, 16th Congress of the International Society for Human and Animal Mycology, Paris, France, Chair, 6/2006

Chair, Symposium: Alternative Imaging in invasive pulmonary aspergillosis, 3rd Advance Against Aspergillosis, Miami, FL, Chair, 2008

Scientific Committee, 3rd Advance Against Aspergillosis, Miami, FL, Chairman, 2008

Chair in mycology session and member of the conference committee. Second Symposium on Infections in Cancer, MD Anderson Cancer Center, Houston, TX, Chair, 2/2008

Program Committee, Infectious Disease Society of America (IDSA), 2009

Chair, Tandem BMT Symposium: "Clinical considerations for resistant pathogens in transplantation," , Tampa, FL, 2/2009

Chair, Division of Internal Medicine Research Retreat, MD Anderson Cancer Center, Houston, TX, 4/2009

Chair, plenary session: Transatlantic view points (us and them). 4th Trends in Medical Mycology (TIMM-4), Athens, Greece, Chair, 10/2009

Scientific Committee, 4th Trends In Medical Mycology (TIMM-4), Athens, Greece, Committee Member, 10/2009

Chair, Advances in antifungal therapy: current strategies and the role of combination approaches. 2nd annual symposium of Mycoses Study Group Meeting, Philadelphia, PA, 4/2010

Chair, 2nd International forum on Zygomycosis, "Animal models of zygomycosis," , Peloponese, Greece, 5/2010

Chair, 10th International Symposium on Infections on the Immunocompromised Host, "Geographical challenges in the Immunocompromised host: A pathogen-oriented roundtable," , Budapest, Hungary, 6/2010

Program Committee, 16th International Symposium on Infections in the Immunocompromised Host, Budapest, Hungary, 6/2010

Program Committee, Supportive Care, 6th International Conference of GOAL (Global Organization Against Leukemia), Houston, TX, Committee Member, 10/2010

Invited Co-chair, 51st ICAAC. Session: "Promises and pitfalls of Translational Mycology," , Chicago, IL, Co-Chair, 9/2011

Invited Chair, Session: Non-antifungal approaches to treat mycoses, 5th Trends in Medical Mycology (TIMM-5), Valencia, Spain, Chair, 10/2011

Abstract Selection Committee, Infectious Disease Society of America (IDSA), 2012

Program Committee, Infectious Disease Society of America (IDSA), 2012

Scientific Committee and moderator, 5th Advance Against Aspergillosis, Istanbul, Turkey, Moderator, 2012

Program Committee, First symposium on the Toxicities and Symptoms of Cancer Research, UT MD Anderson Cancer Center, Houston, TX, Member, 4/2012

Program Committee, 17th International Symposium on Infections in the Immunocompromised Host, Genoa, Italy, Member, 6/2012

Invited moderator, 52nd ICAAC. Mycology Symposium "Best 10 papers in Mycology," , Moderator, 9/2012

Program Committee, Infectious Disease Society of America (IDSA), 2013

Program Committee, 2nd Conference on Medical Issues in Cancer Patients & Survivors, UT MD Anderson Cancer Center, Houston, TX, Member, 2/2013

Acute Leukemia Forum 2013, "Rational approach to diffuse pulmonary infiltrates in leukemia and transplantation," , San Francisco, CA, Member, 4/2013

Convener, Emerging Zygomycetes workshop of the ECMM/ISHAM working group on Zygomycetes, "From clinics to the lab," CBS-KNAW Fungal Biodiversity Center, Utrecht, Netherlands, Convener, 4/2013

Chair in mycology session and member of the conference scientific committee, Third Infections in Cancer Symposium, MD Anderson Cancer Center, Houston, TX, 2014

Program Committee (Mycology Section, Transplantation Section), International Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Member, 2014

Program Committee, Infectious Disease Society of America (IDSA), 2014

Scientific Committee and moderator, 6th Advances Against Aspergillosis, Madrid, Spain, 2/2014

18th International Conference on Infections in the Immunocompromised Host, Berlin, Germany, Scientific Committee & Moderator, 6/2014

Program Committee (Mycology Section, Transplantation Section), International Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Member, 2015

Program Committee, Infectious Disease Society of America (IDSA), 2015

Chair, New Developments in Fungal Infections in BMT, 2015 BMT Tandem Meeting, San Diego, CA, Chair, 2/2015

Chair, In Symposium "New Antifungal Pipeline" 55th ICAAC, San Diego, CA, 9/2015

Program Committee (Mycology Section, Transplantation Section), International Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Member, 2016

Program Scientific Committee, European Confederation of Clinical Microbiology, 2016

Program Scientific Committee, International Society of Human and Animal Mycology (ISHAM), Amsterdam, Netherlands, 2016

ECCMID 2016, Infection Prevention in Transplant Recipients, Amsterdam, Netherlands, Chair, 4/2016

Program Scientific Committee, MSD Global Infectious Disease Forum, Rome, Italy, 11/2016

Program Committee (Mycology Section, Transplantation Section), International Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Member, 2017

Program Scientific Committee, European Confederation of Clinical Microbiology, 2017

Program Scientific Committee, European Confederation of Clinical Microbiology, 2018

Program Scientific Committee, International Society of Human and Animal Mycology (ISHAM), Amsterdam, Netherlands, 2018

Program Scientific Committee, 8th Advances Against Aspergillosis Meeting, Lisbon, Portugal, Member, 2/2018

Chair, Scientific Committee, 20th Immunocompromised Host Society (ICHHS) Meeting, Athens, Greece, 6/2018

Co-Chair, The Henry Schueler 41 & 9 Foundation 2nd International Forum for Mucormycosis, Chicago, IL, 11/2019

Chair in mycology session and member of the conference scientific committee, Fourth Infections in Cancer Symposium,, MD Anderson Cancer Center, Houston, TX, Chair, 2020

Program Scientific Committee, 21st Immunocompromised Host Society (ICHHS) Meeting, Melbourne, Australia, 2/2021

Chair, Symposium: Clinical risk and prevention of IFIs in patients receiving biologics and targeted therapies. 10th Trends in Medical Mycology (TIMM-10), Aberdeen, Scotland, United Kingdom, Chair, 10/2021

Program Scientific Committee, 10th Advances Against Aspergillosis and Mucormycosis Virtual Meeting, Chair, 2/2022

Co-Chair, Invasive fungal infections in patients with COVID-19 Symposium, ID Week 2022, Washington, DC, Chair, 10/2022

ID Week 2022, IDSA, Washington, DC, Distinguished Faculty, Abstract Appreciation Program, 10/2022

ID Week 2022, Infectious Diseases Society of America, Distinguished Faculty, Washington DC, Abstract Appreciation Program, 10/2022

### **Presentations at National or International Conferences**

#### **Invited**

Fusarialhyalohyphomycosis: Clinical spectrum, prognosis, treatment, Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 10/1/1990

SCH 39304 for the treatment of invasive mold infections in neutropenic cancer patients, Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 10/1/1990

Dissection of fluconazole resistance by transposon mutagenesis in *Saccharomyces cerevisiae*, Infectious Diseases Society of America, Denver, CO, 11/1/1998

Pdr5p could regulate ergosterol homeostasis in *Saccharomyces cerevisiae*, Infectious Diseases Society of America, Denver, CO, 11/1/1998

Fluconazole inhibits agar invasion in *Candida albicans*, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 9/1/1999

Fluconazole inhibits pseudohyphal growth in *Saccharomyces cerevisiae*, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 9/1/1999

Overexpression of Erg11p by the regulatable GAL1 promoter confers azole resistance in *Saccharomyces cerevisiae*, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 9/1/1999

Activated Ras and azole resistance in *S. cerevisiae*, 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, 11/1/1999

Images of infectious diseases, 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, 11/1/1999

Mucormycosis in the 90s in a tertiary care cancer center, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 11/1/1999

The significance of aspergillemia in patients with cancer: a 10 year study, 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, 11/1/1999

Cryptococcosis in the 90s in a tertiary care cancer center, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 9/1/2000

Delta-aminolevulinic acid ( $\delta$ -ALA) modulates the resistance to fluconazole in the hem1 mutant, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 9/1/2000

Infection and immunity in leukemia: (Chronic Lymphocytic Leukemia), First International Conference of GOAL (Global Organization Against Leukemia): Leukemia 2000-Towards a cure, Houston, TX, 9/1/2000

Risk factors for *Candida tropicalis* fungemia in patients with cancer, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 9/1/2000

New frontiers in antifungal therapy in neutropenic patients, 8th International Symposium on Febrile Neutropenia, Athens, Greece, 1/1/2001

Comparison of breakthrough candidemia and de novo candidemia in cancer patients, 39th Annual Meeting of the Infectious Diseases Society of America (IDSA), San Francisco, CA, 10/1/2001

Infections in patients with aplastic anemia: The experience of a tertiary care cancer center, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 12/1/2001

Initial Experience with FK463 for the treatment of candidemia in cancer patients, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 12/1/2001

L-685, 818, a Non-immunosuppressive calcineurin inhibitor enhances the activity of caspofungin, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 12/1/2001

Lack of catheter colonization by the *cph1/cph1 efg1/efg1* double null mutant, a *C. albicans* strain that is defective in filamentous growth, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 12/1/2001

Overexpression of Sbe2p, a golgi protein involved in cell wall formation confers resistance to caspofungin in *Saccharomyces cerevisiae*, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 12/1/2001

Pulmonary candidiasis in cancer patients: An autopsy study, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 12/1/2001

Trends in antifungal drug resistance, ICAAC symposium SOAR II, Chicago, IL, 12/1/2001

Antifungal agents: A review of pharmacology, pharmacokinetics/pharmacodynamics, and clinical efficacy of available and investigational agents, 42nd ICAAC Meeting Workshop, San Diego, CA, 9/1/2002

Deletion of *hogA* gene, an osmotic stress regulator, results in hypersensitivity to caspofungin in the model mold *A. nidulans*, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 9/1/2002

Efficacy and toxicity of the caspofungin/liposomal amphotericin B combination in documented or possible invasive aspergillosis in patients with hematologic malignancies, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 9/1/2002

In vitro susceptibility and tolerance of aspergillus species in a Tertiary Care Cancer Center. Correlation with invasive aspergillosis and its outcome, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 9/1/2002

In vitro susceptibility of bloodstream candidiasis in cancer patients: Correlation with outcome of antifungal therapy, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 9/1/2002

Infections in CLL, Second International Conference of GOAL (Global Organization Against Leukemia): Leukemia 2000-Towards a cure, Miami, FL, 9/1/2002

Preexposure of *A. fumigatus* to fluconazole induces tolerance to itraconazole in vitro, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 9/1/2002

Sequential exposure of *A. fumigatus* to itraconazole and caspofungin: Evidence of enhanced in vitro activity of this combination, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 9/1/2002

Risk factors of poor outcome of fusariosis in a tertiary care cancer center, 40th Annual Meeting of the Infectious Diseases Society of America (IDSA), Chicago, IL, 10/1/2002

Sequential antifungal therapy in aspergillosis: From the clinic to bench and back, 15th Congress of the International Society for Human and Animal Mycology (ISHAM), San Antonio, TX, 5/1/2003

Antifungal agents: A review of pharmacology, pharmacokinetics/pharmacodynamics, and clinical efficacy of available and investigational agents, 43rd ICAAC Meeting Workshop, Chicago, IL, 9/1/2003

The significance of isolation of rare molds from the respiratory tract in patients with cancer, 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, 9/1/2003

The new frontiers of fungal diagnostics and therapeutics: Combination antifungal therapy: is there a role?, 41st Annual meeting of Infectious Diseases Society of America Meeting IDSA, San Diego, CA, 10/1/2003

Empiric Antifungal Therapy, 11th International Congress on Infectious Diseases, Cancun, Mexico, 3/1/2004

What Beneficial Role May the Laboratory Play Involving Aspergillosis – Isolation, Identification, Serologic Diagnosis, Susceptibility Testing, Epidemiology?, 14th Focus on Fungal Infections, New Orleans, LA, 3/1/2004

Alternative animal models in aspergillosis, First International Conference on Aspergillosis Symposium, San Francisco, CA, 9/1/2004

Unusual infections in CLL, Second International Conference of GOAL (Global Organization Against Leukemia): Leukemia 2000-Towards a cure, Houston, TX, 9/1/2004

Zygomycosis in the era of voriconazole in a cancer center: A matched case-control observational study of 27 recent patients, 44th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, 10/1/2004

Antifungal agents: A review of pharmacology, pharmacokinetics/pharmacodynamics, and clinical efficacy of available and investigational agents, 44th ICAAC Meeting Workshop, Washington, DC, 11/1/2004

Clinical approach to the management of the febrile neutropenic patients, 14th Mediterranean Congress of Chemotherapy, Cyprus, 11/1/2004

Future frontiers in management of zygomycosis, 44th ICAAC Meeting Workshop, Washington, DC, 11/1/2004

The role of voriconazole for the treatment of aspergillosis, 10th Panellenic Conference of Hematology, 11/1/2004

Trends in incidence of invasive fungal infections at a tertiary cancer center over 14 year period: an autopsy study, 15th European Congress of Clinical Microbiology & Infectious Diseases, Copenhagen, 1/1/2005

State of the Art" Mini-lecture in slide section entitled" Experimental Mycology," topic: "Alternative mini-host animal models for fungal pathogenesis, 45th ICAAC Meeting, Washington, DC, 9/1/2005

Breaking the mold: Treatment strategies for emerging mycoses," 43rd IDSA satellite symposium, San Francisco, CA, 10/2005

Antifungal agents: A review of pharmacology, pharmacokinetics/pharmacodynamics, and clinical efficacy of available and investigational agents, 45th ICAAC Meeting Workshop, Washington, DC, 12/1/2005

Invasive fungal infections in Patients with hematological malignancies (1989-2003): an autopsy study, 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, 12/1/2005



Techniques in the diagnosis of aspergillosis: antigen, radiology, 2nd International Conference, "Advances Against Aspergillosis," , Greece, 2/2006

Filamentous Fungal Infections: Changes in epidemiology and controversies in management," Astellas Satellite Symposium, 16th Focus on Fungal Infections, Las Vegas, NV, 3/2006

Refining the diagnosis of Aspergillus: What tools are available?, ECCMID Symposium, Nice, France, 4/2006

Meet the Expert session on approaches to diagnosis of Invasive Mycoses, 14th Symposium on Infections in the Immunocompromised Host (ICHS), Crans-Montana, Switzerland, 7/2006

New insights in pathogenesis of aspergillosis: Implications for management, 14th Symposium on Infections in the Immunocompromised Host (ICSH), Crans-Montana, Switzerland, 7/2006

Controversies in the treatment of fungal pneumonia: Role of combination therapy, surgery and immunomodulation, 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9/2006

The role of mini-host models for the identification of novel antifungal targets and for the study of fungal pathogenesis, 3rd International Biotechnology Forum, Athens, Greece, 10/2006

Symposium: "Clinical considerations for empiric antifungal therapy," Tandem BMT Symposium, Keystone, CO, 2/2007

Symposium: "Bringing in the new: How can we improve clinical trial design strategies for invasive fungal infections?," MSG Focus, San Diego, CA, 3/2007

Unappreciated risk factors for Invasive Fungal Infections," 17th Focus on Fungal Infections, San Diego, CA, 3/2007

Invited lecturer, "Current thinking regarding pre-emptive antifungal therapy," 17th ECCMID satellite symposium, Munich, Germany, 4/2007

Antifungal agents: A review of pharmacology, pharmacokinetics/pharmacodynamics, and clinical efficacy of available and investigational agents," 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, 9/2007

Meet the Expert Session: "New immunomodulators and risk for fungal infection," 47th meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC, Chicago, IL, 9/2007

Invasive aspergillosis in steroid-treated patients, Advances Against Aspergillosis (AAA), Miami, FL, 1/2008

Antifungal Drug Resistance, International Symposium on Antimicrobial Resistance, Cartagena, Colombia, 3/2008

Mini-host models of fungal infections, ASM Meeting Symposium, Boston, CA, 6/2008

ICAAC & IDSA. Difficult mycology questions for the ID Consultant, ICAAC & IDSA (joint symposium), San Diego, CA, 9/2008

Fungal Infections in 2008-How do we prevent and treat them?, 4th International Conference of Global Organization Against Leukemia (GOAL): Leukemia 2008-Towards a Cure, Houston, TX, 9/2008

Meet the MDACC infectious diseases experts: "Management of invasive aspergillosis in the hematological patient," 1st Symposium on Infections in the Hematological Patient, Madrid, Spain, 10/2008

Invited lecturer, "Clinical assessment of the transplant patient with fever," BMT tandem Meetings, Tampa, FL, 2/2009

"Meet the expert session on special challenges in antifungal therapeutics," 47th Meeting, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, 9/2009

- Symposium: "Animal models of disease diagnosis and therapy," Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9/2009
- Zygomycosis, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9/2009
- Experimental pathogenesis and virulence in fungi, 4th Trends in Medical Mycology (TIMM-4), Athens, Greece, 10/2009
- Fitness cost and echinocandin resistance in *C. albicans*, 4th Trends in Medical Mycology (TIMM-4), Athens, Greece, 10/2009
- Invited Lecturer, Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients 2000-006: Overview of the TRANSNET database. 47th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, 11/2009
- Moderator, In symposium: antifungal prophylaxis strategies: Mycology and Transplant ID., 47th Annual IDSA Meeting, Philadelphia, PA, 11/2009
- Moderator, Oral abstract session: Mycology and Transplant ID, 47th annual IDSA Meeting, Philadelphia, PA, 11/2009
- "Guru's Session: Difficult castes in Mycology," 4th International Conference, Advances Against Aspergillosis (AAA), Rome, Italy, 2/2010
- Lecturer, Current strategies for managing candidiasis, coccidiomycosis and mucormycosis. 2nd annual symposium of Mycoses Study Group Meeting, Philadelphia, PA, 4/2010
- Invited Lecturer, 2nd International forum on Zygomycosis, "Combination of amphotericin B with echinocandins in zygomycosis," , Rome, Italy, 5/2010
- Meet the expert session, 10th International Symposium on Infections on the Immunocompromised Host, "Fungal Infections," , Budapest, Hungary, 6/2010
- Activity of deferasirox in Mucorales: Influences of species and exogenous iron (oral presentation), 50th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, 9/2010
- Invited Lecturer, A novel fly model of systemic mycoses, 1st International Conference on Model Hosts, Hersonisos, Crete, Greece, 9/2010
- Moderator, in symposium: "Mold Pneumonia in patients with hematologic malignancy.," 48th annual IDSA Meeting, Vancouver, Canada, 10/2010
- Symposium Moderator, in symposium: "Echinocandin non-susceptibility in *Candida*," 48th annual IDSA Meeting, Vancouver, Canada, 10/2010
- Symposium Moderator: "Mold Pneumonia in patients with hematologic malignancy," 48th annual IDSA meeting, Vancouver, Canada, 10/2010
- Invited Lecturer, "Candida biofilms and the role of the echinocandins, 9th Echinocandin Forum, Tokyo, Japan, 3/2011
- Symposium Moderator: "New approaches in management of fungal infections in stem cell transplantation.," Annual EBMT Meeting, Paris, France, 4/2011
- The Upcoming Decade of Medical Mycology, DMykG, the German Mycological Society, Essen, Germany, 6/2011
- Experimental models for invasive fungal infections, 5th Trends in Medical Mycology (TIMM-5), Valencia, Spain, 10/2011
- Invited Lecturer, Experimental models for invasive fungal infections, 5Th trends in Medical Mycology (TIMM-5), Valencia, Spain, 10/2011

Moderator, in symposium: "On the shoulders of Giants: Foundations, progress and future challenges in management of infections in patients with cancer," 49th annual IDSA Meeting, Boston, MA, 10/2011

Symposium Moderator: "Candidiasis in 2011," 29th annual IDSA meeting, Boston, MA, 10/2011

Invited lecturer, "Aspergillus resistance and clinical guidelines," 5th Advances Against Aspergillosis, Istanbul, Turkey, 1/2012

Invited lecturer, Meeting: Newer Antifungals: Ongoing research data, 22nd European Society of Clinical Microbiology and Infectious Diseases (ESCMID), London, United Kingdom, 4/2012

Meet the Expert, Meeting: Infectious complications of the new biological agents, 22nd European Society of Clinical Microbiology and Infectious Diseases (ESCMID), London, United Kingdom, 4/2012

Invited lecturer, "Cerebral mycoses: virulence from the fungal perspective," 18th Congress of the International Society of Humane and Animal Mycology (ISHAM), Berlin, Germany, 6/2012

Invited lecturer, "Mini-Host models as alternative infection models for invasive mycoses, 18th Congress of the International Society of Human and Animal Mycology (ISHAM), Berlin, Germany, 6/2012

Invited lecturer, "Mucormycosis: A review of diagnosis and treatment," 18th Congress of the International Society of Human and Animal Mycology (ISHAM), Berlin, Germany, 6/2012

Invited lecturer, "Recent research on pathogenesis of mucormycosis," 18th Congress of the International Society of Human and Animal Mycology (ISHAM), Berlin, Germany, 6/2012

Invited Lecturer, "Unmet clinical needs for the management of fungal infections," 17th International Symposium on Infections in the Immunocompromised Host, Genoa, Italy, 6/2012

Meet the Professor, "Molecular methods to diagnose fungal infections," 17th International Symposium on Infections in the Immunocompromised Host, Genoa, Italy, 6/2012

Meet the Professor, "Mucormycosis," 17th International Symposium on Infections in the Immunocompromised Host, Genoa, Italy, 6/2012

Plenary speaker, "Treatment of fungal infections: from guidelines to clinical practice, 17th International Symposium on Infections in the Immunocompromised Host, Genoa, Italy, 6/2012

Anidulafungin Compared to Caspofungin in a Con-Neutropenic Mouse Model of Invasive Candidiasis Caused by ANF Susceptible *C. Parapsilosis* Isolates with Different Degrees of In Vitro Non-Susceptibility to CAS: "MIC Does Not Tell the Whole Story" (oral presentation), 52nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9/2012

Invited Lecturer, "Immunopharmacology of antifungals," 2012 Immunology of Fungal Infections Gordon Research Conference, Galveston, TX, 1/2013

Plenary Speaker, Section F: "Destroying nosocomial outbreaks of invasive fungal infections, ASM General Meeting, Denver, CO, 5/2013

Invited panelist, Mycology 2013 Symposium, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 9/2013

Combination therapy for Aspergillus: Where is the evidence today?, IDSA/ID Week, San Francisco, CA, 10/2013

Invited Lecturer, Non-vertebrate animal models, 6th Trends in Medical Mycology (TIMM-6), Copenhagen, Denmark, 10/2013

Invited Lecturer, Symposium: Difficult aspergillosis cases, 5th Conference Advances Against Aspergillosis (AAA), Madrid, Spain, 3/2014

Invited Lecturer, "Standards on Prophylaxis: Prevention of Aspergillosis," 16th International Congress on Infectious Diseases and International Society of Infectious Diseases, Cape Town, South Africa, 4/2014

Plenary Speaker, "Management of Breakthrough Fungal Infections," 18th Symposium on Infections in the Immunocompromised Host (ICHS), Berlin, Germany, 6/2014

A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients, IDWeek, Philadelphia, PA, 10/2014

Plenary Speaker, "The Upcoming Decade in Medical Mycology," Hellenic Mycology Society Annual Meeting, Athens, Greece, 12/2014

Switching from Posaconazole OS to Tablet: Impact on serum drug levels, 2015 EBMT Meeting, Istanbul, Turkey, 3/22/2015

Invited Lecturer, Switching from Posaconazole OS to Tablet: Impact on serum drug levels, 2015 ECCMID, Copenhagen, Denmark, 4/25/2015

Infectious Diseases in Adults Course, Harvard Medical School, Boston, MA, 5/2015

Efficacy of anidulafungin C. parapsilosis fungemia, 7th TIMM, Lisbon, Portugal, 10/2015

Meet the Expert Session, Infections due to unusual Mucorales, 7th TIMM, Lisbon, Portugal, 10/2015

Plenary Speaker, Drouhet Lecturer, "Mucormycosis: The Evolution of a Human Super Pathogen," TIMM-7, Lisbon, Portugal, 10/2015

Principles for Management of Invasive Molds, ID Week/IDSA, San Diego, CA, 10/2015

New Options for Antifungal Prophylaxis in Hematology Patients, INFOCUS Satellite Symposium, Argentina, 11/2015

Invited Lecturer, Assessing the Individual Risk for Infection, 26th ECCMID, Amsterdam, Netherlands, 2016

Invited lecturer, "Antifungal Prophylaxis in daily clinical practices," 26th ECCMID, Amsterdam, Netherlands, 4/2016

Novel antifungal medications and approaches in patients with hematologic malignancy, Patients with Malignancy or Bone Marrow Transplant Group, Mayo Clinic ID Subspecialties Update, Dallas, TX, 5/2016

Chair, Symposium: Aspergillosis after viral Infections, ASM/Microbe 2016 Meeting, Boston, MA, 6/2016

Moderator, Clinical Mycology, ASM/Microbe 2016 Meeting, Boston, MA, 6/2016

Invited Lecturer, "Invasive Mold Infections: Emerging Approaches," MSGERC Symposium, ID Week, New Orleans, LA, 10/2016

Invited Lecturer, In Symposium "Novel Insights Into Fungal Pathogenesis," ID Week, New Orleans, LA, 10/2016

Invited Panelist, "Difficult Cases in Infectious Diseases," ID Week, New Orleans, LA, 10/2016

Course Director and Speaker, Preventing and Managing CMV and Invasive Fungal Infections after Hematopoietic Stem Cell Transplantation, 2017 BMT Tandem Meeting, Orlando, FL, 2017

Chair, Symposium "Invasive Candidiasis in 2017," 27th ECCMID, Vienna, Austria, 4/2017

Invited Lecturer, "Candidiasis in ICU Cancer Patients: An Update," 1st Global Oncology Critical Care Symposium, Houston, TX, 5/2017

Invited Lecturer, 2nd Symposium on Infectious Diseases in the Immunocompromised Host, Seattle, WA, 6/2017

- Invited Lecturer, Debate: Combination Antifungal Therapy for Mold Infections, ID Week, San Diego, CA, 10/2017
- Moderator, Oral Session "The Fungus Among Us-Clinical Advances," ID Week, San Diego, CA, 10/2017
- Invited Lecturer, "How to Reduce Empiricism in the Treatment of Aspergillosis," 8th Advances Against Aspergillosis (AAA) Meeting, Lisbon, Portugal, 2/2018
- Invited Lecturer, Bad News from Fungi: Emerging Multidrug-Resistant Species, "MDR-Fungi and Patients' Outcomes," 28th ECCMID, Madrid, Spain, 4/2018
- Invited Lecturer, Infections and Biologicals: A Real Concern, "Immunotherapy (T-Cell Checkpoint Blockade): What to expect?," 28th ECCMID, Madrid, Spain, 4/2018
- Invited Panelist, Clinical Grand Rounds 2018, 28th ECCMID, Madrid, Spain, 4/2018
- Invited Panelist in the Interactive Symposium, "Navigating the phenotype vs genotype conundrum in resistance: A case-based symposium," ID Week, San Francisco, CA, 10/2018
- Keynote Speaker, "Invasive fungal Infections in Cancer Patients: The Next Decade," 11th Congress Paulista De Infectologia, Sao Paulo, Brazil, 10/2018
- Keynote Speaker, "Outbreaks related to health care due to mucorales and other unusual fungi," 11th Congress Paulista De Infectologia, Sao Paulo, Brazil, 10/2018
- Meet the Professor, "Complex fungal infections in stem cell transplant recipients," ID Week, San Francisco, CA, 10/2018
- Invited Lecturer, "Managing resistant fungal infections in the hematology patient," 16th InFocus, Santiago de Cali, Colombia, 11/2018
- Invited Speaker, Meet the Professor, "Galactomannan Use in Clinical Practice," 16th InFocus, Santiago de Cali, Colombia, 11/2018
- Keynote Speaker, "New Oncology Drugs and Fungal Risk," 16th InFocus, Santiago de Cali, Colombia, 11/2018
- Invited Lecturer, "Clinical issues with immunotherapy of fungal infections," Gordon Research Conference on Immunology of Fungal Infections, Galveston, TX, 1/2019
- Invited Lecturer, Educational Workshop Antifungal Therapy: "Combine or not combine, this is the question! The case pro combination therapy," 29th ECCMID, Amsterdam, Netherlands, 4/2019
- Invited Lecturer. Symposium More about Candida auris- killer yeast here to stay?: "Worldwide epidemiology and burden of Candida auris," 29th ECCMID, Amsterdam, Netherlands, 4/2019
- Invited Panelist, Clinical Grand Rounds 2019, 29th ECCMID, Amsterdam, Netherlands, 4/2019
- Invited Panelist, 3rd Symposium on Infectious Diseases in the Immunocompromised Host, Seattle, WA, 6/2019
- Invited Speaker, "Studying Opportunistic Mycoses: From Flies to Fish," MMSA Symposium, ASM Microbe Meeting/MMSA Symposium, San Francisco, CA, 6/2019
- Chair, "Immunotherapy for Opportunistic Fungal Infections," 9th Trends in Medical Mycology (TIMM-9), Nice, France, 10/2019
- Invited Lecturer, "CAR-T cells, NK cells," 9th Trends in Medical Mycology (TIMM-9), Nice, France, 10/2019
- Invited Speaker, "Combination Antifungal Therapy for Treatment of Mucormycosis," The Henry Schueler 41 & 9 Foundation Second International Forum for Mucormycosis: Meeting the Evolving Challenges of a Lethal Infection, Chicago, IL, 11/2019



Invited Speaker, "Future Directions," The Henry Schueler 41 & 9 Foundation Second International Forum for Mucormycosis: Meeting the Evolving Challenges of a Lethal Infection, Chicago, IL, 11/2019

Invited Speaker, "Insights into Pathogenesis of Mucormycosis from Invertebrate Models," The Henry Schueler 41 & 9 Foundation Second International Forum for Mucormycosis: Meeting the Evolving Challenges of a Lethal Infection, Chicago, IL, 11/2019

Antifungal management in cancer patients: past, present and future, Hellenic Mycology Society, Thessaloniki, Greece, 3/2020

Invited Key Note speaker (webinar), Fungal infections in COVID19 era, Hellenic Mycology Society, 7/2020

Invited lecturer, The conundrums of COVID 19 in cancer patients: unique considerations of risk of severity and management, Gilead, ESCMID Virtual Conference on Coronavirus Disease (ECCVID) Symposium: Invasive fungal Infections and COVID-19: Expect the unexpected?, 9/2020

Invited speaker (Virtual Conference), T Cells and KN cells for treatment of mycoses, Munich Mycology meeting, Germany, 10/2020

Invited lecturer, Progress & Promise in the Management of COVID19 and Invasive Fungal Infections, Essentials Principles in the Management of Invasive Mold Infections, The Worldwide Institute for Medical Education (International Virtual Webinar), 11/2020

Keynote speaker, Invasive fungal infections in the era of COVID19, Annual Hellenic Mycology Society (Virtual Conference), Athens, Greece, 1/2021

Invited lecturer, "New directions in the management of mucormycosis," Bodey Lectureship, The Worldwide Institute for Medical Education, 21st ICHS symposium on Infections in Immunocompromised Hosts (Virtual Conference), Melbourne, Australia, 2/2021

Invited lecturer, New antifungals pipeline, INFOCUS Symposium: fungal infections and future directions, 21st ICHS symposium on Infections in Immunocompromised Hosts (Virtual conference), Melbourne, Australia, 2/2021

Immunotherapy and infection: Not everything is bad with biologicals (virtual lecture), ESGICH Post Graduate Educational Course on Safety of Targeted and Biological therapies: an infectious diseases perspective, 3/2022

Invited lecturer, Workshop: Fungal diagnostics: questions from the bedside and answers from the bench, "Fungal infections, not just in neutropenia!," 32nd ECCMID, Lisbon, Portugal, 4/2022

Invited lecturer, Cross-talk Symposium, Fungii enter the AMR Arena, topic: The clinical significance of MDR fungi, ASM Microbe, Washington, DC, 6/2022

Invited lecturer, Special topics in antifungal therapy, New cancer drugs/immunosuppressives: Impact on invasive fungal infections, MSGERC 2022, Albuquerque, NM, 9/2022

Invited lecturer, ID Invasive fungal infections: Not only neutropenia! (virtual lecture), Balcan Fungus 2022, Thessaloniki, Greece, 10/2022

Invited lecturer, Invasive fungal infections and COVID-19 Symposium, Mucormycosis in patients with COVID-19, ID Week, Washington, DC, 10/2022

COVID-19 associated mucormycosis, ASM Meeting - Texas Branch, Houston, TX, 11/2022

Keynote speaker, COVID19-associated Mucormycosis: Lessons learned Annual Hellenic Mycology Society, Virtual Conference, Athens, Greece, 3/2023

Keynote speaker, Fungii: their role in modern world, history and human disease: 11th Annual Hellenic Conference of Clinical Microbiology, Virtual Conference, Athens, Greece, 3/2023

Invited Clinical Panelist, 4th Symposium on Infectious Diseases in the Immunocompromised Host, Seattle, WA, 4/2023

Invited Lecturer, New Antifungals, 4th Symposium on Infectious Diseases in the Immunocompromised Host, Seattle, WA, 4/2023

Invited Panelist, Clinical Grand Rounds 2019, 33rdh ECCMID, Copenhagen, Denmark, 4/2023

The Gulf Coast Consortia and the ASM-TMC monthly seminar series on antibiotic resistance, Implications of fungal resistance-A clinician's view, Houston, TX, 4/2023

Invited Lecturer, ID Week, Symposium: "Difficult to diagnose, difficult to treat infections in neutropenic and post stem cell transplant patients," topic: "It is getting hot there: Persistent fever in neutropenic patients on empiric antimicrobial therapy," , Boston, MA, 10/2023

Invited Lecturer, ID Week, Symposium: "Understand evolving, novel approaches to prevent and treat invasive fungal infections" topic: "CAR T cells for the treatment of invasive mold infections," , Boston, MA, 10/2023

Invited Lecturer, Immunotherapy for refractory mycoses: Ready for prime time? ICHS International, Virtual Webinar, 11/2023

#### **Other, Including Scientific Exhibitions**

Fluconazole sensitivity is modulated by the interaction of mitochondria and Erg3p in *Saccharomyces cerevisiae*, Infectious Diseases Society of America, Denver, CO, 11/1/1998

The role of broad spectrum antibiotics for the management of febrile neutropenia, Wayne Ebrite Investigators Conference, 11/1/1999

Invited Lecturer. Treatment Paradigms in the face of new choices, 43rd ICAAC satellite symposium, Chicago, IL, 9/1/2003

Invited Lecturer, "New developments in fungal diagnostics," 16th ECCMID satellite symposium, Nice, France, 4/2006

"Clinical counterpoint: Treating severe fungal infections in today's clinical environment," 44th IDSA Satellite Symposium, Toronto, Canada, 10/2006

Clinical Update-Focus on Caspofungin, ASH Satellite Symposium, Orlando, FL, 12/2006

Invited Lecturer "Treatment strategies for systemic mycoses," 3rd Pan-Hellenic Congress of Hellenic Society of Medical Mycology, Athens, Greece, 10/2009

Invited Lecturer, Posaconazole Clinical Update Meeting, "Effect of recent clinical practice on the incidence of zygomycosis, London, United Kingdom, 11/2009

Invited Lecturer, Henry Schueller Foundation Forum on Zygomycosis, Chicago, IL, 1/2010

Moderator, in symposium: "Great debates in Mycology," 49th annual IDSA Meeting, Boston, MA, 10/2011

Combination antifungal therapy in patients with hematologic cancer and mucormycosis: A propensity score analysis, 54th ICAAC, San Diego, CA, 9/2015

Invited lecturer, Infectious Diseases in Adults, Harvard Medical School, Boston, MA, 5/2016

Keynote Speaker, 1st Seminar of Hellenic Oncology - Infectious Diseases Study Group, Athens, Greece, 10/2016

Panelist, Athens Health Summit: Emerging stronger from the pandemic, topic: How the mRNA technology will change the future of medicine, 11/2021

Invited lecturer, Future directions in translational research and management of mucormycosis, Symposium on the Basal Fungal Kingdom, 16th European Conference in Fungal Genetics, Innsbruck, Austria, 3/2023

#### **Seminar Invitations from Other Institutions**

Genetic dissection of fluconazole resistance in *Saccharomyces cerevisiae*, Massachusetts General Hospital, Harvard Medical Sc, Boston, MA, 3/1/1997

Genetic dissection of azole resistance by transposon mutagenesis in *Saccharomyces cerevisiae*, Duke University Medical Center, Durham, NC, 11/1/1997

Mechanisms of azole sensitivity and resistance in *Saccharomyces cerevisiae*, Invited lecturer, Infectious Diseases Unit Research Seminar, UT MD Anderson Cancer Center, Houston, TX, 11/1997

Newer antifungals, Invited Lecturer, Hematology Division Seminar, Baylor College of Medicine, Houston, TX, 5/1/2003

Update on aspergillosis, Invited Lecturer, Department of Medicine Grand Rounds, The Methodist Hospital, Dallas, TX, 9/1/2004

*Drosophila*: a novel mini-host model to study systemic mycoses, University of Athens Medical School, Athens, Greece, 11/1/2004

An empirical approach to antifungal therapy in persistent febrile neutropenia, Invited lecturer, Hermann Hospital, Houston, TX, 11/2005

The Changing Face of candidemia: The Medical Patient, Invited lecturer, The Methodist Hospital, Houston, 3/2006

The role of mini-host models in experimental mycology in *Infection and Immunity*, Invited Lecturer, Graduate Program in Clinical Investigation, University of Crete Medical School, Heraklion, Greece, 10/2006

A fly model to study fungal infections, Invited lecturer, Texas A&M Institute of Biotechnology, Houston, TX, 11/2007

State of the art update on candidiasis, Invited lecturer, Presbyterian Hospital Grand Rounds, 4/2009

Meet the Expert, CEPAS Oncohematologic Conference, Madrid, Spain, 4/2012

Biomarkers in Medical Mycology, Mexican Mycology Network/Mexican Society of Infectious Diseases, Mexico City, Mexico, 9/2013

Helping each other to advance as a group, Summit on the Future of Medical Mycology in the US, San Antonio, TX, 6/2015

Immunotherapy of Fungal Infections, 23rd Annual Course in Advances in Tissue Engineering, Rice University, Visiting Lecturer, Rice University, Houston, TX, 8/2015

Mini Host Models to Study Pathogenesis and Drug Discovery, 24th Annual Course in Advances in Tissue Engineering, Visiting Lecturer, Rice University, Houston, TX, 8/2016

Two Tales of Immunomodulation of Antifungal Therapy Implication for Tissue Engineering, 25th Annual Course in Advances in Tissue Engineering, Invited Lecturer, Rice University, Houston, TX, 8/2017

Tissue engineering and Infectious Diseases, 26th Annual Course in Advances in Tissue Engineering, Invited Lecturer, Rice University, Houston, TX, 8/2018

Invited Lecturer, An innovative zebra fish model and new microscopy methods to study fungal pathogenesis and treatment, 27th Annual Course in Advances in Tissue Engineering, Rice University, Houston, TX, 8/2019

Invited Lecturer, Microbiome and its role in tissue repair and regeneration, 28th Annual Course in Advances in Tissue Engineering, Rice University, Houston, TX, 8/2021

Invited Lecturer, mRNA technology and the future of medicine, 29th Annual Course in Advances in Tissue Engineering, Rice University, Houston, TX, 8/2022

Invited lecturer, TBA, 30th Annual Course in Advances in Tissue Engineering, Rice University, Houston, TX, 8/2023

#### **Lectureships and Visiting Professorships**

Cabot Clinicopathological Conference, Massachusetts General Hospital and Harvard Medical, Boston, MA, 5/1/2000

Fungal Infections in patients with cancer, Sismanoglion Hospital, Athens, Greece, 10/1/2000

Invasive aspergillosis in 2001, UTHS-San Antonio, Grand Rounds, The University of Texas Health Science Center-San Antonio, San Antonio, TX, 3/1/2001

Treatment strategies for fungal infections, UTMB-Galveston, Grand Rounds, The University of Texas Medical Branch-Galveston, Galveston, TX, 10/1/2001

Update on opportunistic fungal infections, Grand Rounds, St. Paul Medical Center, Dallas, TX, 10/1/2001

Mycoses 2001: Future trends and clinical implications, Medical Grand Rounds, University of West Virginia, Morgantown, WV, 11/1/2001

Update on fungal infections, UPMC Shadyside Hospital, Pittsburgh, PA, 11/1/2001

Update on fungal infections, Medical Grand Rounds, Baylor Medical Center, Dallas, TX, 11/1/2001

Clinicopathologic Conference, Department of Medicine Grand Rounds, Baylor College of Medicine, Houston, TX, 2/1/2002

Antifungal resistance, National and Kapodistrian University of Athens/Hel, Athens, Greece, 6/1/2002

Emerging opportunistic fungi, National and Kapodistrian University of Athens/Hel, Athens, Greece, 6/1/2002

Update in antifungal combination, National and Kapodistrian University of Athens/Hel, Athens, Greece, 6/1/2002

Balancing risk and reward: antifungal therapy in high risk patients, William Beaumont Army Medical Center, El Paso, TX, 10/1/2002

Filamentous fungii, Grand Rounds, Cleveland Clinic Infectious Diseases, Cleveland, OH, 11/1/2002

Evolving epidemiology of fungal infections, Division of Infectious Diseases Grand Rounds, University of South California, Los Angeles, CA, 2/1/2003

Update on opportunistic filamentous fungi, Division of Infectious Diseases Grand Rounds, Georgetown University Hospital, Washington, DC, 4/1/2003

Empiric antifungal therapy, Division of Infectious Diseases Grand Rounds, Presbyterian Medical Center - NY Hospital – Columbia Medical Center, New York, NY, 6/1/2003

Emerging opportunistic mold infections, Visiting Professorship, Grand Rounds, Tufts New England Medical Center, Boston, MA, 10/1/2003

Fusariosis and other emerging opportunistic mold infections, Visiting Professorship, Grand Rounds, University of Michigan Ann Arbor, Ann Arbor, MI, 10/1/2003

Treatment of fungal infections in high risk (neutropenic) patients, Visiting Professorship, Grand Rounds, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 10/1/2003

Zygomycosis , fusariosis and other emerging opportunistic mold infections, Visiting Professorship, Grand Rounds, University of Pittsburgh, Pittsburgh, PA, 4/1/2004

Antigen detection in aspergillosis, Visiting Professorship, Grand Rounds, University of Maryland, MD, 6/1/2004

Changing epidemiology of candidiasis, Visiting Professorship, Grand Rounds, Detroit Medical Center Karmanos Cancer Institute, Detroit, MI, 9/1/2004

Update on antifungal therapy, Visiting Professorship, Grand Rounds, Roswell Park Cancer Institute, Buffalo, NY, 9/1/2004

Update on antifungal therapy: Focus on aspergillosis, Visiting Professorship, Grand Rounds, Methodist Dallas Medical Center, Dallas, TX, 9/1/2004

Mycofungin, Grand Rounds, The University of Texas Health Science Center-San Antonio, San Antonio, TX, 5/1/2005

New frontiers in mycology, Parkland Hospital Grand Rounds, The University of Texas Southwestern Medical Center, Dallas, TX, 5/1/2005

New Antifungals, Grand Rounds, Children's Hospital/LSU, New Orleans, LA, 8/1/2005

Invited Lecturer, "Empiric Antifungal Therapy: An Update," Stanford University, Palo Alto, CA, 11/2005

An empirical approach to antifungal therapy in persistent febrile neutropenia, Invited lecturer, Division of Hematology/Oncology, Hahnemann University Hospital, Philadelphia, PA, 5/2006

Candidiasis: The surgical patient, Invited lecturer, Loma Linda University, Loma Linda, CA, 6/2006

Advanced topics in infectious diseases, Invited lecturer, Infectious Diseases Grand Rounds, Memorial Sloan Kettering and Cornell University, New York, NY, 9/2006

New frontiers in management of mycoses, Invited lecturer, Department of Internal Medicine Grand Rounds, Vanderbilt University, Nashville, TN, 11/2006

Update in zygomycosis, Invited lecturer, ID Grand Rounds, University of Alabama, Birmingham, AL, 12/2006

Update in zygomycosis, Invited lecturer, Professors Grand Rounds, Denver Children's Hospital, Denver, CO, Denver, CO, 1/2007

Systemic Fungal infections, Invited lecturer, Grand Rounds, University of Kansas, Wichita, KS, 2/2007

Opportunistic mycoses in 2007, Invited Lecturer, Royal Hospital, Australia, Melbourne, Australia, 5/2007

Systemic Fungal infections: Consensus and Controversies, Invited lecturer, Grand Rounds, Western Pennsylvania Hospital Cancer Institute, Pittsburgh, PA, 5/2007

Caspofungin: The MD Anderson perspective, Invited lecturer, Royal Free Hospital, London, UK, London, United Kingdom, 6/2007

Caspofungin: The MD Anderson perspective, Invited lecturer, Queen Elizabeth Hospital, London, Birmingham, UK, London, Birmingham, United Kingdom, 6/2007

Caspofungin: The MD Anderson perspective, Invited lecturer, Royal Liverpool University Hospital, Liverpool, UK, Liverpool, United Kingdom, 6/2007

Mini-host models to study fungal pathogenesis, Invited lecturer, Harbor-UCLA Medical Center, Los Angeles, CA, Los Angeles, CA, 6/2007

Systemic Fungal infections: Advances and Controversies, Invited lecturer, Grand Rounds, Univ of Illinois Chicago Medical Center, Chicago, IL, Chicago, IL, 6/2007

Zygomycosis, Invited lecturer, Grand Rounds, Northwestern University, Chicago, IL, Chicago, IL, 6/2007

New insights into the mechanism of action of antifungals, New England Medical Center, Boston, MA, 9/2007

A clinical approach to the immunosuppressed patients with fever, 4th Top-Ten on Infections Annual Conference, 4th Top-Ten on Infections Annual Conference, Athens, Greece, 2/2008

Management of fungal infections in immunosuppressed hosts, Visiting professor, Turkish Febrile neutropenia meeting, Hacettepe University, Ankara, Turkey, Ankara, Turkey, 2/2008



- Invasive fungal infections in allogeneic hematopoietic stem cell transplantation: New challenges, Invited lecturer, NIAID Grand Rounds, Bethesda, MD, 5/2008
- Update on antifungal therapy, Invited lecturer, University of Utah Grand Rounds, Salt Lake City, UT, 9/2008
- Consensus and controversies in modern mycology, Invited lecturer, Internal Medicine Grand Rounds/VAMC, University of Minnesota, Saint Paul, MN, 11/2008
- Invasive Fungal Infections: when to use a polyene, Invited lecturer, University Hospitals Case Medical Center, Cleveland, OH, 10/2009
- Visiting professor, Cleveland Clinic Foundation, Cleveland, OH, Cleveland, 10/2009
- Breakthrough mold infections in patients with hematologic malignancies, Invited lecturer, Grand Rounds, Infectious Disease Division, Johns Hopkins University, Baltimore, MD, 4/2010
- Combination therapy in Zygomycosis, 2nd International forum on Zygomycosis, Peloponnese, Greece, Greece, 5/2010
- New frontiers in Mycology, Visiting lecturer, Spanish Hematology Annual Meeting, Canary Islands, Spain, Spain, 10/2010
- Aspergillosis in 2010: Consensus and Controversies, Visiting Lecturer, Greek Hematology Annual Meeting, Thessaloniki, Greece, 11/2010
- Internal Medicine Grand Rounds, Visiting professor, University of New Mexico, Albuquerque, NM, 2/2011
- Visiting professor, Infectious Diseases Grand Rounds, Albert Einstein School of Medicine-Montefiore Hospital, Albuquerque, NM, 3/2011
- Aspergillosis in 2010: Consensus and Controversies, Visiting lecturer, Greek Hematology Annual Meeting, Thessaloniki, Greece, 4/2011
- Visiting Professor, Hospital Necker De Maladies Infectieuses, Paris, France, 4/2011
- Visiting Professor, Institute Pasteur, Paris, France, 4/2011
- Immunopathogenesis of fungal pneumonia: Recent insights, Baylor College of Medicine, Division of Infectious diseases, 5/2011
- Grand Rounds: The upcoming decade in Mycology, Massachusetts General Hospital, Boston, MA, 10/2011
- Visiting Professor, Massachusetts General Hospital, Department of Surgery, Boston, MA, 10/2011
- Visiting Professor, Elbert Einstein-Montefiore Medical Center, Division of Infectious Diseases, New York, NY, 11/2011
- Visiting Professor, University of Wisconsin, 11/2011
- Difficult cases in Mycology, Visiting Professor, University of Melbourne, University of Brisbane, University of Sydney, Sydney, Australia, 3/2012
- Visiting Professor, Memorial-Sloan Kettering, New York, NY, 3/2012
- Visiting Professor, Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, WI, 4/2012
- Visiting Professor, The Cancer Center Hackensack University Medical Center, 10/2012
- Visiting Professor, University of Singapore, Singapore, Singapore, 11/2012
- Visiting Professor, Mayo Clinic, Division of Infectious Diseases, Rochester, MI, 5/2013
- Visiting Professor, University of Athens Medical School, Athens, Greece, 12/2013
- Visiting Professor, MYCONON Conference, Kolkata, India, 10/2014

Visiting Professor, The Immunopharmacology of Echinocandins, University of Texas, Department of Molecular Microbiology, Houston, TX, 2/2015

Visiting Professor, Breakthrough mold Infections, University of Melbourne, New Zealand, Australia, 9/2015

Visiting Professor, Department of Hematology, Auckland City Hospital, Auckland, New Zealand, 9/2015

Visiting Professor, Soroka Hospital, Beer Sheva, Israel, 12/15/2015

Visiting Professor, Rambam Hospital, Haifa, Israel, 12/16/2015

Visiting Professor, Hadassah Hospital, Jerusalem, Israel, 12/17/2015

Visiting Professor, Ichilov Hospital, Tel Aviv, Israel, 12/18/2015

Invited Lecturer, Advances Against Aspergillosis, 6th Conference, Pipeline for New Drugs Against Aspergillosis, Manchester, United Kingdom, 3/2016

Invited Lecturer, ECCMID, Approaches to individualized management of invasive fungal disease, Amsterdam, Netherlands, 4/2016

Invited Lecturer, 2016 Texas Infectious Diseases Society, Non-Aspergillus Molds: Mucormycosis, Fusaricosis, Scedosporiosis, San Antonio, TX, 6/2016

Visiting Professor, University of Toronto, 8/2016

Visiting Professor, Evidence Based Strategies for Antifungal Prophylaxis: Focus on Posaconazole, National Cancer Center, South Korea, 10/12/2016

Visiting Professor, Evidence Based Strategies for Antifungal Prophylaxis: Focus on Posaconazole, Shinchon Severance Hospital, South Korea, 10/12/2016

Visiting Professor, Evidence Based Strategies for Antifungal Prophylaxis: Focus on Posaconazole, Ulsan National University Hospital, South Korea, 10/13/2016

Visiting Professor, Evidence Based Strategies for Antifungal Prophylaxis: Focus on Posaconazole, HwasoonCheonnam University Hospital, South Korea, 10/14/2016

Invited Lecturer, 19th Symposium of Infectious Diseases in Immunocompromised Host, Echinocandins: Are all the same?, Santiago, Chile, 11/2016

Invited Lecturer, Meet the Experts: How I treat mucormycosis, 19th Symposium of Infections in the Immunocompromised Host, Santiago, Chile, 11/2016

Visiting Professor, ClinicaAlemana - Universidad del Desarrollo, Santiago, Chile, 11/2016

Visiting Professor, CDC, Atlanta, GA, 1/2017

Visiting Professor, Mucormycosis, Laikon Hospital and University of Athens, Athens, Greece, 1/2017

Visiting Professor, University of Bern, Bern, Switzerland, 4/2017

Visiting Professor, University of Lausanne, Lausanne, Switzerland, 4/2017

Visiting Professor, University of Basel, Basel, Switzerland, 4/2017

Visiting Professor, San Antonio Military Medical Center, San Antonio, TX, 5/2017

Visiting Professor, University of Edmonton, Edmonton, Canada, 5/2017

Visiting Professor, University of Calgary, Calgary, Canada, 5/2017

Visiting Professor, University of Vancouver, Vancouver, Canada, 5/2017

Invited Lecturer, 2nd Symposium on Infectious Diseases in the Immunocompromised Host, "Combination Antifungal Therapy: A Debate," , Seattle, WA, 6/2017

ECCMID-MSD Symposium, "How to optimize antifungal prophylaxis in your immunosuppressed patients," 28th ECCMID, Madrid, Spain, 4/2018

- Visiting Professor, Hospitale Civico, Lugano, Switzerland, 9/2018
- Visiting Professor, University of Zurich, Zurich, Switzerland, 9/2018
- Visiting Professor, "Risk Stratification and Principles of Antifungal Therapy," University of Geneva, Geneva, Switzerland, 9/2018
- Visiting Professor, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 10/2018
- ECCMID-Gilead Symposium, "Emerging populations at an increased fungal risk," 29th ECCMID, Amsterdam, Netherlands, 4/2019
- Invited moderator, 3rd Symposium on Infectious Disease in the Immunocompromised Host, Seattle, WA, 6/2019
- Invited Lecture, Practical Applications in Oncology Meeting, "Fungal Immunotherapy: T cells and NK cells," University of Texas at San Antonio, San Antonio, TX, 2/2020
- Invited discussant (Virtual meeting), Stump the Stars Case Conference, University of Utah, Salt Lake City, UT, 11/2020
- Invited Lecturer, Clinically significant interactions between azoles and leukemia drugs (Virtual meeting), Gilead Symposium-2021 EBMT meeting, 3/2021
- New prophylactic formulations of posaconazole, Merck Gulf Symposium in United Arab Emirates (Virtual meeting), 4/2021
- Workshop participant, Medical Research Council, Drivers of antifungal Resistance, University of Exeter (Virtual meeting), United Kingdom, 5/2021
- Visiting professor, University of Crete, Heraklion Hospital, 8/2021
- 30 years of Ambisome-Importance of early treatment in the era of prophylaxis, Gilead webinar (Virtual meeting), 9/2021
- Clinically significant interactions between azoles and leukemia drugs, Gilead webinar-Australia meeting (virtual meeting), 9/2021
- New prophylactic formulations of posaconazole, Merck Gulf Symposium in Qatar (Virtual meeting), 10/2021
- Invited lecturer, Infectious Diseases Department Grand Rounds, "Invasive mycoses in patients with hematologic cancer," Cleveland Clinic Foundation (Virtual meeting), 2/2022
- Visiting Professor, The new decade of medical mycology, University of Athens/Attikon Hospital, Chaidari, Greece, 8/2022
- Invited lecturer, Fungal Infections in Transplantation, Carol and Burt Keenan Symposium, Houston Methodist Hospital, Houston, TX, 11/2022
- Visiting Professor, New risk factors for invasive fungal infections (virtual lecture), University of Heraklion, Crete, Greece, 12/2022
- Visiting Professor, University of Innsbruck, Department of Microbiology, Innsbruck, Austria, 3/2023
- Invited Lecturer, New Biologicals and Risk for Fungal Infections (virtual lecture), Internal Medicine Grand Rounds, Medical College of Georgia/Augusta University, Augusta, GA, 5/2023

**Other Presentations at State and Local Conferences**

- Opportunistic fungal infections in cancer patients, Infectious Disease Unit Lecture series, Saint Luke's Episcopal Hospital, Baylor College of Medicine, 12/1/1992
- Carcinoma of unknown primary site, Saint Luke's Episcopal Hospital, Baylor College of Medicine, Houston, TX, 5/1/1993
- Arterial thrombosis, Citywide Hematology Rounds, Baylor College of Medicine, 6/1/1993
- Infectious Disease case management rounds, Massachusetts General Hospital, 1/1/1994

- Harvard-wide Infectious Disease rounds, Boston, MA, 1/1/1994
- Clinical Pathological Conference, monthly, Veterans Administration Medical Center, Baylor College of Medicine, 1/1994
- Morbidity and Mortality Conference, Monthly, Veterans Administration Medical Center, Baylor College of Medicine, 1/1994
- Molecular pathogenesis of the acute renal failure in sepsis, The Methodist Hospital, Baylor College of Medicine, 4/1/1994
- Clinicopathological Conference, Grand Rounds, Baylor College of Medicine, 6/1994
- Clinicopathological Conference, bi-monthly, Massachusetts General Hospital, 7/1994
- Virulence factors of *Candida albicans*, Infectious Disease Unit lecture series, Massachusetts General Hospital, 5/1/1995
- Biotechnology: From bench to bedside, Whitehead Institute winter lecture series for high school students, Whitehead Institute, Boston, MA, 2/1/1996
- PDR5-mediated resistance to fluconazole in *S. cerevisiae*, Children Nutrition Research Center, Baylor College, 8/1/1998
- Quantitative b-galactosidase assay, Children Nutrition Center, Baylor College of Medicine, 2/1/1999
- Antifungal drug resistance in the 21st century: diagnosis, epidemiology, mechanisms and future prospects, 6th World Hellenic Bio-Medical Congress, Athens, Greece, 10/1/2000
- Mycoses in 2000: New and old syndromes, 6th World Hellenic Bio-Medical Congress, Athens, Greece, 10/1/2000
- Mycoses in 2000: An update, Houston Medical Center-wide seminar on fungal infections, Houston, TX, 1/1/2001
- Advances in antifungal therapy, Medical Education Program, Austin, TX, 9/1/2002
- Advances in antifungal Therapy, Medical Education Program, Houston, TX, 10/1/2002
- Fungal infections in the immunocompromised host: Management challenges for the 21st Century, Worldwide Institute for Medical Education, Houston, TX, 12/1/2002
- Evolving epidemiology of fungal infections in cancer patients and management challenges, Worldwide Institute for Medical Education, Houston, TX, 5/1/2005
- New Developments in mycology, Houston Northwest Medical Center, Houston, TX, 11/2005
- Systemic mycoses in cancer patients, 1st Conference in Infections in Cancer Patients, MD Anderson Cancer Center, Houston, TX, 11/1/2005
- "Mini-host models to study fungal virulence and antifungals," South Central Medical Mycology Group 4th Annual Meeting, South Central Medical Mycology Group, 10/2006
- Fungal infections in the immunocompromised host: New therapeutic agents, World-wide Institute for Medical Education, Symposium, World-wide Institute for Medical Education, 2/2007
- New antifungal agents, Infectious Diseases Society, San Antonio, TX, 6/2007
- Chair, Division of Internal Medicine Research Retreat, Organizing Committee, UT MD Anderson Cancer Center, Houston, TX, 2008
- Candida* biofilms and the role of the echinocandins, 9th Echinocandin Forum, Astellas Tokyo 9th Echinocandin Forum, 3/2009
- New developments in experimental mycology, Houston Infectious Diseases Society, Houston, TX, 3/2009
- New Developments in experimental mycology, Invited Lecturer, Annual Houston Infectious Diseases Society of Pharmacists meeting, Houston, TX, 7/2009
- Update on Fungal Pneumonia, 62nd Annual KOPPA Conference, Hunt, TX, 8/2009

Candida biofilms and the role of the echinocandins, 9th Echinocandin Forum, Tokyo, Japan, 3/2011

Update on Fungal pneumonia, 62nd Annual KOPPA Conference, Hunt, TX, 3/2011

"Serious infections in cancer patients, Worldwide Institute for Medical Education, Symposium, Houston, TX, 9/2011

Antifungal Stewardship, Lessons for the ICU, Society of Critical Care Medicine, Phoenix, AZ, 1/2015

Advances in Prevention and Prophylaxis of Invasive Fungal Infections, Fungal Infections in Cancer and Transplant Patients: Management Challenges for the 21st Century, Houston, TX, 3/2015

Update on fungal diagnostics, St. Luke's Hospital, Houston, TX, 5/2015

Invited Lecturer, Mucormycosis in 2016: Update in Diagnosis and Management, The Houston Infectious Diseases Society, Houston, TX, 12/2016

Fungi: Their role in modern world, history and human disease, Hellenic Professional Society of Houston, Houston, TX, 2/2017

Panelist, Invasive Fungal Infection Course, ACCP / ASCO, Houston, TX, 2/2018

"Resistance in mold infections," Texas Medical Center Antimicrobial Resistance and Stewardship Conference, Houston, TX, 1/2019

GAP 2019, "Invasive Pulmonary Aspergillosis in Patients with Hematologic Cancer: An Update," The University of MD Anderson Cancer Center, Houston, TX, 5/2019

Lecturer, COVID19 related fungal infections: An illustrative case and discussion of the challenges in diagnosis and management, MD Anderson Cancer Center, Department of Infectious Diseases COVID19 Journal Club, 12/2020

Lecturer, "New Antifungals," AMR Symposium, Houston, TX, 1/2022

Invited expert discussant, Morbidity and Mortality Conference, Brown Alpert Medical School/Department of Medicine Grand Rounds (virtual), 2/2023

The tangled history of mRNA technology and the future of medicine, Hellenic Professional Society of Texas, Houston, TX, 2/2023

## **PROFESSIONAL MEMBERSHIPS/ACTIVITIES**

### **Professional Society Activities, with Offices Held**

#### **National and International**

American College of Physicians  
Fellow, 1/1994-present

Infectious Diseases Society of America  
Fellow, 1/1995-present

American Society of Microbiology  
Member, 1/1998-present

Harvard Alumni Society  
Member, 1/1998-present

Harvard-MIT Health Sciences and Technology alumni society  
Member, 1/1998-present

Hellenic Professional Society of Texas  
Member, 1998-present

Hellenic Bio Scientific Association in the USA,  
Member, 1/2007-present

International Society of Human and Animal Mycology (ISHAM)



Member, 1/2007-present  
The Texas Faculty Association  
Member, 4/2011-present  
The American Association for the Advancement of Science (AAAS)  
Member, 12/2012-present  
Medical Mycological Society of America  
Member, 2013-present  
European Confederation of Medical Mycology (ECMM)  
Member, 2014-present  
Mycoses Study Group Steering Committee  
Member, 2014-present  
Hellenic Mycology Society, Athens, Greece  
Honorary Member, 12/2014-present  
ECCMID  
Member, 2015-present  
ESCMID (European Society of Clinical Microbiology and Infectious Diseases)  
Member, 2015-present  
European Confederation of Medical Mycology (ECMM)  
Fellow, 2015-present  
International Immunocompromised Host Society  
President Elect, 2016-2018  
Mycoses Study Group Education and Research Consortium (MSGERC)  
Founding Member at large, 2016-present  
President-Elect, 2024-2026  
European Academy of Arts and Sciences  
Member, 2018-present  
American Association of Physicians (AAP)  
Member, 2023-present

**Local/State**

Texas Infectious Diseases Society  
Member, 1/2001-present  
Harris County Medical Society, Houston, TX  
Member, 2007-present  
Houston Infectious Diseases Society  
Member, 1/2009-present  
Houston Harvard University Club, Houston, TX  
Member, 2012-present

**UNIQUE ACTIVITIES**

1. Volunteer, Debate Judge, Bellaire High School
  
2. Invited Speaker, Houston Hellenic Professional Society

**DATE OF LAST CV UPDATE**

4/6/2023

**Θέμα:** Fwd: Αίτηση υποψηφιότητας του Καθηγητή Δημήτριου Π. Κοντογιάννη για εξωτερικό μέλος του Συμβουλίου Διοίκησης του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών  
**Από:** Μάρθα Μπάρκα <mbarka@uoa.gr>  
**Ημερομηνία:** 10/4/2023, 11:24 π.μ.  
**Προς:** protokollo@uoa.gr

----- Forwarded Message -----


**Subject:** Αίτηση υποψηφιότητας του Καθηγητή Δημήτριου Π. Κοντογιάννη για εξωτερικό μέλος του Συμβουλίου Διοίκησης του Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών  
**Date:** Fri, 7 Apr 2023 20:56:58 +0000  
**From:** Kontoyiannis, Dimitrios P <dkontoyi@mdanderson.org>  
**To:** [diradmin@uoa.gr](mailto:diradmin@uoa.gr) <[diradmin@uoa.gr](mailto:diradmin@uoa.gr)>

Αγαπητή Επιτροπή

Έχω την τιμή να υποβάλλω υποψηφιότητα για εξωτερικό μέλος του Συμβουλίου Διοίκησης του Εθ  
Με εκτίμηση

Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FIDSA, FAAM, FAAAS  
Robert C Hickey Chair in Clinical Care  
Deputy Head, Division of Internal Medicine  
[dkontoyi@mdanderson.org](mailto:dkontoyi@mdanderson.org)

ECMM Diamond Excellence in Mycology Center/[www.ecmm.info](http://www.ecmm.info)



The information contained in this e-mail message may be privileged, confidential, and/or protected from disclosure. This e-mail message may contain protected health information (PHI); dissemination of PHI should comply with applicable federal and state laws. If you are not the intended recipient, or an authorized representative of the intended recipient, any further review, disclosure, use, dissemination, distribution, or copying of this message or any attachment (or the information contained therein) is strictly prohibited. If you think that you have received this e-mail message in error, please notify the sender by return e-mail and delete all references to it and its contents from your systems.

— Συνημμένα: —

ΔΙΕΘΝΗΣ ΔΗΜΟΣΙΑ ΠΡΟΣΚΛΗΣΗ ΕΞΩΤΕΡΙΚΩΝ ΜΕΛΩΝ Σ.Δ. DP

98,8 KB

**KONTOYIANNIS.docx**

<b>Dr Dimitrios P Kontoyiannis -External Advisory Board University of Athens - greek LOI.docx</b>	<b>284 KB</b>
<b>Dr Dimitrios P Kontoyiannis LOI-External Advisory Board University of Athens.docx</b>	<b>294 KB</b>
<b>DP Kontoyiannis Narrative Bio 4-2023.docx</b>	<b>16,4 KB</b>
<b>DP Kontoyiannis CV_April-6-23.docx</b>	<b>194 KB</b>
<b>DP Kontoyiannis Greek passport.pdf</b>	<b>467 KB</b>
<b>DP KONTOYIANNIS Greek ID card-1.pdf</b>	<b>193 KB</b>
<b>DP KONTOYIANNIS Greek ID Card -2.pdf</b>	<b>162 KB</b>